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ABSTRACT 
 
Swine dysentery (SD) is an important endemic infection in many piggeries, and control can be 
problematic. In this study, the gene encoding a 29.7 kDa outer membrane lipoprotein of the 
causative intestinal spirochaete Brachyspira hyodysenteriae, was identified and sequenced. An 
816 bp hypothetical open reading frame (ORF) was identified, with a potential ribosome 
binding site, and putative –10 and –35 promoter regions upstream from the start of the ORF. 
The 29.7 kDa outer membrane lipoprotein was designated Bhlp29.7 and the encoding gene 
named bhlp29.7.  
 
The amino acid sequence of Bhlp29.7 included a 19 residue hydrophobic signal peptide, 
incorporating a potential signal peptidase cleavage site and membrane lipoprotein lipid 
attachment site. In silico analysis of this protein together with lipidation studies further 
supported its probable outer membrane localisation. Comparison of the Bhlp29.7 sequence 
with public sequence databases showed that it had up to 40% similarity with the D-methionine 
substrate-binding outer membrane lipoprotein (MetQ) of a number of bacterial pathogens. The 
Bhlp29.7 gene was detected in all 48 strains of B. hyodysenteriae examined, and in 
Brachyspira innocens strain B256
T, but not in 10 other strains of B. innocens or in 42 strains of 
other Brachyspira spp. The gene was sequenced from B. innocens strain B256
T and from 11 
strains of B. hyodysenteriae. The B. hyodysenteriae genes shared 97.9-100% nucleotide 
sequence identity and had 97.5-99.5% identity with the gene of B. innocens strain B256
T. The 
Bhlp29.7 gene was subsequently cloned and expressed as a histidine fusion-protein in an 
Escherichia coli expression system. 
 
An ELISA test using recombinant his-tagged Bhlp29.7 (His6-Bhlp29.7) as the detecting 
antigen was developed and evaluated. The threshold value of the test was chosen to provide a 
highly stringent assessment of the disease status of a herd. The sensitivity and specificity of the 
test was 100%. When the test was applied to sera from eight herds with suspected SD, four   v
gave ELISA values indicating that the herds were diseased. The remaining four herds gave 
ELISA values below the threshold value. These results indicated that the Bhlp29.7-ELISA was 
useful as an indirect test for exposure of a herd to B. hyodysenteriae and may be a helpful 
complement to current methods of SD diagnosis.  
 
Recombinant His6-Bhlp29.7 was evaluated as a vaccine subunit for prevention of SD. The 
His6-Bhlp29.7 was shown to be immunogenic in mice following two intramuscular injections. 
Vaccination of mice with His6-Bhlp29.7 provided full protection after oral challenge with B. 
hyodysenteriae. In two experiments, intramuscular and oral vaccination of pigs with the His6-
Bhlp29.7 resulted in a 50% reduction in incidence of SD compared to unvaccinated control 
pigs (P=0.047). This is the first subunit vaccine shown to provide pigs with protection from 
SD. Further work is needed to optimise delivery routes and adjuvants for commercial 
development of the vaccine.   vi
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CHAPTER 1: LITERATURE REVIEW 
 
1.1. GENERAL INTRODUCTION 
Swine dysentery (SD) is a contagious severe mucohaemorrhagic diarrhoeal disease of pigs which 
primarily occurs in pigs from weaning up to 20 weeks of age, although the disease may also occur 
in breeding herds where it affects sows (Alexander and Taylor, 1969; Meyer, 1978; Achacha and 
Messier, 1991; Harris et al., 1999). Pigs affected by SD show signs of dehydration, emaciation and 
rapid loss of weight. In severe cases, the disease can cause death (Alexander and Taylor, 1969; 
Olson, 1974). SD is potentially one of the most economically significant diseases of pigs and 
occurs in most pig-producing countries, including Australia (Hampson and Trott, 1995; Hampson 
et al., 1997). Economic losses due to SD result mainly from growth retardation, costs of drug 
medication, and mortality (Hampson et al., 1997; Harris et al., 1999). Internationally SD remains a 
major problem, and the worldwide market for an effective solution is substantial. 
 
This chapter provides a review of the current literature relating to aspects of serological detection 
and prevention of SD, with the key emphasis on antigens which have been identified as putative 
immunogens for the development of serological assays and vaccine subunits. The chapter 
concludes with an outline of the main aims and objectives of the project.   2
1.2. AETIOLOGY OF SD 
The causative agent of SD was first identified and characterized in 1971 (Taylor and Alexander, 
1971; Taylor and Blakemore, 1971), and named Treponema hyodysenteriae (Glock and Harris, 
1972; Harris et al., 1972). This anaerobic spirochaete was later transferred to the new genus 
Serpula (Stanton et al., 1991), then to Serpulina (Stanton, 1992), and now has been reassigned to 
the genus Brachyspira as Brachyspira hyodysenteriae based on results of 16S rRNA gene 
sequence analysis (Ochiai et al., 1997). B. hyodysenteriae is a Gram-negative, anaerobic, loosely 
coiled, β-haemolytic spirochaete. It is six to 11 μm long and 0.32 to 0.38 μm in diameter. The 
organism consists of a helical protoplasmic cylinder enveloped by a loose outer membrane (Fig. 
1.1). It possesses seven to 14 periplasmic flagella which are inserted sub-terminally in two rows at 
the ends and overlap at the centre of the protoplastic cylinder (Harris et al., 1972; Meyer, 1978; 
Blaha and Gunther, 1985; Lee et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
  Figure 1.1. Transmission electron micrograph of B78
T, the type strain of B. hyodysenteriae, 
showing eight periplasmic flagella at each cell end, and the blunt ends of the cell.   3
B. hyodysenteriae is an actively motile bacterium which displays the ability to move through semi-
solid and liquid media. The most commonly used liquid medium for propogation is comprised of 
Trypticase Soy Broth (TSB) supplemented with 10% (v/v) foetal bovine serum, whilst the most 
commonly used solid medium is Trypticase Soy Agar (TSA) supplemented with 5% (v/v) sheep 
blood. B. hyodysenteriae also requires both cholesterol and a phospholipid for growth. Cells grow 
more rapidly at 42°C than at 37°C, although they do not grow at temperatures between 25°C and 
30°C. The presence of strong β-haemolysis around the growth on agar plates containing blood is 
characteristic of B. hyodysenteriae (Kinyon and Harris, 1974; Lemcke et al., 1979; Kunkle et al., 
1986; Stanton, 1987). The other four Brachyspira species that colonise the pig are all weakly 
haemolytic (Table 1.1). 
 
1.3. CLINICAL SIGNS 
The most consistent indication of SD is diarrhoea, although the severity of the clinical signs may 
vary considerably. The first evidence of disease in most animals is the passage of soft, yellow to 
grey faeces (Meyer, 1978). Reduced appetite and increased rectal temperature may also be evident 
in some animals. More severely affected animals are anorexic and depressed. In the subsequent 
stages of the disease, large amounts of mucus and flecks of blood can be seen in the faeces. As the 
diarrhoea progresses, the faeces becomes dark and watery containing mucus, blood and white 
microfibrinous exudate. The hindquarters of affected animals are often wet and stained with faecal 
discharge. Affected pigs generally appear gaunt with arched backs, protruding ribs and have a 
rough hairy coat. Prolonged diarrhoea usually leads to dehydration, weight loss, weakness, 
incoordination, emaciation and eventually death. The cause of death in most pigs is usually 
associated with dehydration, acidosis, hyperkalaemia and toxaemia (Harris et al., 1999). 
   4
Table 1.1. Biochemical properties used to differentiate between the Brachyspira species which colonise pigs.  
 
  Enzyme activity*  Utilisation of sugars   
Species Haemolysis  Indole  Hippurate 
Flagella 
per cell 
α-glucosidase  α-galactosidase  β-glucosidase D-Ribose L-Fructose D-cellulose 
MLEE 
grouping 
Mol% 
G + C 
content 
B. hyodysenteriae  S +
†  -  22 - 28  +/-  -  +  -  -  -  I  25.8 
B. intermedia  W  +  -  24 - 28  +  -  +  -  +  -  II  25 
B. innocens  W  -  -  20 - 26  +/-  -  +  -  +  +  III  25.6 
B. murdochii  W  -  -  22 - 26  -  -  +  -  +  +  V  27 
B. pilosicoli  W  - (v)  +  8 - 12  +/-  +/-  -  +  +  +  VI  24.9 
 
Table based on those of Stanton et al., (1991, 1996, 1997, 1998), with information from Hovind-Hougen et al., (1982), Trott et al., (1996), Ochiai et al. 
(1997) and Kraaz et al., (2000). 
Key: S – strong, W – weak, v – variable, + – positive, - – negative, +/- – strains can be positive or negative. 
† indole negative strains have been described (Hommez et al., 1998; Fellström  et al., 1999). 
MLEE, multilocus enzyme electrophoresis 
ND, not determined 
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1.4. PATHOGENICITY 
SD is associated with the proliferation of B. hyodysenteriae in the lumen of the large intestine and 
invasion of the colonic crypts (Kinyon and Harris, 1979). SD is initiated after susceptible pigs 
ingest dysenteric faeces containing B. hyodysenteriae. An inoculum of 10
5 colony forming units 
(cfu) is usually sufficient to cause SD (Kinyon and Harris, 1979). The spirochaetes survive 
passage through the acidic environment of the stomach, presumably protected in faeces, and 
eventually arrive in the large intestine. The ability of B. hyodysenteriae to colonise is influenced 
by factors in the local environment, particularly those associated with the diet and the resident 
microflora (Hampson et al., 2006a). B. hyodysenteriae may have a selective advantage in 
colonising the colon since it can utilise substrate amounts of oxygen, and its ability to dispose of 
NADH in several ways also contributes to its increased metabolic efficiency (Stanton, 1989). B. 
hyodysenteriae is motile due to the action of the periplasmic flagella, which allows the spirochaete 
to move efficiently through viscous material such as mucus to gain access to the epithelial cells in 
the colon. The motility of the spirochaete is essential for its virulence (Rosey et al., 1995; Rosey et 
al., 1996). In vitro studies have shown that B. hyodysenteriae elicits a chemotactic response to 
mucus (Lysons et al., 1984; Kennedy et al., 1988), and it is proposed that the chemotactic 
response together with strong motility, enables the spirochaetes to penetrate the mucus layer and 
invade the colonic crypts. Strains apparently lacking this strong chemotactic response are thought 
to be less virulent (Milner and Sellwood, 1994). At the colonic crypts, the presence of the 
spirochaete stimulates an outpouring of mucus into the lumen. Clinical signs and lesions begin to 
develop as B. hyodysenteriae numbers reach 10
6 cfu per cm
2 of mucosa (Hughes et al., 1977; 
Whipp et al., 1979). At this time, there is a shift in the microflora composition in the colon from 
predominantly Gram positive in healthy animals to predominantly Gram negative in pigs with 
dysentery (Pohlenz et al., 1984). 
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At the lumen, motile B. hyodysenteriae cells enter goblet cells in the colonic crypts and penetrate 
intracellular gaps in the epithelium (Sueyoshi and Adachi, 1990). There is an associated loss of 
cohesion between colonic enterocytes subsequently resulting in necrosis and shedding of the 
epithelium. The spirochaetes attach to the luminal surface and enter the disrupted epithelial cells. 
Some spirochaetes may also be seen in the lamina propria, particularly around blood vessels. 
Bleeding occurs from small blood vessels located under eroded areas of epithelium. Although 
typical lesions have been associated with the presence of B. hyodysenteriae in the cytoplasm of 
epithelial cells and within the lamina propria of the colonic tissue, invasion may not be essential 
for lesion production (Glock et al., 1974; Albassam et al., 1985). In vitro attachment of B. 
hyodysenteriae to intestinal cell lines also indicated that attachment of the spirochaete did not 
necessarily cause cytopathological changes or invasion of the infected cells. The frequency of 
attachment in these systems was also dependent on the viability of the organism (Knoop et al., 
1979; Wilcock and Olander, 1979; Bowden et al., 1989). It has not been clearly demonstrated 
whether attachment is a significant feature in the disease. 
 
The mechanisms responsible for the enterocyte disruption and subsequent necrosis, which are 
central characteristics of SD, have not been fully elucidated. Two possible toxic components 
which may contribute to lesion production have been described and characterised. These include: 
1) the endotoxic effect of the spirochaete’s lipopolysaccharide (LPS) (Baum and Joens, 1979a; 
Nuessen et al., 1982; Nuessen et al., 1983), and 2) the cytotoxic effects of the haemolysin(s) 
secreted by B. hyodysenteriae (Kinyon and Harris, 1979; Knoop, 1981; Kent et al., 1988; ter 
Huurne et al., 1993). 
 
B. hyodysenteriae does not invade beyond the lamina propria of the large intestine and the lack of 
significant lesions and/or the presence of the spirochaete in other organs suggest that the enteric 
lesions directly characterise the entire pathogenesis of SD (Glock et al., 1974). Diarrhoea and the   7
presence of mucus and blood in the faeces is a consequence of colonic malabsorption and erosive 
colitis. The colonic malabsorption, and subsequently fluid loss, is caused by the failure of the 
epithelial transport system to actively transport sodium and chloride from the lumen to the blood 
(Argenzio et al., 1980; Schmall et al., 1983). As much as 30-50% of the daily extracellular fluid 
volume of a pig is presented to the colon for absorption in the form of exogenous secretions, and 
failure to reabsorb these exogenous secretions exclusively results in fluid losses by the animal. 
Therefore, colonic malabsorption alone is sufficient to account for the progressive dehydration and 
death associated with the disease. 
 
1.5. PATHOLOGICAL CHANGES 
1.5.1. Macroscopic lesions 
A consistent characteristic of SD is the presence of lesions in the large intestine but not the small 
intestine. Colitis and typhlitis are the main gross findings. There is a characteristic catarrhal 
inflammation and superficial necrosis of the mucosa of the colon and caecum. In the acute stages, 
hyperaemia and oedema of the walls and mesentery of the large intestine are typical changes. The 
inflammation may also induce congestion of the mesenteric lymph nodes and the formation of 
small amounts of clear ascites as well as a rugose appearance of the colon covered with mucus, 
blood and fibrin. The contents of the colon are soft and watery. As the disease advances, the 
mucosal surface becomes reddened with a granular appearance, and fibronecrotic diphtheritic 
membranes develop (Fig. 1.2). As the lesions become more chronic, strands of fibrin become 
visible on the surface of the colonic mucosa giving the appearance of superficial necrosis. Large 
numbers of B. hyodysenteriae can be detected on the mucosal surface of these lesions (Hughes et 
al., 1977; Griffin and Hutchings, 1980; Harris et al., 1999).  
   8
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2. Microscopic lesions 
In the acute stage of SD, vascular congestion, together with accumulation of fluids and leucocytes 
results in the obvious thickening of the colonic mucosa. Hyperplasia and swelling of the goblet 
cells lead to the production of a thick column of mucus. Epithelial cells at the base of the crypts 
may become elongated and hyperchromic. An accumulation of neutrophils is commonly observed 
in and surrounding capillaries near the lumen, and this increases as necrosis occurs. Focal areas of 
haemorrhage occur in the superficial lamina propria resulting in the exposure of capillaries and a 
typical blood-flecked appearance of the colonic contents. Later changes consist of the 
accumulation of large amounts of fibrin, mucus and cellular debris in the mucosal crypts and on 
the luminal surface of the large intestine. Increased numbers of neutrophils may also be observed 
in the lamina propria. Chronic changes include milder hyperaemia and oedema, although these 
changes are not specific. Superficial necrosis may be extensive but deep ulceration is not typical, 
unless there are secondary infections with Salmonella spp.. Advance superficial necrosis of the 
Figure 1.2. Macroscopic lesions of the large intestine of a pig suffering SD.   9
mucosa often occurs, and usually is covered by a thick and fibrinous pseudomembrane. In all 
stages of the disease, B. hyodysenteriae cells are found in the lumen and within the crypts, 
although large numbers are only found in the acute stages (Hughes et al., 1977; Harris et al., 
1999). 
 
1.6. IMMUNITY 
1.6.1. Humoral immunity  
Studies of immune mechanisms in SD have concentrated on antibody mediated immunity, and 
these have shown that there is no direct relationship between serum antibody titres and protection 
against SD. A proportion of pigs that have recovered from SD, naturally or after medication, will 
be protected from subsequent challenge for up to 17 weeks after the initial exposure (Joens and 
Glock, 1979). Joens et al. (1979) used a microtitration agglutination test (MAT) to investigate the 
serological status of 29 pigs that had been challenged with B. hyodysenteriae and then allowed to 
recover. Circulating antibodies against B. hyodysenteriae from recovered pigs were observed for 
only approximately eight weeks after inoculation. Thirteen of the 29 pigs developed diarrhoea 
when re-exposed to the organisms after one to 28 days, however only two suffered from clinical 
dysentery. Elevated antibody titres also have been demonstrated in infected and convalescent pigs 
by other workers, but again there was no clear relationship between the magnitude of titres, degree 
of protection, and frequency or duration of faecal shedding of B. hyodysenteriae (Fisher and 
Olander, 1981; Fernie et al., 1983). 
 
Experiments in which mouse peritoneal cells were used to phagocytose B. hyodysenteriae showed 
that opsonisation with antibody was an important event in the process. The opsonising antibody 
worked best if it had been raised against the same serotype of B. hyodysenteriae, although some 
effects were seen with heterologous serotype antisera (Nuessen and Joens, 1982). These serotype-
specific antigens are thought to be largely lipopolysaccharide (LPS) in nature (Baum and Joens,   10
1979b). Pigs vaccinated with formalinised bacterins also have shown serotype specificity in their 
host defence mechanisms, although some cross-protection between serotypes does occur (Parizek 
et al., 1985).  
 
Joens  et al. (1983) further demonstrated the serotype-specific nature of protective immunity 
against SD in the colon using colonic loops prepared in pigs. Pigs were infected with one or other 
strains of different serotypes of B. hyodysenteriae and allowed to recover. A series of surgically-
prepared ligated colonic loops were then inoculated either with homologous serotype strains or 
with other heterologous serotype strains. Generally, lesions developed in the loops inoculated with 
heterologous serotypes, but not in the loops inoculated with homologous serotypes. A limited 
amount of cross-protection between serotypes was observed in some loops, but overall immunity 
appeared to be largely serotype specific, and therefore probably directed against LPS antigens. It is 
uncommon for herds to be infected with more than one strain of B. hyodysenteriae, so that 
serotype-specific immunity is unlikely to be important in preventing a given strain proliferating 
whilst allowing another of a different serotype to establish itself (Combs et al., 1992). 
 
Ligated colonic loops prepared in pigs have also been used to demonstrate passive protection 
against SD (Joens et al., 1985). When immune serum, containing complement components, and 
the homologous strains of B. hyodysenteriae were inoculated into colonic loops, 83% (ten of 12 
loops) were protected from developing lesions of SD. Of these 12 loops, protection was obtained 
in 72% (eight of 11 loops) inoculated with the homologous organism and antiserum that had been 
heat-inactivated to remove complement components, whilst only 23% (three of 13 loops) 
inoculated with heat-inactivated antiserum and heterologous isolates were protected. This suggests 
that complement components and serum IgG secreted into the colon may contribute to the 
protection seen in convalescent pigs. 
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Antibodies directed against LPS have been found in sera and colonic secretions of convalescent 
pigs using enzyme-linked immunosorbent assays and immunoblotting (Egan et al., 1983; 
Wannemuehler et al., 1988; Wannemuehler and Galvin, 1994). Following infection, an increase in 
B. hyodysenteriae-specific circulating and local antibodies can be detected. High levels of 
circulating IgG in the serum tend to be correlated with the duration of clinical signs rather than 
with the degree of protection against SD, whilst secretory IgA levels in the colons, faeces and bile 
indicate recent exposure to B. hyodysenteriae (Rees et al., 1989). In one study, a production peak 
of coproantibody (predominantly IgA, with IgG and IgM) was detected in the colon prior to the 
production of circulating antibody (Jenkins and Roberts, 1980). This suggested that methods 
which stimulate mucosal immunity may be a good means to induce protection against SD. 
 
1.6.2. Cell-mediated immunity 
Cell mediated immunity also may be important in SD since there is evidence for inhibition of 
peripheral blood leukocyte migration, a delayed hypersensitivity response, and a T-cell 
proliferative response in the peripheral blood of pigs convalescent from SD (Jenkins et al., 1982; 
Kennedy et al., 1992; Waters et al., 1999a; Waters et al., 1999b). In mouse models of the disease, 
however, there are no significant changes in T-cell subsets in the lamina propria, and changes 
observed in local mast cell population numbers were not correlated with development of lesions 
following infection (Nibbelink and Wannemuehler, 1992).  
 
It has been well established that CD4
+ T-cells are involved in the induction of inflammatory bowel 
diseases (Cong et al., 2000; Strober et al., 2002). Inflammatory bowel diseases may result from 
deficient regulation of CD4
+ T-cell responses to antigens from normal large intestinal microflora 
resulting in a consequent cytokine imbalance (Cong et al., 2000; Annacker and Powrie, 2002; 
Kullberg et al., 2003). During SD, CD4
+ and γδ T-cells in the peripheral blood and colonic lymph 
nodes of intramuscularly immunised pigs have been shown to proliferate to B. hyodysenteriae   12
antigens ex vivo. These circulating CD4
+ T-cells secrete interferon-γ (INF-γ) upon stimulation with 
B. hyodysenteriae antigens during the infection, and this response was down-regulated by 
exogenous interleukin-10 (IL-10) post-infection. In addition, INF-γ expression in the colonic 
lymph nodes of SD pigs was up-regulated (Waters et al., 1999a; Waters et al., 1999b; Hontecillas 
et al., 2002; Hontecillas and Bassaganya-Riera, 2003). These results suggested that a predominant 
T helper type 1 response was established during B. hyodysenteriae-induced colitis, contributing to 
the overall inflammation and necrosis of the colon.  
 
Recently, Jonasson et al. (2004) investigated levels of circulating leukocytes and lymphocyte 
subpopulations in pigs before and after experimentally induced SD. By comparing results from 
pigs that did or did not succumb to disease, the authors deduced that γδ T-cells and CD8+ cells 
may be associated with susceptibility to infection, whilst monocytes and CD4+ CD8+ T-cells 
appeared to be the major responding lymphocytes to infection. More recently, a report showed that 
ex vivo γδ T-cell responses to B. hyodysenteriae antigens were not different between control pigs 
and pigs experimentally challenged with B. hyodysenteriae (Hontecillas et al., 2005). In addition, 
γδ T-cells of infected pigs were significantly depleted from the epithelial layer, although their 
numbers in the lamina propria maintained unaltered. No differences were found in the numbers of 
circulating and colonic lymph node γδ T-cells between control and dysenteric pigs. Most recently, 
Jonasson  et al. (2006) showed that following experimental infection of pigs with B. 
hyodysenteriae, increased levels of circulating monocytes, neutrophils and CD8α+ cells correlated 
with the development of clinical SD. During the recovery period, γδ T cells were found to increase 
and high levels of circulating neutrophils were also observed. Pigs with SD showed decreased 
levels of CD21+ cells in the blood during disease and recovery, but developed B. hyodysenteriae-
specific antibodies from the first day of recovery. Taken together, these results indicate that   13
infection with B. hyodysenteriae induces a mucosal T-cell response and points to these responses 
being important contributors to the immunopathogenesis of SD. 
 
Although it has been suggested that both the peripheral and mucosal T-cell response of the host 
contributes to the development of lesions associated with B. hyodysenteriae-induced colitis, the 
implication of these responses to the development of more effective vaccines still remains unclear. 
Further dissection of the nature of the mucosal T-cell response during SD would be beneficial.  
 
1.7. DIAGNOSIS 
SD is a relatively common disease which occurs in all major pig-producing countries (Roncalli 
and Leaning, 1976; Hampson and Trott, 1995; Hampson et al., 1997; Harris et al., 1999). When 
SD first enters a herd, exposure of the pigs to low infectious doses initially results in disease in 
only one or two pigs. As infectious faeces accumulate, the disease continues to spread to the 
remaining members of the herd. The rate of spread depends on the type of contact with the 
infected material. Once the infection becomes endemic within a piggery, the disease spectrum can 
vary from being mild, transient or unapparent, to severe and even fatal. Medication strategies on 
individual piggeries may mask clinical signs. Whether or not obvious disease is present, B. 
hyodysenteriae may persist in infected pigs, or in other reservoir hosts such as mice, or the 
environment. All these sources pose potential for transmission of the disease between herds 
(Hampson and Trott, 1995; Hampson et al., 1997; Harris et al., 1999). 
 
1.7.1. Conventional methods 
Various methods for the diagnosis of SD have been used over the years. In the first instance, 
observation of the clinical signs of the disease, including the presence of bloody and/or mucus-
containing diarrhoea, are commonly suggestive indications (Harris et al., 1999). Similar clinical 
signs however may also be seen in salmonellosis, swine fever and intestinal spirochaetosis   14
(Hampson et al., 1997). A definitive diagnosis of SD still involves the isolation and identification 
of B. hyodysenteriae from the faeces or mucosa of the diseased pigs (Jensen, 1997; Harris et al., 
1999). Major problems involved in achieving this include the slow growth and fastidious 
nutritional requirements of the bacteria, and confusion due to the presence of morphologically 
similar spirochaetes in the normal flora of the pig intestine (Hudson et al., 1976a; Joens and 
Harris, 1980). Fortunately, these other species are weakly β-haemolytic (Fig. 1.3). Biochemical 
reactions of B. hyodysenteriae, and comparison with those of other porcine Brachyspira species 
are shown in Table 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  A 
Figure 1.3. Demonstration of strong β-haemolysis produced by B. hyodysenteriae type strain 
B78
T (A), and weak β-haemolysis produced by B. innocens type strain B256
T (B) on a blood 
agar plate. Taken from Hampson et al., 2006a.   15
1.7.2. Molecular biological methods 
Significant improvements in diagnosis of SD in individual pigs were achieved with the 
development of specific and sensitive nucleic acid-based assays, such as DNA probes (Jensen et 
al., 1990; Sotiropoulos et al., 1993; Harel and Forget, 1995) and polymerase chain reaction (PCR) 
assays (Elder et al., 1994; Harel and Forget, 1995; Leser et al., 1997; Atyeo et al., 1998; Atyeo et 
al., 1999; La et al., 2003; La et al., 2005) for the detection of spirochaetes in faeces. It has been 
suggested that PCR can detect as few as 10 spirochaete cells per gram of faeces, however in 
practical applications the limit of detection of PCR consistently has been reported to be in the 
range of 10
3-10
4 cells per gram of faeces. Although PCR can be a sensitive and rapid method for 
detection of B. hyodysenteriae, it requires the availability of a diagnostic laboratory with 
specialised equipment. The inability of PCR to detect low numbers of cells present in the faeces 
also limits its application for the detection of carrier animals with subclinical infections. 
 
1.7.3. Serological methods 
Generally there is little difficulty in isolating and identifying B. hyodysenteriae in pigs with 
clinical SD. The main difficulty comes in detecting herds with subclinical infections, and 
individual healthy carrier animals which may be introduced into uninfected herds. As a 
consequence, there is a clear need to develop an effective diagnostic tool capable of detecting B. 
hyodysenteriae infection at the herd and individual pig level. Colonisation by B. hyodysenteriae 
elicits a strong immunological response against the spirochaete, hence indirect evidence of 
exposure to B. hyodysenteriae can be obtained by measuring circulating antibody titres in the 
blood of infected animals. These antibody titres have been reported to be maintained at low levels, 
even in animals that have recovered from SD (Joens et al., 1979; Fisher and Olander, 1981; Joens 
et al., 1982). Serological tests therefore have considerable potential for detecting recovered carrier 
pigs that may otherwise have undetectable numbers of spirochaetes in their large intestines.   16
A number of techniques have been developed to demonstrate the presence of circulating antibodies 
directed against B. hyodysenteriae. These have included indirect fluorescent antibody tests (IFAT), 
haemagglutination tests (HAT), microtitration agglutination tests (MAT), complement fixation 
tests (CFT) and enzyme linked immunosorbent assays (ELISA) using either lipopolysaccharide 
(LPS) or whole sonicated spirochaetes as antigen. All these tests can be useful for detecting 
infected herds, but they are less useful at identifying individual infected pigs. To date, no 
completely sensitive and specific assays are available for the detection of antibodies against B. 
hyodysenteriae in infected pigs.  
 
1.7.3.1. Indirect fluorescent antibody test (IFAT) 
Lee and Olson (1976) examined sera from 119 pigs that were exposed to B. hyodysenteriae, and 
then medicated with various drugs. They used an indirect fluorescent antibody test (IFAT) to 
detect serum antibodies generated against B. hyodysenteriae in these treated pigs and compared the 
results with those for 20 non-medicated pigs that had recovered naturally. Fluorescence was 
observed when the sera from 18 of the 20 non-medicated pigs were used, but none of the sera from 
the medicated pigs reacted at high titre. The more efficacious drugs apparently reduced the 
severity of the disease and resulted in the production of lower titres, which were still detectable in 
this simple assay. The specificity of the reaction for B. hyodysenteriae was not investigated. 
 
1.7.3.2. Haemagglutination test (HAT) 
Using sera from pigs experimentally infected with B. hyodysenteriae, Jenkins et al. (1976) were 
able to detect antibody against B. hyodysenteriae in a haemagglutination (passive haemolysis) test 
as early as one week after infection. Peak titres occurred six weeks after infection. In this test red 
blood cells were coated with guinea pig complement. Absorption of immune sera with 5% (v/v) 
sheep red blood cells reduced the haemolytic titres, indicating that some of the haemolysis of 
unabsorbed sera was probably due to heterogeneous antibodies. When hyperimmune sera were   17
absorbed with organisms such as Escherichia coli and Salmonella spp. there was no effect on the 
resultant titre. It was therefore suggested that the haemagglutination test could be a useful 
diagnostic tool as it was rapid to perform, required minute quantities of reagents and was highly 
sensitive. However, the macroscopic scale of the reactions (two millilitre final volume) would 
limit the number of samples which could be processed at one time. A small-scale variation of the 
assay in microtitre plates may overcome this problem. The specificity of this assay requires testing 
using sera from healthy pigs from a range of herds. 
 
1.7.3.3. Complement fixation test (CFT) 
Adachi et al. (1979) compared the specificity of agglutinating and complement fixing antigens for 
the detection of antibody to B. hyodysenteriae. They found that agglutination reactions differed 
between strains. In contrast the complement fixation test showed reactions with all strains, 
although these were slightly weaker with heterogeneous strains than with the homologous strain. 
Furthermore, agglutination tests had the advantage of being about two to eight fold more sensitive 
than the CFT at detecting antibody against B. hyodysenteriae. The CFT for SD has not been 
developed further. 
 
1.7.3.4. Microtitration agglutination test (MAT) 
Joens et al. (1978; 1980) developed a microtitration agglutination test to detect serum antibody to 
surface antigens of B. hyodysenteriae. This test was used to detect antibodies against B. 
hyodysenteriae in experimentally infected pigs, and was shown to have a high sensitivity and 
repeatability. Peak agglutinating titres occurred three to four weeks after the pigs were 
experimentally challenged with the organism. Only low cross-reacting antibody titres were 
produced against isolates of Brachyspira innocens, a non-pathogenic commensal spirochaete that 
commonly colonises pigs, thus suggesting that the test was specific. The inactivated whole 
bacterial antigen used in this test remained stable for up to ten days.   18
 
Diarra et al. (1994; 1995) evaluated the usefulness of MAT, HAT and haemolysis for the detection 
of antibody against B. hyodysenteriae in pig sera. They concluded that a boiled cell suspension 
used as antigen in MAT was reliable for the diagnosis of SD on a herd basis. They also found that 
upon boiling the antigen, cross-reactions between B. hyodysenteriae and B. innocens were 
significantly reduced. Although this test appeared to be reasonably specific and sensitive, it lacked 
standardization to allow its use for routine diagnosis. The antigen used consisted of a complex 
mixture of inactivated whole bacteria, which would differ in composition depending on the culture 
conditions used. An incubation time of 18 to 36 hours was required, making this test rather slow 
for diagnostic testing. In general, pigs usually develop circulating antibody titres to B. 
hyodysenteriae from one to two weeks after inoculation (Joens et al., 1979; Joens et al., 1982). 
MAT detected agglutinating antibody titres three to four weeks post-inoculation, suggesting that 
this test did not have sufficient sensitivity for detecting pigs with low titres of antibody. An 
overlying disadvantage of the MAT is that it can only be used to measure total antibody produced 
against the spirochaete, thus subjecting it to variations depending on the strain of B. 
hyodysenteriae the pig was infected with.  
 
1.7.3.5. Enzyme-linked immunosorbent assay (ELISA) with LPS as antigen 
An enzyme-linked immunosorbent assay (ELISA) using LPS extracted by the hot phenol-water 
method as a plate coating antigen has been used for the detection of antibody against B. 
hyodysenteriae infection in swine (Joens et al., 1982). Infected pigs were detected within one to 
two weeks post-inoculation, and circulating antibody could be demonstrated in convalescent pigs 
for as long as 19 weeks post-inoculation. Egan et al. (1983) compared the accuracy and sensitivity 
of MAT and ELISA and concluded that the ELISA was more useful, but it still was not suitable 
for detection of individual infected pigs because false-positive and false-negative results occurred. 
B. hyodysenteriae isolates have been divided into nine or more serogroups based on their LPS   19
components and cross-reactivities with absorbed antisera (Lau and Hampson, 1992; Hampson et 
al., 1997). Knowing this, it is expected that no one extract of LPS can be used as a general antigen 
in the ELISA. Each serum must be tested with a range of different LPS antigen standards because 
of the serotype specificity of the LPS (Egan et al., 1983). Therefore, knowledge of the serogroups 
of the B. hyodysenteriae present in an area is necessary so that appropriate LPS extracts can be 
used (Mhoma et al., 1992). Even then, false-negative reactions may arise from infections with 
members of new or undetermined serogroups. It is known that common LPS reactivities exist 
within serogroups (Wannemuehler et al., 1988; Lau and Hampson, 1992), however, there is no 
evidence showing common LPS reactivities across serogroups. For field conditions, the LPS- 
ELISA appears to be a robust tool for analysis of multiple samples and can be completed with 
reasonably short incubation times. However, without a suitable general antigen specific for B. 
hyodysenteriae, this form of ELISA remains problematic for general use. 
 
1.7.3.6. Enzyme linked immunosorbent assay (ELISA) with sonicated bacteria as antigen 
SD has been detected in herds by the use of an ELISA in which serum antibodies are measured 
using whole sonicated cells of B. hyodysenteriae that are used to coat the wells of the ELISA plate 
(Wright et al., 1989; Smith et al., 1991). This form of ELISA appears to be sensitive enough to 
detect the majority of infected herds. When tested at a herd level, it correctly identified 90% of 
individually infected pigs (Wright et al., 1989). Occasionally, however, it can give false negative 
results, but its most serious limitation is that it can give non-specific cross-reactivity (Burrows et 
al., 1984; Wright et al., 1989). However, the specificity and sensitivity of this form of ELISA for 
detection of antibody to B. hyodysenteriae in pigs can be improved when coupled with 
immunoblotting against outer envelope extracts of B. hyodysenteriae (Smith et al., 1991). The use 
of sonicated spirochaetes in ELISA may be a useful tool for screening herds, however due to the 
many cross-reactivities between B. hyodysenteriae and other related spirochaetes, it still cannot be 
used as a definitive test for SD. Even when coupled with immunoblotting, the possibility of cross-  20
reactivity still exists. The increased complexity of the overall technique also makes this less 
suitable for applications in the field, and it does not appear to have been developed further. 
 
1.8. CONTROL AND PREVENTION 
A number of methods are employed to control SD, varying from the prophylactic/therapeutic use 
of antimicrobial agents, to complete de-stocking of infected herds. The on-going use of 
antimicrobial agents in commercial piggeries is coming under increasing public pressure, and 
resistance to the agents is developing. On the other hand, de-stocking is an extremely expensive 
option, and is not always successful in eradicating the disease. As a result, there is a growing 
worldwide demand for the development of an effective vaccine for the preventative control of SD. 
The following section reviews the common methods currently employed for control of SD in 
piggeries, with greater emphasis placed on vaccination. 
 
1.8.1. Antimicrobial drugs 
Control of SD in endemically diseased herds generally involves the use of prophylactic 
antimicrobials, usually provided in the feed (Harris et al., 1999). Those that have been successfully 
employed to control the disease include tiamulin, ronidazole, carbadox, lincomycin, dimetridazole, 
tylosin and valnemulin (Rainier et al., 1980; Burch, 1982; Olson, 1986; Wood and Lysons, 1988; 
Smith et al., 1990; Buller and Hampson, 1994; Dalziel, 1996; Fellstrom et al., 1996; Molnar, 
1996; Hayashi et al., 1997; Karlsson et al., 2001; Karlsson et al., 2002; Karlsson et al., 2003; 
Rohde et al., 2004). With the use of prophylactic drugs the incidence and severity of SD may be 
reduced. A disadvantage of this approach is that immunity may not develop and although the 
animals look healthy, subclinical infection may occur in the herd resulting in outbreaks after the 
withdrawal of the chemotherapeuticals (Harris et al., 1999). Furthermore, antibiotic resistance in 
medicated herds appears to be becoming more common (Blaha et al., 1987; Buller and Hampson, 
1994; Molnar, 1996; Gresham et al., 1998; Karlsson et al., 1999; Karlsson et al., 2001; Karlsson et   21
al., 2002; Karlsson et al., 2004a; Karlsson et al., 2004b; Lobova et al., 2004; Pringle et al., 2004; 
Rohde et al., 2004) and concerns are growing about the use of certain of these drugs in food 
animals, particularly in relation to the possible presence of drug residues in meat. Strict hygiene 
also needs to be maintained in medicated herds to reduce the level of challenge, and to prevent the 
entry of other strains of B. hyodysenteriae into the piggery, as these may have different patterns of 
drug resistance or degree of virulence (Robertson et al., 1992). 
 
1.8.2. Eradication 
Ideally the best long-term approach to the control of SD is to eliminate B. hyodysenteriae from 
infected herds. This can be achieved by partial destocking followed by the use of prophylactic 
drugs at therapeutic levels of medication on all animals in the herd. Unfortunately this may not be 
successful since there are likely to be reservoirs of infection, such as waste lagoons or infected 
rodents on the property serving as a source of later outbreaks (Songer et al., 1978; Olson, 1992). 
Eradication of SD from herds is most successfully achieved by complete or partial depopulation of 
stock in combination with strict hygiene and medication procedures (Janc et al., 1982). This is 
difficult to carry out in large herds, but has frequently been used to eliminate chronic SD 
(Muirhead, 1987; Harris et al., 1999). In the full depopulation method, all pigs are removed from 
the premises for periods of up to eight weeks and the environment is thoroughly cleaned, after 
which repopulation with new stock from a high health status herd may be carried out. This 
removes potential sources of infection and reduces the likelihood of re-entry of the disease. 
 
1.8.3. Vaccination 
A proportion of pigs which have recovered from acute SD are protected from disease when 
subsequently re-exposed to B. hyodysenteriae (Joens et al., 1979), thus indicating that the infection 
can induce a protective immune response. Despite this, numerous attempts to develop vaccines to 
control SD have met with limited success, either because they have provided inadequate protection   22
on a herd basis, or they have been too costly and difficult to produce to make them commercially 
viable (Galvin et al., 1997). Bacterin vaccines provide some level of protection (Fernie et al., 
1983; Parizek et al., 1985; Hampson et al., 1993; Diego et al., 1995; Waters et al., 1999a; Waters 
et al., 1999b), but they tend to be LPS serogroup-specific, which then requires the use of 
multivalent bacterins. Furthermore, they are difficult and costly to produce on a large scale 
because of the fastidious anaerobic growth requirements of the spirochaete. One study even 
reported that immunisation with a B. hyodysenteriae bacterin exacerbated dysentery (Olson et al., 
1994). Several attempts have been made to develop attenuated live vaccines for SD, including 
laboratory passaged strains (Hudson et al., 1974; Lysons et al., 1987), and specific inactivation of 
genes encoding haemolysin (Hyatt et al., 1994), flagella components (Rosey et al., 1996; Kennedy 
et al., 1997) or NADH oxidase (Stanton et al., 1999). This approach has the disadvantage that 
attenuated strains show reduced colonisation, and hence cause reduced immune stimulation. There 
also is reluctance on the part of producers and veterinarians to use live vaccines for SD because of 
the possibility of reversion to virulence - especially as very little is known about genetic regulation 
and organization in B. hyodysenteriae.  
 
Until recently, one vaccine for SD was commercially available in the USA. This vaccine was 
based on a proteinase digest of the B. hyodysenteriae whole cells and was formulated for serotypes 
1 and 2 (the main types present in the USA) (Waters et al., 1999b). The vaccine provided only 
partial protection, although pigs showing clinical signs usually had mild diarrhoea and continued 
to gain weight. The vaccination was unable to provide sterilising immunity since protected pigs 
still continued to shed the spirochaete. The immunity did not appear to be mediated by the LPS 
content of the vaccine as pigs vaccinated with purified LPS were not protected despite their sero-
conversion.  Although the immunological role of LPS remains unclear, it must still be important 
since challenge of vaccinated pigs with heterologous strains does not result in the same level of 
protection (Hampson et al., 2006a).   23
 
The use of recombinant subunit vaccines is an attractive alternative to other methods, since the 
products would be well-defined (highly advantageous for registration purposes), and relatively 
easy to produce on a large scale. A number of attempts have been made to identify surface 
exposed proteins from B. hyodysenteriae that could be used as recombinant vaccine components, 
but again no successful vaccine has yet been made. A much more global approach is needed for 
the identification of potentially useful immunogenic recombinant proteins from B. hyodysenteriae. 
Likely targets would reside in the spirochaete outer membrane (i.e. surface exposed lipoproteins 
and transmembrane proteins/porins), as well as secreted proteins involved in the pathogenesis of 
the disease. These proteins are likely to induce an immune response during natural infection, 
although it is possible that other surface proteins that are not expressed during active infection 
could also be used to induce a protective immune response. Several proteins have been 
investigated for their potential efficacy for providing protection in pigs against SD. These proteins 
will be reviewed in more detail in the following sections. 
 
1.8.3.1. Haemolysin 
B. hyodysenteriae produces strong β-haemolysis after four to six days when grown on sheep blood 
agar, whilst non-pathogenic B. innocens produces only weak β-haemolysis (Hudson et al., 1976a; 
Kinyon et al., 1977; Kinyon and Harris, 1979). Many workers have considered that the presence of 
the strong β-haemolytic activity is associated with the pathogenicity of SD (Hughes et al., 1975; 
Lysons et al., 1991; ter Huurne et al., 1993). The haemolysins of many bacterial species, including 
E. coli (van den Bosch et al., 1982), Actinobacillus pleuropneumoniae (Frey and Nicolet, 1988), 
Listeria monocytogenes (Geoffroy et al., 1987) and Leptospira interrogans (del Real et al., 1989) 
have been associated with virulence.  
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A B. hyodysenteriae haemolysin has been purified and injected into ligated ileal and colonic loops 
in germ-free pigs (Lysons et al., 1991). The epithelium of the colon was severely damaged, and 
the changes were similar to those seen in natural cases of SD. The haemolysin therefore was 
considered to be a potent cytotoxin for pig enterocytes and a virulence factor in SD. However, 
after at least 80 subcultures in vitro, a strain of B. hyodysenteriae lost its pathogenicity to pigs but 
retained its haemolytic activity (Hudson et al., 1974). Other factors therefore also are liable to be 
involved in virulence.  
 
Saheb  et al. (1980) characterised a purified B. hyodysenteriae haemolysin as being oxygen-
resistant, proteinase K-sensitive, heat-labile and inactivated over a wide pH range between 2 to 10. 
The haemolysin, with a molecular mass of 74 kDa, was probably a polypeptide or a protein 
associated with lipids and nucleotides. The size of purified haemolysin of B. hyodysenteriae has 
been estimated to be 68 kDa by SDS-PAGE (Knoop, 1981) and 19 kDa (Kent et al., 1988) or 74 
kDa (Saheb et al., 1980; Hyatt et al., 1994) by gel filtration. The conflict over the molecular mass 
may be due to the different methods of extraction and the use of different elution buffers. Equally, 
it was later recognised that B. hyodysenteriae possessed at least three haemolysins (ter Huurne et 
al., 1993; 1994), so there is the possibility that different molecules were being examined. 
 
The gene tly, encoding a B. hyodysenteriae haemolysin, was cloned and sequenced by Muir et al. 
(1992). This gene was present in single copy in all pathogenic serotypes of B. hyodysenteriae 
tested, and was not present in the weakly β-haemolytic non-pathogenic organism B. innocens. The 
recombinant 26.9 kDa protein encoded by the tly gene was EDTA insensitive, thermolabile, 
haemolytic for erythrocytes, and cytotoxic for several eukaryotic cell lines. To elucidate the 
molecular basis of virulence, a tlyA (previously named tly) mutant strain of B. hyodysenteriae was 
constructed by transformation of a disrupted tlyA gene (ter Huurne et al., 1992). The recombinant 
mutant was able to colonise the caecum of mice, but produced fewer caecal lesions than the wild-  25
type B. hyodysenteriae. This virulence test indicated that the tlyA-encoded haemolysin may be an 
important contributor of virulence, in combination with numerous other factors. Hyatt et al. (1994) 
tested the virulence of tlyA mutants in pigs and demonstrated that pigs previously inoculated 
intragastrically with tlyA mutants were partially protected against subsequent challenge with a 
virulent B. hyodysenteriae strain. 
 
Two other genes associated with β-haemolysis, designated tlyB and tlyC, were later identified and 
characterised based on their ability to induce a haemolytic phenotype in E. coli (ter Huurne et al., 
1994). When expressed in E. coli, the tlyB and tlyC genes encoded heat-labile, protease-sensitive 
proteins which exhibit in vitro haemolytic and cytotoxic activity. The calculated molecular 
weights of the tlyB and tlyC gene products were 93.3 kDa and 30.8 kDa, respectively. TlyB was 
similar to other bacterial Clp protease proteins, whereas TlyC showed no homology with other 
protein sequences. Southern hybridization showed that these genes are present as a single copy on 
the chromosome of B. hyodysenteriae. 
 
More recently, a distinct gene (hlyA) has been characterised that encodes an 8.93 kDa polypeptide 
of B. hyodysenteriae which has haemolytic activity (Hsu et al. 2001). Haemolysis-negative E. coli 
strains expressing the HlyA gene was β-haemolytic on blood agar. The recombinant haemolysin 
had identical protease and lipase sensitivities and electrophoretic mobility to those of native B. 
hyodysenteriae  β-haemolysin. It now appears that the tly genes may be regulatory elements 
required for haemolysin production, rather than encoding the haemolysins themselves (Hampson 
et al., 2006a). Nevertheless, the outcomes of the experiments on both the tlyA and hlyA genes 
emphasise the likely role of haemolysin(s) in the virulence of B. hyodysenteriae. 
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1.8.3.2. Flagellar proteins 
The periplasmic flagella of spirochaetal cells are structurally and chemically similar to the external 
flagella of other bacteria (Johnson, 1977; Li et al., 2000). However, unlike other bacterial flagella, 
they are permanently wound around the cell body and are entirely enclosed by the outer sheath 
(Canale-Parola, 1984). The periplasmic flagella consist of three structural components: the 
filament, the hook, and the basal body (Nauman et al., 1969; Holt, 1978; Dettori et al., 1987; 
Charon et al., 1992). 
 
Intestinal spirochaetes possess two wound bundles of periplasmic flagella which are inserted sub-
terminally at each cell end, and extend toward the opposite pole of the cell. The flagella are 
located between the outer membrane and the cytoplasmic cylinder and thus are completely 
contained within the outer envelope (Canale-Parola, 1978; Dettori et al., 1987 ). The periplasmic 
flagella are essential for the typical motility of spirochaetes. The flagella of Treponema, 
Spirochaeta, Borrelia and Brachyspira overlap in the central portion of cells, unlike leptospiral 
flagella (Johnson, 1977; Li et al., 2000). The diameter of periplasmic flagella is approximately 12-
25 nm (Blaha and Gunther, 1985). Most bacterial flagella have only one major flagella protein, but 
the flagella of spirochaetes are complex and contained multiple major proteins (Holt, 1978; 
Cockayne et al., 1987). Miller et al. (1988) purified B. hyodysenteriae periplasmic flagella and 
observed six major bands by SDS-PAGE electrophoresis, with approximate molecular mass of 39, 
29, 27, 22, 21 and 18.5 kDa respectively. All these proteins cross-reacted in immunoblots with 
antiserum raised against B. innocens. 
 
Kent  et al. (1989) demonstrated that purified periplasmic flagella from eight serotypes of B. 
hyodysenteriae and two non-pathogenic intestinal spirochaetes had similar SDS-PAGE profiles, 
with molecular masses of 43.8, 38, 34.8, 32.8 and 29.4 kDa. Five major periplasmic flagella 
polypeptides were identified and these proteins were present in all the other serotypes as well as in   27
non-pathogens. Convalescent serum also showed a strong antibody response to the periplasmic 
flagella polypeptides in an immunoblot assay. This investigation indicated that the periplasmic 
flagella of B. hyodysenteriae are major immunodominant antigens.  
 
Koopman  et al. (1992a) purified and characterised the major components of the periplasmic 
flagella of B. hyodysenteriae strain C5. The periplasmic flagella were composed of two sheath 
proteins (molecular masses 44 and 35 kDa) and three core proteins (37, 34, and 32 kDa). The 44 
kDa sheath protein and the 34 kDa core protein were further characterised by cloning the 
corresponding genes and DNA sequence analysis of these. The 44 kDa sheath protein consisted of 
320 amino acids, and was homologous to the flagella sheath proteins of the spirochaetes T. 
pallidum and S. aurantia, but not to any other flagella proteins (Koopman et al., 1992b). The 34 
kDa core protein consisted of 285 amino acids and had significant similarity with the core 
flagellins of other spirochaetes (Koopman et al., 1993). 
 
Li et al. (1993) reported that a periplasmic flagella sheath protein of molecular mass 44 kDa was 
present in all B. hyodysenteriae reference strains, but absent in B. innocens. In contrast, the flagella 
core proteins of molecular masses 39, 35, 32, 30 and 29 kDa antigenically cross-reacted with the 
periplasmic flagella proteins of B. innocens. Therefore, they suggested that the 44 kDa flagella 
protein was a species-specific antigen of B. hyodysenteriae. The difference in number and 
molecular mass of periplasmic flagella proteins reported by different researchers may be related to 
the different methods used to extract the flagella, and to subsequent electrophoretic analysis. 
 
Boyden et al. (1989) cloned the gene that codes for an B. hyodysenteriae periplasmic flagella 
antigen of molecular mass 25 kDa, and this cloned antigen was used to immunise CF-1 mice. 
Partially purified preparations of the recombinant product were injected intraperitoneally into CF-
1 mice model, and these were protected against oral challenge with both homologous and   28
heterologous serotypes of B. hyodysenteriae. Gabe et al. (1995) cloned a 38 kDa periplasmic 
flagella protein of B. hyodysenteriae into E. coli, and vaccinated pigs with this encoded protein. 
This recombinant protein did not protect the animals from experimental challenge with an 
inoculum of the homologous strain. The incubation period however was shorter in control pigs 
(14.4 ± 4.7 days) than it was in the vaccinated animals (24.0 ±10.7 days). This failure of protection 
is likely to relate specifically to the particular recombinant protein used, as well as to other more 
down-stream issues such as delivery systems and routes, dose rates, and choice of adjuvants used. 
 
Rosey et al. (1996) selectively disrupted the flaA1 and flaB1 genes of B. hyodysenteriae using 
allelic exchange. Western blot analysis indicated that expression of the gene products had been 
successfully abolished. Electron microscopy showed that the dual mutation had not affected the 
ability of the spirochaete to assemble its periplasmic flagella. The virulence of the mutants was 
assessed using a murine model of SD. The dual flaA1 flaB1 mutant of B. hyodysenteriae showed 
severe attenuation compared to the wild-type. This study showed that the FlaA1 and FlaB1 
proteins were dispensable for flagella assembly but critical for normal flagella function and 
subsequently influence the virulence of the spirochaete.  
 
1.8.3.3. Surface-exposed proteins 
The outer surface of B. hyodysenteriae can be extracted using procedures based on its solubility in 
detergent and the gravitational fractionation of proteins in a density gradient. Using the appropriate 
characterised markers, proteins associated with the outer and inner membranes can then be 
identified (Chatfield et al., 1988a; Chatfield et al., 1988b; Sellwood et al., 1989; Smith et al., 
1990; Thomas et al., 1992; Joens et al., 1993; Plaza et al., 1997; Trott et al., 2001). Sarkosyl-
insoluble fractions of B. hyodysenteriae were examined by Joens et al. (1993) using SDS-PAGE 
and Western blotting with convalescent pig serum against B. hyodysenteriae. Seven major protein 
bands were observed. Six of these were periplasmic flagella proteins in the molecular mass range   29
of 32 to 42 kDa, and the other was a 16 kDa band. Acute pig serum against SD only recognized 
some of these proteins (Joens et al., 1993). Smith et al. (1990) compared Sarkosyl-insoluble 
fractions of B. hyodysenteriae and B. innocens, and found a distinct band with a molecular mass of 
approximately 39 kDa specific to B. hyodysenteriae. Plaza et al. (1997) also identified a 
predominant protein with an approximate molecular mass of 39 kDa in the outer membranes of B. 
hyodysenteriae purified using discontinuous sucrose density gradients. This protein has since been 
identified as a major cell surface protein, and the eight linked gene copies, designated vspABCD 
and  vspEFGH, encoding variable surface proteins homologous to it have been cloned and 
sequenced (Gabe et al., 1998; McCaman et al., 1999; McCaman et al., 2003). These eight genes 
are present on two non-adjacent loci and do not appear to have arisen from a gene duplication 
event. Gene products of the two unlinked four-member gene cluster share between 41% and 93% 
similarity, and expression of the individual open-reading frames appear to be regulated by a set of 
similar but distinct regulatory elements (McCaman et al., 2003). Hydrophobicity plots of VspA-D 
and VspE-H indicated that their highly variable hydrophilic regions would allow these proteins to 
span the outer membrane and be present on the outer surface of the spirochaete (Gabe et al., 1998; 
McCaman et al., 1999; McCaman et al., 2003). Although this 39 kDa protein may contain regions 
of variability, conserved regions which exist could be useful for detection of antibody specific for 
B. hyodysenteriae. The cell surface location of this protein also makes it potentially useful as the 
basis of a subunit vaccine. The vspABCD and vspEFGH loci has recently been renamed 
bhmp39abcdefgh in light of the new nomenclature (Witchell et al., 2006) 
 
Sodium dodecyl sulfate (SDS)-soluble proteins were extracted from B. hyodysenteriae and 
analysed by Chatfield et al. (1988a, b). Porcine hyperimmune serum to B. hyodysenteriae detected 
polypeptide antigens of molecular mass within the range 30 and 36 kDa. When the cell envelope 
from  B. hyodysenteriae was extracted using Triton X-100, several major immunogenic 
polypeptides with molecular mass between 24 and 45 kDa were detected using serum from a pig   30
vaccinated with whole cells of B. hyodysenteriae (Chatfield et al., 1988a). A 36 kDa antigen 
associated with the cell envelope was immunologically distinct in B. hyodysenteriae, and antibody 
against this antigen was not removed by absorption with whole B. innocens cells. This 36 kDa 
protein may be related to the 39 kDa protein observed by Smith et al. (1990) and Plaza et al., 
(1997). 
 
Sellwood et al. (1989) found a prominent 16 kDa protein of B. hyodysenteriae which was soluble 
in SDS and reacted strongly with hyperimmune and convalescent pig sera. Subsequently, this 
protein was cloned and characterised as a 16 kDa membrane-associated lipoprotein common to 
many strains of B. hyodysenteriae. The identified and sequenced gene encoding the 16 kDa 
lipoprotein was designated smpA (Thomas and Sellwood, 1992; Thomas et al., 1992; Thomas and 
Sellwood, 1993). A monoclonal antibody specific for the SmpA lipoprotein was used to develop 
an ELISA for detecting SmpA in the faeces of pigs infected with B. hyodysenteriae (Sellwood et 
al., 1995). When pigs were experimentally challenged with B. hyodysenteriae, SmpA was detected 
only during the initial post-challenge period and failed to be detected after the onset of clinical SD. 
When the inoculated strain of B. hyodysenteriae was isolated and re-cultured in vitro, SmpA was 
detected. This loss of in vivo expression was proposed to be due to the down-regulated expression 
of the gene encoding SmpA during colonisation. The low antibody titres which developed against 
SmpA were believed to be a result of its repressed in vivo expression, and this prevented its use as 
the basis of a serologic assay. The lack of in vivo expression of smpA also limits its usefulness as a 
subunit vaccine for B. hyodysenteriae. 
 
A gene encoding an outer membrane protein of similar size to SmpA was recently identified and 
designated  smpB (Holden et al., 2006). Although SmpB shares no detectable similarity with 
SmpA, both are similar in size, SmpB being slightly larger at 17.6 kDa, and they possess an 
identical 10 residue leader peptide sequence. SmpB was shown to be specific to B. hyodysenteriae   31
using Southern blotting and reactivity with rabbit serum raised against B. hyodysenteriae whole 
cells. Southern blot analysis also revealed that smpA and smpB reside at the same locus, however 
strains possess either one or the other gene. There was no evidence suggesting both genes were 
present in the same strain. Western blotting using polyclonal sera also indicated that no cross-
reactivity was present between a strain which possessed smpA and a strain which possessed smpB.  
 
Li et al. (1995) reported that B. hyodysenteriae expressed at least three iron-regulated proteins 
with approximate molecular masses of 109, 134 and greater than 200 kDa when grown under iron-
limited conditions. Western blotting with serum from an experimentally challenged pig showed 
that the 109 kDa major iron-regulated protein was expressed in vivo and was conserved amongst 
all  B. hyodysenteriae strains tested. However, the iron-regulated proteins are presumably not 
antigenically specific for B. hyodysenteriae since they are also expressed in B. innocens. 
 
Recently, a locus encoding four paralogous outer membrane lipoproteins of B. hyodysenteriae was 
cloned, characterised and designated blpGFEA (Cullen et al., 2003). Since the blpA member of the 
gene cluster is identical to the gene under study in this thesis, further review of the blpGFEA loci 
will be presented in a later chapter. 
 
1.8.3.4. DNA Vaccination 
To date, only one study using DNA for vaccination against SD has been reported. In this study, the 
B. hyodysenteriae ftnA gene, encoding a putative ferritin, was cloned into an E. coli plasmid and 
the plasmid DNA used to coat gold beads for ballistic vaccination. A murine model for SD was 
used to determine the protective nature of vaccination with DNA and/or recombinant protein. 
Vaccination with recombinant protein induced a good systemic response against ferritin, however 
vaccination with DNA induced a barely detectable serological response. Vaccination with DNA 
followed by a boost with recombinant protein induced a systemic immune response to ferritin only   32
after boosting with protein. However, none of the vaccination regimes tested was able to provide 
mice with protection against B. hyodysenteriae colonisation and the associated lesions. 
Interestingly, vaccination of the mice with DNA alone also resulted in significant exacerbation of 
disease (Davis et al., 2005). 
 
1.9. AIMS OF THE PROJECT 
In order to minimise the economic losses caused by SD, extensive studies have been performed to 
develop a vaccine against SD. When studies described in this thesis began, no subunit vaccine had 
been identified with certainty, and published experimental vaccines gave only partial protection. 
Little was known of the molecular biology of B. hyodysenteriae, and Brachyspira spp. in general. 
Genetic approaches to elucidate the pathogenesis of B. hyodysenteriae infections had been 
hampered by a lack of sufficient genomic data for the spirochaete. A monoclonal antibody 
(BJL/SH1) specific for B. hyodysenteriae had been produced and characterised (Lee and 
Hampson, 1996). A genomic library for B. hyodysenteriae, produced in bacteriophage lambda, had 
been screened using this monoclonal antibody. Phage clones possessing fragments of the B. 
hyodysenteriae genome and reacting with the monoclonal antibody had been isolated, although the 
DNA sequence encoding the protein responsible for this reactivity had not been identified (Lee, 
1996). 
 
Therefore, the aim of the work presented in this thesis was to assess the usefulness of the protein, 
responsible for interacting with the monoclonal antibody BJL/SH1, as a subunit for vaccination 
and/or serological diagnosis of SD. To achieve this, it was necessary to identify and characterise 
the gene encoding this protein of interest. At this stage, it may be useful to mention that the work 
presented in this thesis was started in 1998, and its presentation has been delayed until now due to 
the need to preserve its commercial confidentiality. 
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Consequently, to achieve the desired aims, the specific objectives of this study were as follows: 
1) To confirm the reactivity of the monoclonal antibody BJL/SH1 with the identified reactive 
phage clone. 
2) To determine the nucleotide sequence of the B. hyodysenteriae genomic DNA fragment which 
was incorporated into the genome of the lambda bacteriophage clone. 
3) To determine the gene sequence encoding the protein responsible for the interaction with the 
monoclonal antibody (BJL/SH1) and to determine its likely identity. 
4) To confirm that the protein was a lipoprotein by radioactive labelling with tritiated palmitate. 
5) To check the distribution of the gene in all Brachyspira species. 
6) To clone the identified gene into an E. coli expression system and purify the recombinant 
protein in preparative-scale and large-scale. 
7) To assess the usefulness of the recombinant protein as an antigen for an ELISA test. 
8) To evaluate the immunogenicity of the recombinant protein when used to vaccinate mice. 
9) To evaluate the efficacy of vaccination with the recombinant protein in pigs experimental 
challenged with B. hyodysenteriae.   34
CHAPTER 2: IDENTIFICATION AND CHARACTERISATION 
OF A 29.7 KDA OUTER MEMBRANE LIPOPROTEIN OF 
BRACHYSPIRA HYODYSENTERIAE 
 
2.1. INTRODUCTION 
This chapter describes the screening of a Brachyspira hyodysenteriae genomic library prepared in 
bacteriophage λ to identify and subsequently characterise the gene encoding a 29.7 kDa outer 
membrane lipoprotein. Since the work was completed in 1999, the general approach has been 
somewhat superceded. For that reason, more recent approaches will be briefly mentioned here. 
Recent advances in recombinant DNA technology, in combination with robotic automation of 
molecular processes, now have allowed sequencing of whole bacterial genomes to be 
accomplished in relatively short time-frames. Bioinformatics has emerged as a hot-spot area of 
research, with several hundred bacterial genomes sequenced to completion since the sequencing of 
the first bacterial genome (Haemophilus influenzae) (Fleischmann et al., 1995). Prior to the 
feasibility of whole genome sequencing and large-scale annotation of gene sequences, identifying 
and characterising individual genes or gene clusters involved screening of genomic libraries using 
antibodies or labelled probes, as was done in the work described in this thesis. 
 
Genomic libraries generally are constructed by cloning random fragments of genomic DNA into 
either plasmid vectors or λ bacteriophage. The fragments of genomic DNA to be cloned are 
generated by mechanically shearing the DNA followed by enzyme-mediated fill-in of protruding 
terminal ends, or by partial digestion with a frequent-cutting restriction endonuclease. Generally, 
random fragments of a specified length are selected for cloning by centrifugation through a density 
gradient prior to cloning into the bacteriophage vector (Sambrook et al., 1989). Although genomic 
libraries generated in plasmid vectors are not uncommon, λ bacteriophage vectors are preferred   35
due to their capacity to ligate larger-sized insert DNA, and their suitability for screening with 
either antibodies or probes (Young and Davis, 1983a; Young and Davis, 1983b). Bacteriophage λ 
has a double stranded DNA genome and adsorbs to receptors on the outer membrane of E. coli, 
from which it is transported into the cell. The virus replicates and accumulates in the cell until 
lysis is induced. In the case of many λ vectors, lysis is facilitated by a temperature sensitive 
transcription repressor so that at high temperatures, the mutated repressor is unable to maintain 
lysogeny (Johnson et al., 1979). Lambda vectors are commonly supplied as insertion vectors with 
a multiple cloning site located in the N-terminal portion of the lacZ gene such that if the cloned 
DNA is in-frame with the lacZ sequence, a fusion protein may be expressed and detected by 
antibody screening (Frischauf et al., 1983). A further advantage of some λ vectors is the ability to 
be excised in vivo and converted to plasmid (phagemid) in the presence of M13 helper phage. 
Combined with blue-white (colour) identification when plated on lac
+ hosts in the presence of 
isopropyl-β-D-thio-galacto-pyranoside (IPTG) and 5-bromo-4-chloro-3-indoyl-β-D-galacto-
pyranoside (X-gal), the bacteriophage λ vectors allow efficient construction and screening of the 
genomic library. 
 
Screening of the λ genomic library usually involves plaque-lifts whereby the DNA or expressed 
protein from single bacteriophage plaques are passively transferred onto nitrocellulose and used 
for probe hybridisation or immuno-blotting. Infection of E. coli cells with λ bacteriophage results 
in the lysis of the cell. As a result, spread of the bacteriophage infection leads to the formation of 
cleared-zones on a bacterial lawn, termed plaques. These plaques contain not only the DNA of the 
bacteriophage clone but also the proteins expressed by the phage. Screening of the plaque-lift 
membranes can be done using DNA hybridisation probes, monoclonal antibodies or polyclonal 
serum. The choice of screening method largely depends on availability of a probe/antibody, the 
sensitivity of detection required, and the intended purpose of the identified gene. For example, if a   36
gene being identified is intended for a potential vaccine antigen, screening the genomic library 
with convalescent polyclonal serum may be preferred. 
 
Once a bacteriophage clone has been isolated, the recombinant region of the phage genome can be 
sequenced and potential open reading frames identified. Various computational analyses of the 
identified gene sequence can be performed to provide further information as to the possible 
function of the gene or gene product. These annotation tools are based largely on homology with 
other genes present in the cross-referenced databases. Ultimately, the true function of the 
identified gene sequence needs to be determined using experimental molecular and biochemical 
techniques. 
 
Identification of bacterial genes using bacteriophage genomic libraries has been a common method 
in the “pre-bioinformatics” era. Notably, very little has been published for the Brachyspira genus. 
Of the few genes described, most have been identified by the screening of genomic libraries 
constructed in bacteriophage λ (Thomas and Sellwood, 1993; Gabe et al., 1998; Rayment et al., 
1998; Cullen et al., 2003; McCaman et al., 2003). In this chapter, the identification, 
characterisation and immuno-reactivity of a ~30 kDa outer membrane protein of B. hyodysenteriae 
is described. The generation of a genomic library for B. hyodysenteriae in bacteriophage λ, and the 
subsequent screening of this library with the monoclonal antibody BJL/SH1 have been described 
in a previous PhD thesis (Lee, 1996). Parts of the work were repeated here, and the study was 
extended to fully sequence and identify the gene encoding the membrane protein and analyse its 
distribution in Brachyspira spp. strains.   37
2.2. MATERIALS AND METHODS 
Abbreviations used in this chapter, and those to follow, are listed on pages xxiv-xxv. 
Manufacturers of key reagents and consumables are listed in appendix A.1 together with the place 
of manufacture. Details of major buffers and solutions used are listed in appendix A.2, and will 
therefore not be given in the body of the text. 
 
2.2.1. Production of monoclonal antibody BJL/SH1 
The monoclonal antibody (Mab) BJL/SH1 used in this experiment was prepared and characterised 
previously (Lee and Hampson, 1996). It has been shown to react with a species-specific 30 kDa 
outer envelope protein of B. hyodysenteriae. The hybridomas were stored in liquid nitrogen in 
Dulbecco's Modified Eagle Medium (DMEM; Gibco-BRL Life Sciences) containing 10% (v/v) 
foetal calf serum (FCS; Commonwealth Serum Laboratories) and 10% (v/v) dimethyl sulfoxide 
(DMSO). Frozen stocks of hybridoma were taken from liquid nitrogen and immediately thawed in 
a 37°C waterbath. The thawed cells were transferred to a 10 ml centrifuge tube containing 9 ml 
pre-warmed DMEM and centrifuged at 1,000 × g for 5 min. The supernatant was discarded and the 
cell pellet resuspended with 2 ml DMEM supplemented with 100 μM hypoxanthine, 0.4 μM 
aminopterin, 16 μM thymidine, 0.58 mg/ml glutamine, 0.22 mg/ml sodium pyruvate, 200 IU/ml 
penicillin, 200 μg/ml streptomycin, 0.05 mg/ml gentamycin (DMEM-HAT) and containing 20% 
(v/v) FCS. The hybridomas were first recovered in 96-well flat bottom tissue culture plates, then in 
24-well tissue culture plates, and finally in 25 cm
2 tissue culture flasks. During flask culture, the 
DMEM-HAT medium was supplemented with 10% (v/v) FCS. At this stage, the hybridoma cells 
were allowed to grow until the cells were at the point of death and then the culture supernatant was 
clarified by centrifugation at 2,500 ×  g for 5 min. Prior to storage at -20°C, tissue culture 
supernatant was tested by Western blot analysis (section 2.2.5) against a whole-cell preparation of 
B. hyodysenteriae strain WA1. Undiluted tissue culture supernatant containing the Mab was used 
in all plaque-lift assays and Western blotting, unless otherwise stated.    38
2.2.2. Screening of the genomic library 
A Lambda ZAP II bacteriophage library (Stratagene) prepared from B. hyodysenteriae strain P18A 
was screened for expression of the 29.7 kDa antigen by B. J. Lee (Lee, 1996) using Mab BJL/SHl 
in a plaque-lift method. Five phagemid clones (designated pSHA, pSHB, pSHC, pSHD, and 
pSHE) were excised by combining the Mab-screened phage isolate with ExAssist helper phage 
(Stratagene) and transfected into E. coli XLOLR cells (Stratagene). The cells were stored at -80°C 
in Luria-Bertani (LB) broth containing 20% (v/v) glycerol (Lee, 1996). 
 
2.2.3. Expression of the gene encoding the 30 kDa protein in E. coli 
The E. coli XLOLR clones harbouring the recombinant phagemids were streaked out onto LB agar 
plates supplemented with 50 mg/L kanamycin and incubated at 37°C overnight. A single colony 
was used to inoculate 10 ml of LB broth supplemented with 50 mg/l kanamycin, 1 mM 
phenylmethylsulphonyl fluoride (PMSF) and 1 mM IPTG. The broth culture was incubated at 
37°C for 12 h with shaking. One ml of each culture was centrifuged at 2,500 × g for 15 min and 
washed three times. The washing process involved resuspension of the cell pellet with 1 ml 
phosphate buffered saline (PBS) and centrifugation at 2,500 × g. The washed cell pellets were 
resuspended in 100 μl of PBS ready for sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting. 
 
2.2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
All SDS-PAGE analysis of protein involved electrophoretic separation using the discontinuous 
Tris-glycine buffer system of Laemmli (Laemmli, 1970). Thirty μl of protein sample were mixed 
with 10 μl of 4× sample treatment buffer. Samples were boiled for 5 min immediately prior to 
loading 10 μl of the sample into wells in the gel. The gel comprised a stacking gel and a separating 
gel. These gels were polymerised by the addition of 0.1% (v/v) N,N,N',N'-Tetramethyl-
ethylenediamine (TEMED) and 0.05% (w/v) freshly prepared ammonium sulphate solution and   39
cast into the mini-Protean dual slab cell (Bio-Rad Laboratories). Samples were electrophoresed at 
150 V at room temperature (RT) until the bromophenol blue dye-front reached the bottom of the 
gel. Pre-stained molecular mass standards were electrophoresed in parallel with the samples in 
order to allow molecular mass estimations. After electrophoresis, the gel was immediately 
subjected to electro-transfer onto a nitrocellulose membrane for Western blotting. 
 
2.2.5. Western Blot Analysis 
Electrophoretic transfer of separated proteins from the SDS-PAGE gel to a nitrocellulose 
membrane was performed using the method of Towbin (Towbin et al., 1979). After 
electrophoresis, the gel was equilibrated in transfer buffer for 15 min. The proteins in the gel were 
transferred to a nitrocellulose membrane (Schleicher & Schuell) using the Mini-Protean Trans-
Blot apparatus (Bio-Rad Laboratories) and electrophoretic transfer was performed at 30 V 
overnight at 4°C. The freshly transferred nitrocellulose membrane containing the separated 
proteins was blocked with 10 ml of Tris buffered saline (TBS) containing 5% (w/v) skim milk 
powder for 1 h at RT. The membrane was washed with TBS containing 0.05% (v/v) Tween 20 
(TBST) and then incubated with 10 ml BJL/SH1 (diluted 10-fold with TBST) for 1 h at RT. After 
washing three times for 5 min with TBST, the membrane was incubated with 10 ml goat anti-
mouse IgG-HRP (Sigma Chemical Company) diluted 2,000-fold in TBST for 1 h at RT. The 
membrane was developed with 10 ml 3-3’ diaminobenzidinetetrahydrochloride (DAB) substrate 
solution (Sigma Chemical Company). The development reaction was stopped by washing the 
membrane with distilled water. The membrane was then dried and scanned for presentation. 
 
2.2.6. Sequencing of the B. hyodysenteriae insert 
The phagemid pSHA was chosen for direct sequencing of the B. hyodysenteriae genomic insert 
using the ABI 373A DNA Sequencer (PE Applied Biosystems). Previously it had not been 
successfully sequenced (Lee, 1996). The phagemid was purified from the E. coli XLOLR cells   40
using the QIAprep Spin Miniprep Kit (Qiagen). Briefly, 5 ml of an overnight culture was pelleted 
by centrifugation at 5,000 × g for 10 min. The cell pellet was thoroughly resuspended in 250 μl of 
buffer P1 by repeated aspiration, before adding 250 μl of buffer P2. The tube was mixed 
thoroughly by vortexing. Three hundred and fifty μl of buffer N3 was added to the slurry and the 
tube was gently inverted to mix. Cellular debris was removed by centrifugation at 20,000 × g for 5 
min. The supernatant was transferred to a spin column and centrifuged at 6,000 × g for 1 min. The 
flow-through was discarded and 500 μl of buffer PE was added to the column before centrifuging 
at 6,000 × g for 1 min. The column was dried by centrifugation at 20,000 × g before 50 μl of 
buffer AE was added directly to the column filter. To improve elution, the column was incubated 
at RT for 2 min before centrifugation at 10,000 × g for 1 min. The eluted purified plasmid DNA 
was stored at -20°C. 
 
The initial insert sequences were obtained using commercially available T3 and T7 
oligonucleotides (Stratagene) which annealed to the vector regions flanking either ends of the 
insert. The remaining oligonucleotides were designed based on the 3’-OH end of the upstream 
insert sequences (Table 2.1). Each sequencing reaction was performed in a 10 μl volume 
consisting of 300 ng of phagemid, 4 pmol of primer, and 4 μl of the ABI PRISM™ Dye 
Terminator Cycle Sequencing Ready Reaction Mix (PE Applied Biosystems). Cycling conditions 
involved a 2 min denaturing step at 96°C, followed by 25 cycles of denaturation at 96°C for 10s, 
annealing at the primer’s melting temperature (Table 2.1) for 5s, and primer extension at 60°C for 
4 min. Residual dye terminators were removed from the sequencing products by precipitation with 
95% (v/v) ethanol containing 120 mM sodium acetate (pH 4.6), and vacuum dried. The 
sequencing products were analysed using an ABI 373A DNA Sequencer (PE Applied 
Biosystems). 
   41
Table 2.1.  Oligonucleotide primers used for PCR and sequencing of bhlp29.7. 
Primer name  TA (°C)  Sequence (5’-3’)  Use 
T3 60  TAACCCTCACTAAAGGGAAC  Phagemid  sequencing 
T7 60  GTAATACGACTCACTATAGGGC  Phagemid  sequencing 
SHA-R1  50  GCTGA ACTTATATATCTGC  Phagemid sequencing 
SHA-R2 55  GTTCTTATCTTCCTACTTGG  Phagemid  sequencing 
SHA-F3 55  GCGGAGAAGTTCATGACTCC Phagemid  sequencing 
SHA-F2 50  TCTATGTTGAATAAAGCGGC Phagemid  sequencing 
SHA-F1 55  AGGCGCAGAAGATTCAAGAG Phagemid  sequencing 
Bhlp29.7-US 50 AAAAGAGGTTGTAGAATCAG  bhlp29.7 sequencing 
Bhlp29.7-DS 50 TGAAGAAGATGATGATATCG  bhlp29.7 sequencing 
Bhlp29.7-F58 60  TGCGGAAATACTTCTTCTGGTG  bhlp29.7 PCR and sequencing 
Bhlp29.7-R630 60  AGAACCAGGATTCAAACCGAAG  bhlp29.7 PCR and sequencing 
Bhlp29.7-F13  55  TTATTATTGGTATCATCAGC  Probe for hybridisation 
Bhlp29.7-R809  55  CAAGTAGGAAGATAAGAACC  Probe for hybridisation 
H1 52  ACTAAAGATCCTGATGTATTTG  NADH  oxidase  (nox) PCR 
H2 52  CTAATAAACGTCTGCTGC  NADH  oxidase  (nox) PCR 
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2.2.7. In silico analysis of the hypothetical open reading frame 
Sequence results were edited and compiled using SeqEd v1.0.3 (PE Applied Biosystems). The 
nucleotide sequences were analysed using Vector NTI version 6 (InforMax) and the University of 
Wisconsin Genetics Computer Group program. The deduced hypothetical open reading frame 
(ORF) was used to search for homology against all sequence databases available at the National 
Center of Bioinformatics (NCBI). In order to determine the possible subcellular localisation of the 
protein, the translated ORF was analysed using the HMMTOP Prediction of Transmembrane 
Helices and Topology of Proteins Version 2.0 (Tusnady and Simon, 1998; 2001) and PSORTb 
Version 2.0 (Gardy et al., 2005) software. The Antigenic program (Kolaskar and Tongaonkar, 
1990) was used to determine the most antigenic sites of the protein. The ORF was initially 
designated bmpB and the encoded lipoprotein BmpB, however this gene was later renamed as 
bhlp29.7 and the lipoprotein Bhlp29.7 (Hampson et al., 2006b).  
 
2.2.8. Western blot reactivity of convalescent pig sera with B. hyodysenteriae cell envelope 
proteins 
Five serum samples were obtained from pigs suffering from SD in a naturally infected herd. Serum 
samples from two pigs from a high-health status herd free of SD were used as normal pig serum 
controls. Ten μg of a Triton X-114 cell envelope preparation of the fully characterised Western 
Australian  B. hyodysenteriae strain WA1, prepared by I.W.M. Tenaya (Tenaya, 1997), were 
loaded into a 7 cm preparative well, separated by SDS-PAGE (section 2.2.4) and electro-
transferred to a nitrocellulose membrane (section 2.2.5). The membrane was assembled into the 
Deca-Probe apparatus (Hoefer). Individual pig serums were diluted 100-fold in TBST and reacted 
with the immobilised protein in separate lanes of the Deca-Probe. Mab BJL/SH1 diluted 10-fold 
was also included in a separate lane as a positive control. The Western blot was performed as 
described in section 2.2.5. Bound antibodies were detected using goat anti-pig IgG-horse-radish 
peroxidise (HRP) (Southern Biotechnology) diluted 2,000-fold.   43
2.2.9. Spirochaete culture 
2.2.9.1. Preparation of culture media 
Pure isolates of intestinal spirochaetes were grown in modified pre-reduced Kunkle’s broth 
(Kunkle et al., 1986). This pre-reduced anaerobic broth contained 30 g/l Trypticase Soy Broth 
(TSB; Oxoid), 10 g/l yeast extract (Oxoid), 5 g/l glucose and 4 g/l sodium hydrogen carbonate. 
These ingredients were mixed with distilled water and adjusted to pH 6.85 with hydrochloric acid 
before heating and adding 0.5% (v/v) newborn calf serum (Gibco-BRL Laboratories), 2% (v/v) 
FCS (Commonwealth Serum Laboratories), 1 g/l L-cysteine, 0.2 g/l cholesterol and 0.1% (v/v) 
resazurin (Sigma Chemical Company). The mixture was boiled and 10 ml volumes were aliquoted 
into 20 ml test tubes, or 300 ml volumes were poured into 500 ml glass medical flat bottles under a 
stream of deoxygenated N2, and the gas was then bubbled through the media until the colour of the 
resazurin indicated that the oxygen had been eliminated. Rubber bungs were inserted into the 
necks of the glassware, and the tubes or bottles were clamped into metal racks to prevent the bungs 
being expelled. The media were autoclaved at 121°C for 30 min before use. After the glassware 
was cool, small strips of parafilm were wrapped around the interface between the necks of the 
glassware and the bungs to help prevent the bungs from being ejected during storage. Media were 
stored at RT for up to 2 weeks before use. 
 
2.2.9.2. Growth conditions 
Two ml volumes of the pure isolates stored at -80°C were revived by inoculating the entire 2 ml 
volume of thawed culture into 10 ml of anaerobic broth in a test tube. The bungs were flooded 
with 70% (v/v) ethanol before using a 20 gauge needle and syringe to inject the cells into the test 
tube, whilst keeping the medium in the tube anaerobic. The cultures were incubated at 37°C on a 
rocking platform for 72-96 h. Once cultures reached approximately 10
5-10
6 cells per ml, as 
determined by counting in a haemocytometer chamber under a phase-contrast microscope, they 
were transferred into the 300 ml volumes of anaerobic broth in bottles and incubated under the   44
same conditions for 72-96 h or until mid log phase growth (10
8 cells per ml) was observed. The 
spirochaete cells were harvested by centrifugation at 10,000 × g for 20 min and the cell pellet 
stored at -80°C until required. 
 
2.2.10. Spirochaetal strains and chromosomal DNA extraction 
Fully characterised pure cultures of Brachyspira spp. strains (n=102) were obtained from the 
culture collection held at the Reference Centre for Intestinal Spirochaetes at Murdoch University. 
These included 48 strains of B. hyodysenteriae, 18 strains of B. pilosicoli, 12 strains of B. 
innocens, 12 strains of B. intermedia, eight strains of B. murdochii, two strains of “Brachyspira 
canis”, 2 strains of Brachyspira alvinipulli and one strain of Brachyspira aalborgi. The strain 
names are listed in Appendix A.3. These strains were propagated at 37°C in Kunkle's pre-reduced 
anaerobic broth containing 2% (v/v) FCS and a 1% (v/v) ethanolic cholesterol solution (section 
2.2.9).  
 
Chromosomal DNA was prepared from these Brachyspira spp. strains using the DNeasy Tissue 
Kit (Qiagen). Briefly, 400 mg (wet weight) of cell pellet was thoroughly resuspended in 400 μl of 
PBS by repeated aspiration, before adding 40 μl of proteinase K (20 mg/ml; Sigma Chemical 
Company) and 400 μl of buffer AL. The tube was vortexed to mix and incubated at 70°C for 15 
min. Four hundred μl of absolute ethanol was added to the suspension and the tube was gently 
inverted to mix. The entire contents of the tube was divided into two spin columns and centrifuged 
at 6,000 × g for 1 min. The flow-through was discarded and the column washed with 500 μl of 
buffer AW1 followed by 500 μl of buffer AW2. The column was centrifuged at 6,000 × g for 1 
min between wash buffers and the flow-through discarded. The column was dried by 
centrifugation at 20,000 × g before 100 μl of buffer AE was added directly to the column filter. To 
improve elution, the column was incubated at 70°C for 2 min before centrifugation at 10,000 × g   45
for 1 min. The eluted purified DNA from both columns were pooled into a fresh tube and stored at 
-20°C. 
 
2.2.11. Polymerase chain reactions 
PCR assays were performed as follows, unless otherwise stated. The amplification mixture 
consisted of 1× PCR buffer (containing 1.5 mM of MgCl2), 0.5 U of Taq DNA polymerase 
(Biotech International), 0.05 U Pfu DNA polymerase (Promega), 0.2 mM of each dNTP 
(Promega), 0.5 μM of the primer set, and 50-100 ng of chromosomal template DNA in a total 
volume of 50 μl. Cycling conditions involved an initial template denaturation step of 5 min at 
94°C, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, and 
primer extension at 72°C for 2 min. The PCR products were separated by electrophoresis in 1.5% 
(w/v) agarose in 1× Tris-acetate-ethylenediaminetetraacetic acid (TAE) buffer, stained by 
emersion in a 1 μg/ml ethidium bromide solution and viewed over ultraviolet (UV) light.  
 
All oligonucleotide primer sequences and annealing temperatures used for PCR analysis in this 
chapter are listed in Table 2.1. 
 
2.2.12. PCR amplification and sequencing of bhlp29.7 in Brachyspira spp. 
2.2.12.1. PCR amplification of bhlp29.7 
Two pairs of primers that annealed to regions internal and external to the bhlp29.7 coding 
sequence were designed and optimised for PCR detection of bhlp29.7 using chromosomal DNA 
from the 102 strains of Brachyspira species (section 2.2.10). The external primer set used 
consisted of Bhlp29.7-US and Bhlp29.7-DS (Table 2.1) that anneal to complementary sequences 
adjacent to the coding region of bhlp29.7. The internal primer set used consisted of Bhlp29.7-F58 
and Bhlp29.7-R630 (Table 2.1) that amplified a 572 bp region within the coding region of 
bhlp29.7. PCR reactions were performed as outlined in section 2.2.11.   46
2.2.12.2. Purification of PCR products 
Products generated by PCR were purified using the UltraClean PCR Clean-up Kit (Mo Bio 
Laboratories). Briefly, 50 μl of PCR product was mixed with 250 μl of SpinBind buffer. The 
mixture was transferred to a spin column and centrifuged at 6,000 × g for 1 min. The flow-through 
was discarded and 250 μl of SpinClean buffer was added to the column before centrifuging at 
6,000 × g for 1 min. The column was dried by centrifugation at 20,000 × g for 2 min. Fifty μl of 
elution buffer was added directly to the filter of the column and centrifuged at 10,000 × g for 1 
min. The purified PCR product was stored at -20°C. 
 
2.2.12.3. Sequencing of bhlp29.7 
Sequencing of the PCR product from 11 strains of B. hyodysenteriae (B78
T, B169, B204, P18A, 
B/Q02, WA1, WA4, WA5, WA6, WA15 and WA16) and B. innocens strain B256
T was performed 
using the ABI PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Mix (PE Applied 
Biosystems), using the same sets of primers as the PCR (section 2.2.12.1). The sequencing method 
is outlined in section 2.2.6. Sequence results were edited and compiled using SeqEd v1.0.3 (PE 
Applied Biosystems) before being translated into amino acid sequence using the BioEdit Sequence 
Alignment Editor (North Carolina State University). The nucleotide and translated protein 
sequences for all the bhlp29.7 genes detected were compared to generate a pair-wise identity 
matrix.  
 
2.2.13. Slot blotting and Southern hybridisation 
2.2.13.1. Brachyspira strains 
A subset of 25 spirochaete strains was randomly selected to provide a numerically representative 
selection of the whole collection, and tested for bhlp29.7 by PCR. These included 11 strains of B. 
hyodysenteriae (B78
T, P18A, B169, B204, B/Q02, WA1, WA4, WA5, WA6, WA15 and WA16),   47
four strains of B. innocens (B256
T, 4/71, WestA and Q91.1530.1), four strains of B. pilosicoli 
(P43/6/78
T, 95/1000, 1331-6 and B155A), three strains of B. intermedia (PWS/A
T, P280-1 and 
889), and three strains of B. murdochii (56/150
T, 155/20 and 155/21). To ensure that the 
Brachyspira strains were not contaminated with B. hyodysenteriae, the NADH oxidase (nox) PCR, 
which targets a 354-bp region of the nox gene of B. hyodysenteriae, was performed on all cultures 
prior to Southern blot analysis. The PCR was performed as outlined in section 2.2.11 but without 
Pfu DNA polymerase. The primers H1 and H2 (Table 2.1) were used and B. hyodysenteriae strain 
B78
T was the positive control for the assay.  
 
2.2.13.2. Probe preparation 
The bhlp29.7 probe was constructed to represent nearly the entire gene. DNA from positions 13 to 
816 of the bhlp29.7 coding sequence was amplified using the primers Bhlp29.7-F13 and Bhlp29.7-
R809 (Table 2.1) and the PCR product was purified using the UltraClean PCR Clean-up Kit 
(section 2.2.12.2). The purified PCR product was denatured for 10 min and immediately chilled on 
ice. Twelve μl of DIG-High Prime Probe Labelling reagent (Roche) was added to 48 μl of 
denatured PCR product, mixed well and briefly centrifuged to collect the mixture at the bottom of 
the tube. The labelling reaction was incubated at 37°C overnight. The following day, the probe 
labelling reaction was stopped by incubating the reaction at 65°C for 10 min. The DIG-labelled 
DNA probe was stored at -20°C. 
  
2.2.13.3. Slot blot preparation 
Chromosomal DNA (0.5 μg) from the 25 Brachyspira strains was digested to completion at 37°C 
overnight with 20U of HindIII (Promega) in 1× HindIII buffer and transferred onto Hybond N+ 
membranes (Amersham Pharmacia Biotech) using the Bio-Dot SF apparatus (Bio-Rad 
Laboratories). The membrane was then semi-dried and cross-linked at 150 mJ using the GS Gene   48
Linker
TM (Bio-Rad Laboratories) and stored between two sheets of filter paper at RT until 
required. 
 
2.2.13.4. Southern hybridisation preparation 
Chromosomal DNA (0.5 μg) from B. pilosicoli strain 95/1000, B. innocens strain B256
T,  B. 
intermedia strain P280-1, B. murdochii strain 155/20 and B. hyodysenteriae strains WA1 and B78
T 
were digested to completion at 37°C overnight with 20U of HindIII (Promega) in 1× HindIII 
buffer and the restriction fragments were separated by electrophoresis through a 1% (w/v) agarose 
gel in 1× TAE buffer. The separated restriction fragments were transferred from the agarose gel to 
the Hybond N+ membrane (Amersham Pharmacia Biotech) using vacuum-assisted transfer. The 
gel was de-purinated in 250 mM HCl with gentle shaking for 15 min. The HCl solution was then 
removed and the gel was rinsed twice with distilled water. The gel was then denatured in 500 mM 
NaOH with gentle shaking for 30 min. The vacuum transfer unit (Bio-Rad Laboratories) was used 
to transfer the restricted DNA fragments from the agarose get to the membrane buffered in 10× 
SSC for 1.5 hours at 5 inches Hg pressure. Once the transfer was completed the gel was discarded 
and the membrane incubated in 2× SSC for 5 min. The membrane was then semi-dried and cross-
linked at 150 mJ using the GS Gene Linker
TM (Bio-Rad Laboratories) and stored between two 
sheets of filter paper at RT until required. 
 
2.2.13.5. Probe hybridisation 
Hybridisation of the bhlp29.7 probe onto the slot blot and Southern blot membranes was 
performed under the same conditions. Ten ml of DIG Easy Hyb (Roche) was pre-heated at 50°C 
and used to pre-hybridise the membrane for 30 min with gentle agitation. The DIG-labelled DNA 
probe was diluted to 25 ng/ml in a second 10 ml of DIG Easy Hyb, denatured by boiling for 5 min 
and immediately cooled in ice. The denatured probe was added to another 3.5 ml of pre-heated   49
DIG Easy Hyb solution and mixed gently to avoiding foaming. The pre-hybridisation solution on 
the membrane was discarded and the probe/hybridisation mixture was added to the membrane. The 
membrane was incubated with gentle shaking at 50°C overnight. 
 
After the overnight hybridisation, the membrane was washed twice under the low stringency 
conditions of 2× SSC containing 0.1% (w/v) sodium dodecyl sulfate (SDS) at 37°C with constant 
agitation for 5 min. This was then followed by a further two identical washes. 
 
After the membrane was washed, it was briefly rinsed in washing buffer. The membrane was then 
incubated for 30 min at RT in 100 ml of 1× Blotto (Roche) solution. Following the blocking, the 
membrane was incubated in 20 ml of 1× Blotto solution containing a 10,000-fold dilution of Anti-
Digoxigenin-AP (Roche). The membrane was then washed three times with 100 ml washing buffer 
for 15 min, then equilibrated in 20 ml detection buffer for 5 min. The membrane was placed in a 
hybridisation bag (DNA side facing up) and 1 ml of ready-to-use chemiluminescent substrate for 
alkaline phosphatase development (CSPD; Roche) was applied to the membrane. The membrane 
was immediately covered with another sheet of hybridisation bag to spread the substrate evenly 
and air bubbles smoothed out of the bag. The hybridisation bag was heat-sealed and incubated at 
37°C for 10 min to enhance the luminescent reaction. An autoradiograph was obtained by 
incubating the membrane in a film cassette with pre-flashed Hyperfilm-MP (Amersham Pharmacia 
Biotech) at RT overnight. The autoradiograph was developed and scanned for presentation. 
 
2.2.14. Radioactive palmitate incorporation assay 
Ten ml of Kunkle's pre-reduced anaerobic broth containing 2% (v/v) FCS and a 1% (v/v) ethanolic 
cholesterol solution was inoculated with a 2 ml pure culture of B. hyodysenteriae strain WA1 and 
cultured at 37°C until a cell density of 10
6 cells per ml was obtained. Two hundred μCi of 
3[H]   50
palmitic acid (Amersham Pharmacia Biotech) was then added to the tube and the cells returned for 
further growth at 37°C. When a cell density of approximately 10
9 cells per ml was obtained (72 h), 
the cells were harvested by centrifugation at 10,000 × g for 20 min. All centrifugation procedures 
were performed at 4°C unless otherwise stated. The cells were washed three times by resuspending 
with 10 ml of sterile PBS and centrifuging at 10,000 × g for 20 min. The washed cell pellet was 
resuspended in 1 ml of PBS and lysed by three 30s bursts of sonication on ice. The cells were 
placed on ice for 2 min between sonication bursts. Cellular debris was then removed by 
centrifugation at 20,000 × g for 20 min. SDS-PAGE was used to separate 15 μl of the sample 
(section 2.2.4) and the separated proteins were electro-transferred to nitrocellulose membrane for 
Western blotting with Mab BJL/SH1 (section 2.2.5). After Western blotting, the developed 
membrane was hydrated with Amplify solution (Amersham) and wrapped in plastic food wrap. An 
autoradiograph was obtained by incubating the membrane in a film cassette with pre-flashed 
Hyperfilm-MP (Amersham Pharmacia Biotech) at –80°C for 14 days. The autoradiograph was 
developed and superimposed onto the developed Western blot membrane to identify 
corresponding bands. Both the autoradiograph and Western blot membrane were scanned for 
comparative presentation. 
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2.3. RESULTS 
2.3.1. Isolation and characterisation of recombinant phagemids encoding an approximately 
30 kDa protein band in E. coli 
Mab BJL/SHl reacted strongly with a band of approximately 30 kDa in the whole-cell lysate of all 
E. coli cells containing each of the five phagemids, as well as with two additional bands of 
approximately 31 kDa in cells containing the pSHC clone. In the outer envelope preparation of B. 
hyodysenteriae WA1, Mab BJL/SHI reacted with a band with an apparent molecular mass of 
approximately 30 kDa (Fig. 2.1). 
 
§ 
Figure 2.1.  Western blot reactivity of Mab BJL/SH1 against whole-cell extracts of 
the  E. coli cells expressing phagemids pSHA, pSHB, pSHC, pSHD and pSHE.   
Lane 1, B. hyodysenteriae strain WA1 outer membrane proteins; lanes 3-5, whole 
cell lysates of recombinant E. coli clones containing the phagemids: lane 2, pSHA; 
lane 3, pSHB; lane 4, pSHC; lane 5, pSHD; lane 6, pSHE. The arrow indicates the 
position of the native Bhlp29.7 lipoprotein.   52
2.3.2. Reactivity of serum from naturally infected pigs with the native B. hyodysenteriae 
lipoprotein and the recombinant E.coli expressed protein 
The sera from pigs with natural SD recognised a range of proteins in the Triton X-114 protein 
preparation of B. hyodysenteriae strain WA1. All five serum samples reacted with a protein of 
similar size to the approximately 30 kDa protein that reacted with Mab BJL/SH1. The normal pig 
sera showed no reactivity with proteins of this size (Fig. 2.2). 
 
 
2.3.3. Sequence analysis of the open reading frame 
2.3.3.1. Motifs and conserved domains 
Sequencing of the pSHA phagemid revealed a 3,698 bp insert of B. hyodysenteriae genomic DNA. 
Sequence analysis of the insert DNA revealed a potential ORF (designated bhlp29.7) of 816 bp 
§ 
Figure 2.2. Western blot reactivity of serum from pigs naturally infected with SD 
against Triton X-114 preparation of B. hyodysenteriae WA1. The arrow indicates the 
reaction of an approximately 30 kDa protein with both the Mab BJL/SH1 and the 
serum from the infected pigs. Lane 1, Mab BJL/SH1; lanes 2-6, individual infected pig 
serum; lanes 7-8, normal pig serum.   53
from bases 242 to 1057, with a putative ATG start codon and a TAA stop codon (Fig. 2.3). A 
potential Shine-Dalgarno (Shine and Dalgarno, 1974) ribosome binding site (AGGAG), and 
putative –10 (TATAAT) and –35 (TTGAAA) promoter regions were identified upstream from the 
ATG start codon. A 12 bp region with dyad symmetry was present downstream from the TAA 
stop codon. Analysis of the amino acid sequence showed the presence of a 19 residue lipoprotein 
precursor signal peptide (MKKFLLLVSSAILSLMILS) at the N-terminal of the predicted 
polypeptide. A Kyte-Doolittle hydropathy plot (Kyte and Doolittle, 1982) of the deduced amino 
acid sequence showed this N-terminal to be highly hydrophobic (Fig. 2.4). The theoretical 271 
amino acid (aa) pro-lipoprotein and mature 253 aa lipoprotein had predicted molecular masses of 
29.7 kDa and 27.6 kDa, respectively. These deduced sizes differed slightly from those seen in the 
Western blots. The gene encoding the lipoprotein was designated bhlp29.7, and the lipoprotein 
was designated Bhlp29.7. 
 
                          -35                  -10 
CATCAATTATTAATAGTTTTTATTGAAATTATTCAAAAAATAATATAATC - 50 
 
                                S/D 
TAAATAAATTAATTTCATTAAAATTTTATAAAGGAGCGAAAATGAAAAAA - 100 
                                          M  K  K  
  
TTTTTATTATTGGTATCATCAGCCATATTATCATTAATGATATTATCATG - 150 
 F  L  L  L  V  S  S  A  I  L  S  L  M  I  L  SªC  
  
CGGAAATACTTCTTCTGGTGATCAAAAGATAGTTAAAGTTGGTTTTGCTG - 200 
  G  N  T  S  S  G  D  Q  K  I  V  K  V  G  F  A   
  
GAGAGTCTGATTATCAAATTTGGGATCCTATAGTAGCTAAATTAGCTGAA - 250 
G  E  S  D  Y  Q  I  W  D  P  I  V  A  K  L  A  E  
  
GAAGGAATTAAAGTAGAGCTAGTATCTTTCTCTGATTATACTATACCTAA - 300 
 E  G  I  K  V  E  L  V  S  F  S  D  Y  T  I  P  N  
  
TCAGGCTTTGAATGACGGAGAAATTGACTTGAATGCTTTTCAGCATTATG - 350 
  Q  A  L  N  D  G  E  I  D  L  N  A  F  Q  H  Y  
  
CATACTTTAATGATGAAGTATCAAATAAAGGATATGACTTAACTGCTATT - 400 
A  Y  F  N  D  E  V  S  N  K  G  Y  D  L  T  A  I   
  
GCTGATACTTATATATCTGCTATGAATATTTATTCTACTAATATTACTGA - 450 
 A  D  T  Y  I  S  A  M  N  I  Y  S  T  N  I  T  D   
 
TGTAAAAGAATTAAAAAATGGCGATAAAATAGCTATACCTAATGACCCTT - 500 
  V  K  E  L  K  N  G  D  K  I  A  I  P  N  D  P   
 
CTAATGGAGGAAGAGCTTTAAAAGTTCTTCAGGCTGCAGGAATCATTAAA - 550 
S  N  G  G  R  A  L  K  V  L  Q  A  A  G  I  I  K     54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3.2. Subcellular localisation, topology and antigenicity 
The analysis of the Bhlp29.7 translated amino acid sequence using PSORTb v2.0 predicted that 
the lipoprotein was localised on the outer membrane of the spirochaete. The HMMTOP analysis 
revealed that Bhlp29.7 possessed three hydrophobic helices which were preceded and followed by 
hydrophilic regions. The first hydrophobic helix (residues 20 to 23) immediately followed the 
 
GTAAAACCTGAAGCAGGAGATACTCCTAGCGTAAGCGATATAATAAAAAA - 600 
 V  K  P  E  A  G  D  T  P  S  V  S  D  I  I  K  N   
  
TCCTCTAAATATTGAAATAGTAGAAATGGATGCAGGTGCTATTTACGGTG - 650 
  P  L  N  I  E  I  V  E  M  D  A  G  A  I  Y  G   
  
TTCTTCCTGATGTTGCTTGTGCTGTTATCAATGGAAACTATGCTATATAC - 700 
V  L  P  D  V  A  C  A  V  I  N  G  N  Y  A  I  Y   
  
TTCGGTTTGAATCCTGGTTCTGATTATATATTCAAAGATGATCCTTCTAT - 750 
F  G  L  N  P  G  S  D  Y  I  F  K  D  D  P  S  I   
  
TTACAGCGGAAAATCTTTTGTTAATTTAATAGCTGCAAGAACTAAAGATA - 800 
  Y  S  G  K  S  F  V  N  L  I  A  A  R  T  K  D   
  
AAGATAATGAATTATACAAAAAAGTTGTAGAAACTTATCAATCTGAAATA - 850 
K  D  N  E  L  Y  K  K  V  V  E  T  Y  Q  S  E  I   
  
GTAGAAAAAGTTTATAATGAAAATTTCTTAGGTTCTTATCTTCCTACTTG - 900 
 V  E  K  V  Y  N  E  N  F  L  G  S  Y  L  P  T  W  
  
GAAATAATATAAATATTAATTGAATAATATTTGAATTATAAAAAGAAAAG - 950 
  K  *                                             
 
CATGAGATTTCTTATTATCTCATGCTTTTTTATTTTGTTTTTTATATCAT – 1000 
 
Figure 2.3. Nucleotide sequence and the deduced amino acid sequence of the ORF 
bhlp29.7 encoding a putative lipoprotein designated Bhlp29.7. The ribosome-binding 
site and putative promoter regions are underlined. The region of dyad symmetry, 
which forms a possible ρ-independent transcriptional terminator, is underlined with 
arrows. The potential signal peptide is in bold, and the possible signal peptidase II 
cleavage site is shown by the arrow.   55
signal peptidase II cleavage site and possibly indicated the lipid attachment site. The second 
(residues 100 to 119) and third (residues 182 to 206) hydrophobic helices probably indicated 
transmembrane regions. Three hydrophilic regions were predicted, two of which were on the 
external side of the membrane (residues 24 to 99 and residues 207-271) and one which was on the 
internal side of the membrane (residues 120 to 181). A diagrammatic representation combining the 
PSORTb and HMMTOP predictions is shown in Fig. 2.5. 
 
The most antigenic regions of the Bhlp29.7 lipoprotein were predicted to reside at the C-terminal 
between residues 201 to 268. 
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Figure 2.4. Kyte-Doolittle hydropathy plot of the deduced amino acid sequence of 
the Bhlp29.7 polypeptide. Hydrophobic regions are shown above the line. The 
potential signal peptide is indicated by the arrow. The amino acid positions in the 
ORF are shown on the horizontal axis, and the hydrophobic index is shown on the 
vertical axis.   56
2.3.3.3. Homology 
The translated-BlastP homology search of bhlp29.7 against the SWISS-PROT protein database 
identified 33.9-39.9% homology between this protein and D-methionine-binding lipoproteins 
(MetQ) of other bacteria including E. coli,  Haemophilus influenzae,  Pasteurella multocida, 
Salmonella enterica serovar Typhimurium, S. enterica serovar Typhi, Vibrio cholera and Yersinia 
pestis (Table 2.2). Similarity (32.1-38.4%) was also seen between Bhlp29.7 and the gene products 
(PlpABC) of a tandem multiple gene loci encoding 30 kDa membrane lipoproteins of Pasteurella 
haemolytica (Table 2.2). Comparison of the bhlp29.7 nucleotide sequence with the GenBank 
nucleotide database did not reveal any strong homology with other bacterial genes.  
Figure 2.5. The subcellular localisation and topology of the Bhlp29.7 lipoprotein predicted 
using PSORTb v2.0 and HMMTOP v2.0. OM, outer membrane; A, lipid attachment region; B 
and F, extracellular regions; C and E, transmembrane regions; D, periplasmic region.   57
 
2.3.4. Sequencing of the bhlp29.7 gene present in Brachyspira spp. 
Amongst the 102 Brachyspira spp. analysed for bhlp29.7 by PCR, the gene was identified in all 48 
strains of B. hyodysenteriae, and in B. innocens B256
T, but was not present in any strains of B. 
pilosicoli, B. intermedia, B. murdochii, “B. canis”, B. alvinipulli or B. aalborgi, or in the other 
strains of B. innocens. The level of identity between the Bhlp29.7 gene of the B. hyodysenteriae 
strains and B. innocens B256
T that were sequenced are summarised in Tables 2.3 and 2.4. The 
Bhlp29.7 gene of the 11 B. hyodysenteriae strains shared 97.9-100% identity at the nucleotide 
level (Table 2.3), and 98.5-100% at the protein level (Table 2.4). Western Australian isolates WA4 
Table 2.2. Sequence similarity of translated Bhlp29.7 (271 amino acids) with the amino acid 
sequence of bacterial lipoproteins obtained from the SWISS-PROT database.  
Organism  Protein  Size (aa)  Identity (aa) 
Similarity 
(%) 
Accession 
Number 
Salmonella Typhimurium  MetQ 271  108  39.9  Q8ZRN1 
Escherichia coli K-12  MetQ 271  107  39.5  P28635 
Salmonella Typhi MetQ  271  107  39.5 Q8Z992 
Escherichia coli O157:H7  MetQ  271  106  39.1  Q8X8V9 
Yersinia pestis MetQ  271  105 38.7  Q8ZH40 
Pasteurella haemolytica PlpA  277  87  32.1  Q08868 
 PlpB  276  94  34.7  Q08869 
 PlpC  263  104  38.4  Q08870 
Vibrio cholera MetQ  269 99  36.5  Q9KTJ7 
Haemophilus influenzae MetQ  273  93  34.3  P31728 
Pasteurella multocida MetQ 276  92  33.9  Q9CK95   58
and WA5 were identical at the nucleotide level, as were WA1, WA6, WA15 and WA16. The 
Bhlp29.7 gene of B. innocens B256
T showed slightly more variation, having between 97.5-99.3% 
similarity with the Bhlp29.7 gene of the different B. hyodysenteriae strains at the nucleotide level, 
and 97.5-99.5% at the protein level. Comparison of the amino acid sequences of Bhlp29.7 for the 
B. hyodysenteriae strains with that of B. innocens B256
T identified only one consistent difference 
between the protein in the two species. This was an amino acid dissimilarity at position 210, which 
occurred only in B. innocens B256
T,
 where the serine residue for B. hyodysenteriae was replaced 
by a tyrosine residue for B. innocens. This will be discussed more fully in Chapter 3. 
 
Table 2.3. Nucleotide sequence homology (%) of bhlp29.7 from 11 different B. 
hyodysenteriae strains and B. innocens strain B256
T. All strains posses an 816 bp 
coding sequence. The B. innocens strain is indicated with bold typeface.  
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P18A  100 99.1 99.3 99.6 99.0 98.1 99.5 98.6 
B78
T    100 99.2 99.5 99.8 98.0 99.3 99.5 
B169      100 99.7 99.1 98.2 99.8 98.7 
B204      100  99.3  98.5  99.8  99.0 
B/Q02       100  97.9  99.2  99.3 
WA4,  WA5        100  98.4  97.5 
WA1, WA6, 
WA15, WA16 
       1 0 0   98.8 
B256
T          1 0 0  
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Sequence data for bhlp29.7 in B. hyodysenteriae strains P18A, B78
T, B169, B204, B/Q02, WA1, 
WA4, WA5, WA6, WA15 and WA16 were deposited in GenBank under the respective accession 
numbers AY512343, and AY706759–AY706768. The bhlp29.7 sequence in B. innocens B256
T 
was deposited under accession number AY512344. 
 
 
Table 2.4. Amino acid sequence homology (%) of translated bhlp29.7 from 11 different 
B. hyodysenteriae strains and B. innocens strain B256
T. All strains posses a 271 amino 
acid protein. The B. innocens strain is indicated with bold typeface. 
 
P
1
8
A
 
B
7
8
T
 
B
1
6
9
 
B
2
0
4
 
B
/
Q
0
2
 
W
A
4
,
 
W
A
5
 
W
A
1
,
 
W
A
6
,
 
W
A
1
5
,
 
W
A
1
6
 
B
2
5
6
T
 
P18A  100 99.1 99.3 99.6 99.0 98.1 99.5 98.6 
B78
T    100 99.2 99.5 99.8 98.0 99.3 99.5 
B169      100 99.7 99.1 98.2 99.8 98.7 
B204      100  99.3  98.5  99.8  99.0 
B/Q02       100  97.9  99.2  99.3 
WA4,  WA5        100  98.4  97.5 
WA1, WA6, 
WA15, WA16 
       1 0 0   98.8 
B256
T          100 
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2.3.5. Southern Blot of bhlp29.7 
The low stringency slot-blot DNA hybridisation of a selection of 25 of the Brachyspira spp. 
strains demonstrated that the bhlp29.7 probe hybridised only with the B. hyodysenteriae strains 
and the B. innocens strain B256
T. One representative strain from each Brachyspira spp. analysed 
by slot-blot hybridisation was selected for Southern blot analysis. On Southern blotting, the 
bhlp29.7 probe reacted strongly with a 1.9 kb HindIII fragment of the B. hyodysenteriae genome, 
and with a 3.1 kb fragment of the genome from B. innocens strain B256
T, and again not with 
restriction fragments of the other Brachyspira spp. genomic DNA (Fig. 2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Chemiluminograph of chromosomal DNA from Brachyspira spp. 
digested with HindIII, separated by electrophoresis and hybridised with the 
bhlp29.7 probe under low stringency conditions. Lane 1, bhlp29.7 PCR product; 
lane 2, herring sperm DNA; lane 3, B. pilosicoli strain 95/1000; lane 4, B. 
innocens strain B256
T; lane 5, B. intermedia strain P280-1; lane 6, B. murdochii 
strain155/20; lane 7, B. hyodysenteriae strain WA1; lane 8, B. hyodysenteriae 
strain B78
T. The arrow shows the position of the hybridisation with the two B. 
hyodysenteriae strains. 
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2.3.6. Lipidation of Bhlp29.7 
The tritiated palmitate incorporation study indicated the presence of a range of lipidated proteins in 
the B. hyodysenteriae cell lysate in the range of 15 to 40 kDa. The majority of these lipoproteins 
were concentrated in the range of 15 to 25 kDa. A lipidated protein with an apparent molecular 
mass of 30 kDa was visibly dominant in the cell lysate of B. hydysenteriae. This same lipoprotein 
also was the only lipoprotein cell lysate that reacted with the Mab BJL/SH1 (Fig. 2.7). 
 
 
Figure 2.7. Autoradiograph of cell-lysates of B. hyodysenteriae grown in the 
presence of 
3[H]palmitic acid. A whole-cell preparation of the B. hyodysenteriae 
cells was electrophoresed and transferred to nitrocellulose membrane. The 
membrane was exposed to x-ray film (lane 1) and then immunoblotted with Mab 
BJL/SH1 (lane 2). The arrow indicates the native Bhlp29.7 lipoprotein.   62
2.4. DISCUSSION 
In the present study an 816 bp ORF encoding a 29.7 kDa putative lipoprotein of B. hyodysenteriae, 
reactive with the monoclonal antibody BJL/SH1, was isolated and sequenced. In previous studies 
BJL/SH1 was found to be reactive with B. hyodysenteriae, and not with other species in the genus 
Brachyspira (Lee and Hampson, 1996). The recombinant E. coli clones expressed proteins which 
were of similar apparent molecular mass to the native B. hyodysenteriae protein, and were 
antigenically related to it. In one of the E. coli clones (pSHC), three bands were reactive with 
BJL/SH1, one of which was similar in apparent molecular mass to the native B. hyodysenteriae 
protein. The intensities of the other two bands were much weaker. Differences in molecular mass 
between the native and recombinant lipoprotein may be due to differences in post-translational 
modifications of E. coli and B. hyodysenteriae (Wu et al., 1983). It has been suggested that 
processing of such pro-lipoproteins may not be as effective in E. coli as in B. hyodysenteriae 
(Thomas and Sellwood, 1993). Thomas and Sellwood (1993) also proposed that the efficiency of 
these modifications may be associated with the growth phase at which the cultures were harvested. 
Differences in molecular mass between the deduced amino acid sequence of the 29.7 kDa 
lipoprotein and the apparent molecular mass seen in the Western blot may also be due to minor 
post-translational modifications not accounted for during in silico translation, with SDS-PAGE 
only providing an estimate of the true molecular mass of the protein. 
 
It was initially proposed that the 29.7 kDa outer membrane lipoprotein of B. hyodysenteriae be 
designated BmpB (Brachyspira membrane protein B), and that the encoding gene be designated 
bmpB. This would be in accordance with the nomenclature of the other B. hyodysenteriae outer 
membrane lipoprotein (SmpA) characterised by Thomas and Sellwood (1993), the name of which 
should be amended from SmpA (Serpulina membrane protein A) to BmpA to be consistent with 
the new genus name Brachyspira. However, the nomenclature of Brachyspira outer membrane 
proteins and lipoproteins has since been re-defined to account for the originating species, the class   63
of membrane protein, and the predicted molecular mass of the translated gene. As a result, BmpB 
has been renamed as Bhlp29.7 (29.7 kDa lipoprotein of B. hyodysenteriae) and the gene encoding 
it changed from bmpB to bhlp29.7 (Hampson et al., 2006b). 
 
Analysis of the N-terminal amino acid sequence suggests that bhlp29.7 encodes a potential 
lipoprotein. Lipoproteins generally share common features including a short hydrophobic signal 
peptide containing a 4 residue consensus signal peptidase II cleavage site. Upon cleavage of the 
signal peptide, the cysteine residue in this motif becomes the N-terminal and is also the position of 
lipid attachment (Wu et al., 1983). Examination of the Bhlp29.7 polypeptide indicated the 
presence of a cleavage site (I-3-L-2-S-1-C+1) at the proper positions. The signal peptidase II 
recognition site for Bhlp29.7 is similar to, but does not exactly match the consensus sequence 
determined by the alignment of 26 spirochaetal lipoproteins for which there was experimental 
evidence of lipid modification. The consensus spirochaete signal peptidase II recognition site was 
defined as L(A,S)-4-L(V,F,I)-3-I(V,G,)-2-A(S,G)-1-C+1 (Haake, 2000). The signal peptidase II 
recognition site of Bhlp29.7 differed from this consensus by the presence of a methionine (M) at 
position -4 and leucine (L) at position -2. The signal peptidase II recognition site of the B. 
hyodysenteriae outer membrane lipoprotein SmpA (Thomas and Sellwood, 1993) and B. pilosicoli 
outer membrane lipoprotein BmpC (Trott et al., 2004) also differed from the spirochaetal 
consensus site. It is likely that during the gradual evolutionary divergence of the spirochaetes, 
enzyme recognition sites and sites of cleavage have also evolved. The Kyte-Doolittle hydropathy 
plot of the deduced Bhlp29.7 protein revealed the hydrophobic nature of the precursor signal 
peptide as well as a hydrophilic N-terminal region adjacent to the predicted lipid attachment site, 
which is similar to that of other bacterial lipoproteins (Sharma et al., 1998).  
 
Since Bhlp29.7 was expressed in vitro, it was possible to demonstrate its lipidation by tritiated 
palmitate incorporation, thus confirming that Bhlp29.7 is a lipoprotein. The lipidation assay also   64
indicated that Bhlp29.7 was a dominant lipoprotein on the membrane of B. hyodysenteriae, 
making it an even stronger candidate antigen for use in serological diagnosis of SD and 
vaccination against SD.  
 
Nakai and Kanehisa (1991) developed a scheme for determining the localisation of lipoproteins in 
Gram-negative bacteria. The expert system makes use of various kinds of knowledge, based on 
experimental observations, for theoretically sorting a protein into one or more of four cellular 
compartments: cytoplasm; cytoplasmic (inner) membrane; periplasm; and outer membrane. The 
system was developed for Gram-negative bacteria, but there is reason to believe that spirochaetal 
lipoproteins may be exported to the outer membrane by a unique pathway, which is still not fully 
understood (Haake, 2000). The second and third amino acids of the Bhlp29.7 lipoprotein were 
glycine (G) and asparagine (N), respectively. Both these amino acids are uncharged, therefore 
according to the system of Nakai and Kanehisa, the Bhlp29.7 lipoprotein is possibly localised on 
the outer membrane of B. hyodysenteriae. This was further substantiated by the in silico analysis 
performed using HMMTOP and PSORTb. HMMTOP uses a hidden Markov model-based method 
to identify transmembrane alpha helices, which can then be used to predict proteins which 
spanning the cytoplasmic or outer membranes (Tusnady and Simon, 1998; 2001). The PSORTb 
tool is frequently used for prediction of prokaryotic localisation sites and is especially useful for 
Gram-negative bacteria. It consists of multiple analytical modules, each of which analyses one 
biological feature known to influence or be characteristic of subcellular localisation (Gardy et al., 
2005). When used in combination, these analyses indicated a high probability of Bhlp29.7 being 
localised on the B. hyodysenteriae outer membrane. In addition, the predictions also indicated that 
the Bhlp29.7 polypeptide contained two regions (residues 24 to 99 and 207 to 271) which are 
exposed to the outside of the cell. 
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Although different theoretical subcellular localisation prediction systems were used, computations 
based on amino acid sequence still require experimental evidence before the true localisation of 
lipoproteins can be determined. Detergent-phase partitioning extraction of native Bhlp29.7 and 
immunogold-labeling of B. hyodysenteriae using BJL/SH1 provided further support for an outer 
membrane location of Bhlp29.7 (Lee and Hampson, 1996).  
 
Interestingly, the same gene sequence was independently identified and published four years after 
the identification of bhlp29.7, as described in this chapter, and was designated blpA (Cullen et al., 
2003). The bhlp29.7 and blpA sequence refer to the same gene and share 99.6% similarity at the 
nucleotide level, since bhlp29.7 and blpA were initially sequenced from the B. hyodysenteriae 
stains P18A and B204, respectively. Further data presented by Cullen et al. (2003) indicate that 
bhlp29.7/blpA is a member of a locus encoding four paralogous outer membrane proteins 
(BlpGFEA). However, of these four proteins, only Bhlp29.7/BlpA is transcribed and translated in 
vivo. The palmitate lipidation studies described here and independently undertaken by Cullen et al. 
(2003) indicate that Bhlp29.7/BlpA is a lipoprotein. A possible role for the paralogs could be in 
the evasion of the immune system by antigenic variation of surface exposed proteins, as seen in 
Borrelia burgdorferi (Burkot et al., 1994; Schwan et al., 1995; Montgomery et al., 1996), the 
relapsing fever spirochaete Borellia hermsii (Barbour et al., 1991; Hinnebusch et al., 1998) and 
Leptospira kirschneri (Barnett et al., 1999). Another two loci encoding eight linked gene copies of 
a predominant 39 kDa surface protein (vspABCD and vspEFGH) have been identified for B. 
hyodysenteriae. Of these multi-gene loci, only one gene (vspH) encodes the 39 kDa protein, 
although 83-90% amino acid similarity is shared amongst all the gene products (Gabe et al., 1998; 
McCaman et al., 2003; Witchell et al., 2006). 
 
Annotation of the translated bhlp29.7 gene sequence indicated that its highest homology (33.9-
39.9%) was with a D-methionine binding lipoprotein of various bacteria including E. coli,   66
Haemophilus influenzae,  Pasteurella multocida,  Salmonella enterica serovar Typhimurium, 
Salmonella typhi, Vibrio cholera and Yersinia pestis. Similar homology (32.1-38.4%) was seen 
with the 30 kDa membrane proteins of Mannheimia haemolytica (PlpABC) encoded by tandem 
multiple genes sharing 55-60% nucleotide sequence identity. These homology values were 
calculated based on the number of identically matching amino acids. Direct comparison of the 
Bhlp29.7 nucleotide sequence with available GenBank sequences did not return any significant 
matches.  
 
D-methionine is an effective source of methionine in many enteric bacteria (Cooper, 1966; Kuhn 
and Somerville, 1971; Kadner, 1977). There are currently 48 members of the methionine uptake 
transporter (MUT) family and these include members from both Gram-negative and Gram-positive 
bacteria. The MUT system and its regulation have been extensively investigated in E. coli and 
Salmonella enterica serovar Typhimurium. Recently, this system was fully characterised for E. 
coli. The MUT system is an ATP-binding cassette (ABC) transporter consisting of a 
transmembrane protein, a cytoplasmic ATP-hydrolysing protein, and at least one specific 
substrate-binding receptor. Regulation of the MUT is facilitated by repressor (MetJ) binding which 
negatively controls the expression of the MUT-encoding operon (Zhang et al., 2003). The MUT 
system has also been found to be sensitive to osmotic shock (Cottam and Ayling, 1989). The genes 
encoding the MUT components are located on the metD locus (Kadner and Watson, 1974; Kadner, 
1977) which has since been renamed as the metNIQ gene cluster (Gal et al., 2002; Merlin et al., 
2002). MetD is believed to be a high-affinity methionine transport system which involves an 
ATPase (MetN), permease (MetI) as well as a D-methionine binding protein (MetQ), and is 
capable of transporting both the D- and L-methionine stereoisomers. A low-affinity transport 
system (MetP) operates in parallel, but can only transport the L-methionine stereoisomer. Once D-
methionine has been transported into the cell, it is converted to L-methionine. Deletion of the 
MetD transport system in mutants leads to impaired cell growth on D-methionine as the sole   67
source of sulphur, although they will still grow on L-methionine. A corresponding system with the 
same uptake properties has also been described in S. enterica serovar Typhimurium (Cottam and 
Ayling, 1989; Grundy and Ayling, 1992). In addition, a similar MUT system has been predicted 
from the genome sequence of the spirochaete Treponema pallidum. The MetQ homologue 
(TpN32) in this spirochaete has 25.5% (69 out of 271 aa) homology with Bhlp29.7. A BlastP 
sequence comparison of the translated blpGFE genes, shown to be parologous to bhlp29.7/blpA 
(Cullen et al., 2003), with the SWISS-PROT database identified large regions of conserved 
domains reminiscent of ABC constituents. The combined annotation of bhlp29.7 and the 
homologous blpGFEA loci strongly suggest that these genes belong to the MUT family. 
 
ABC transporters constitute a large superfamily of permeases that are involved in the ATP-
dependent transport of solutes across biological membranes. They are present in both prokaryotes 
and eukaryotes and have relative specificity for a given substrate. Many ABC transporters have 
been identified for the transport of bio-molecules required for catabolism. They are also important 
during adaptation of pathogens to osmotic shock, allowing the accumulation of important 
substrates. These physiological processes are widespread in nature, and play essential roles in the 
virulence of both prokaryotic and eukaryotic pathogens such as entero-aggregative E. coli (Nishi et 
al., 2003), S. enterica (Kingsley et al., 1999), S. enterica serovar Typhimurium (Parra-Lopez et 
al., 1993; Janakiraman and Slauch, 2000; Liao and Maloy, 2001), and Yersinia ruckeri (Fernandez 
et al., 2002). MUT proteins are no exception, and have been found to influence the virulence of 
certain bacteria. One example is the 30 kDa membrane proteins (PlpABC) of M. haemolytica, the 
causative agent of bovine pneumonic pasteurellosis in feedlot cattle, which have been shown to be 
important in generating immunity to the disease. Serological analyses indicate high antibody 
responses to several surface antigens, including the 30 kDa protein, correlate with resistance to 
pneumonic pasteurellosis. Vaccination of cattle with the surface antigens enhances resistance to 
experimental challenge (Mosier et al., 1989). Annotation of PlpABC revealed a high degree of   68
homology with a 28 kDa membrane protein of H. influenzae, which may be associated with 
invasion (Murphy and Whitworth, 1993). In these studies, mutant strains of H. influenzae 
expressing insertion-inactivated 28 kDa protein were less virulent than wild-type strains 
expressing the intact 28 kDa protein, as determined by the ability to cause bacteraemia after 
intranasal inoculation of mice. The role of the protein in virulence is related to the initial invasion 
of the mucosal epithelium, since both wild-type and mutant strains were able to cause bacteraemia 
in animals inoculated intraperitoneally (Chanyangam et al., 1991). The 28 kDa membrane protein 
of H. influenzae has since been re-annotated as a D-methionine binding lipoprotein (Fleischmann 
et al., 1995). Although the pig gastrointestinal tract differs from the respiratory epithelium, the 
suggestion that inactivation of the D-methionine binding lipoprotein homologue can prevent initial 
invasion of mucosal epithelium indicates that immunity to Bhlp29.7 potentially could offer 
protection against lesion development in SD. 
 
Previously, it has been shown that pigs recovering from experimental challenge with B. 
hyodysenteriae develop a humoral immune response to a range of outer membrane proteins 
ranging in size from 30 kDa to 45 kDa (Wannemuehler et al., 1988; Smith et al., 1990; Sellwood 
et al., 1995). Similarly, serum from a pig vaccinated with a B. hyodysenteriae bacterin, which was 
then resistant to SD, reacted with a series of B. hyodysenteriae cell envelope proteins with 
molecular masses between 30 and 36 kDa (Chatfield et al., 1988b). It is presumed that Bhlp29.7 
was represented amongst the cocktail of surface proteins of similar molecular mass that were 
recognised by the pigs. In the current study sera from pigs in a herd with SD recognised a protein 
of similar molecular mass to Bhlp29.7, suggesting that Bhlp29.7 is both immunogenic and 
expressed in vivo. The results of immunofluorescent-antibody tests (IFAT) using Mab BJL/SH1, 
on faeces also support both the outer surface location of Bhlp29.7, and its in vivo expression.  
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Immunisation of mice with the recombinant E. coli cells provided the first evidence that 
recombinant Bhlp29.7 expressed in E. coli was antigenically related to the native B. 
hyodysenteriae lipoprotein (Lee, 1996). The mouse sera showed some cross-reactivity with 
proteins of similar molecular mass in other Brachyspira spp., but this was expected. Structural 
proteins in related organisms are likely to share epitopes which would stimulate cross-reacting 
antibodies when they are used as immunogens. The fact that BJL/SH1 did not react with 
Brachyspira spp. other than B. hyodysenteriae confirmed that the epitope reacting with this Mab 
was unique to B. hyodysenteriae (Lee and Hampson, 1996). However, in the current study the 
Bhlp29.7 gene was found to be present in B. innocens B256
T and the sequence was almost 
identical to the bhlp29.7 of the 11 B. hyodysenteriae strains analysed. Assuming Bhlp29.7 is a D-
methionine binding lipoprotein homologue, and the D-methionine binding lipoprotein may be 
associated with virulence, it is possible that the Bhlp29.7 lipoprotein is not required for the 
survival of non-pathogenic B. innocens, and consequently the expression of bhlp29.7 has been 
silenced during the course of its evolutionary divergence. 
 
The bhlp29.7 gene appeared to be ubiquitous amongst B. hyodysenteriae strains. Its location at a 
single site on a 1.9 kb fragment of the B. hyodysenteriae strains tested suggests that the sequence 
is present as a single copy. The high level of identity between the bhlp29.7 genes of all the B. 
hyodysenteriae strains studied also indicates the highly conserved nature of the Bhlp29.7 
lipoprotein. B. innocens strain B256
T also possessed the bhlp29.7 gene, assessed by PCR and low 
stringency hybridisation, and the nucleotide sequence shared 97.5-99.3% similarity with the B. 
hyodysenteriae sequences. Interestingly, Cullen et al. (2003) also identified blpA in B. innocens 
B256
T, although they did not investigate other B. innocens strains. The presence of the gene in 
strains of B256
T held by different laboratories helps to verify that the culture was not contaminated 
with B. hyodysenteriae. This was further confirmed in the current study by the negative result 
when the culture was amplified using a B. hyodysenteriae-specific PCR based on the NADH   70
oxidase gene. The bhlp29.7 gene also mapped to a different genomic restriction fragment in B256
T 
than it did in the B. hyodysenteriae strains. The presence of bhlp29.7 in a single strain of B. 
innocens  that was originally isolated in the 1970s (Kinyon and Harris, 1979) could also be 
interpreted as arising from a relatively recent strain-specific lateral transfer of the gene from B. 
hyodysenteriae to B. innocens strain B256
T. Such transfer could perhaps involve VSH-1, a 
generalised transducing bacteriophage present in B. hyodysenteriae and other Brachyspira species 
(Humphrey et al., 1995; Stanton et al., 2003).  
 
Generally, lipoproteins are believed to be highly immunogenic due to the attached fatty acid 
moiety and its surface exposure. The significance of this reactivity in relation to protection in 
animals remains uncertain, however the Bhlp29.7 lipoprotein is a potential candidate for use in 
vaccine development. This is particularly so as pigs immunised with E. coli expressing 
recombinant Bhlp29.7 developed serum antibody that reacted with Bhlp29.7 in the outer envelope 
of a range of different strains of B. hyodysenteriae (Lee, 1996). Annotation of Bhlp29.7 suggests 
that this protein may be a homologue of the D-methionine binding lipoprotein associated with the 
ATP-dependent uptake system for methionine. The fact that MUT systems in other bacteria may 
be involved in the virulence of these organisms further supports the potential of Bhlp29.7 as a 
vaccine candidate. 
 
Recombinant Bhlp29.7 may also be useful as an antigen for serological diagnosis of SD, as 
infected pigs recognised Bhlp29.7, whilst healthy uninfected pigs did not. However, the presence 
of a nearly identical Bhlp29.7 gene in a strain of B. innocens may pose a problem to the specificity 
of a Bhlp29.7-based serological assay, as B. innocens is a commensal commonly found amongst 
the porcine gastrointestinal flora. However, if expression of Bhlp29.7 in B. innocens is cryptic, 
then the likelihood of animals colonised with B. innocens having antibody levels against Bhlp29.7 
may be small.    71
 
Further work is required to determine whether recombinant Bhlp29.7 can induce protective 
immunity, and whether it can be adapted for use in the serological diagnosis of SD. Studies on 
these aspects will be presented in the chapters to follow. 
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CHAPTER 3: RECOMBINANT EXPRESSION AND  
PURIFICATION OF BHLP29.7 IN ESCHERICHIA COLI 
 
3.1. INTRODUCTION 
Recombinant proteins are produced by the transcription and translation of a gene of interest in 
a heterologous host. The foreign DNA encoding the protein of interest is cloned into an 
appropriate plasmid expression vector that will allow its expression in a desired heterologous 
host. The successful expression of recombinant proteins in sufficient quantities is a vital 
prerequisite to any detailed downstream application. 
 
Over the last twenty years recombinant protein expression has become a routine tool in most 
molecular biology research laboratories. The relatively recent revolution resulting from the 
development of molecular techniques allowing the genetic manipulation of micro-organisms 
has made a plethora of choices available for in vitro production of proteins in many host 
systems. Selection of the appropriate expression system and host cell-type greatly depends on 
the quality and quantity of the desired protein. Quality encompasses the requirement for post-
translational protein modifications, as well as the purity of the final protein. Quantity is a 
measure of the yield of purified protein required for the intended application. In general terms, 
the higher the degree of post-translational modification required, the smaller the expected yield 
of protein. Eukaryotic recombinant gene expression systems are primarily used for the 
production of high quality proteins where conformation and post-translational modifications 
are desired, but at the expense of quantity. Prokaryotic recombinant protein expression systems 
generally provide low quality proteins in considerably higher quantity. These expression 
systems are ideal for studies which are not dependent on activity or conformation of the 
recombinant protein, such as serological antigens (Gray and Subramanian, 2000). The 
production of recombinant Bhlp29.7 for this study was achieved using a prokaryotic 
expression system (E. coli).   73
Two distinct generations of prokaryotic expression systems have evolved since the early 1980s 
when genetic engineering was first utilised for heterologous protein production. The first 
generation prokaryotic expression systems involved cloning genes of interest into plasmid 
vectors which provided controlled gene expression inside the bacterial host cell. These early 
systems were controlled by well-known bacterial operon systems (such as lacZ and trpE) 
where promoters and factors facilitating expression had been well characterised (reviewed in 
Makrides, 1996; Baneyx, 1999). Purification of recombinant proteins expressed by the first 
generation systems involved traditional chromatography or antibody-based affinity 
chromatography. Inclusion body formation by the host cell made purification problematic due 
to the insoluble state of the aggregates (Coligan et al., 2002). 
 
A second generation of prokaryotic expression systems emerged which improved the 
efficiency of protein purification and allowed universal detection of the expressed protein. 
These upgraded systems included the addition of fusion-proteins or peptides to the gene of 
interest, and often incorporated adjacent protease cleavage sites for removal of the fusion after 
purification. Co-translation of the fusion-protein with the protein of interest allowed specific 
high-affinity purification procedures to be performed followed by removal of the fusion using 
specific protease cleavage, if required. Examples of such fusion-proteins include maltose-
binding protein (MBP, Maina et al., 1988), glutathione S-transferase (GST, Smith and 
Johnson, 1988) and thioredoxin (Trx, LaVallie et al., 1993). Many commercial expression 
systems are supplied with specialised strains of bacteria that provide tolerance of the elevated 
level of foreign protein expression, tight expression control, and reduced proteolytic 
degradation of the expressed protein (Wingfield, 2002). 
 
A commonly used modification of protein fusions are fusion-tags. These tags are small 
stretches of amino acids added to the terminal end of the protein of interest. Although the 
fusion-tags do not usually improve expression levels or protein solubility, they assist with 
purification and detection of the expressed protein. A popular example is the polyhistidine   74
(His6) tag used in the current study. The His6-tag consists of six consecutive histidine residues 
added to the N-terminal of the expressed protein and provides the capability of high-affinity 
purification using metal-chelate resins. In addition, affinity of the His6-tag for the metal-
chelate resin is independent of conformation, thus purification is not affected after treatment 
with denaturants (Janknecht et al., 1991; Schmitt et al., 1993). 
 
Purification of proteins using metal-chelate affinity chromatography (MCAC, also known as 
immobilised-metal affinity chromatography) was first describe in 1975 (Porath et al., 1975) 
and later verified with a variety of different proteins (Sulkowski, 1985). The technology is 
based on the ability of certain animo acids to bind reversibly to transition-metal ions that have 
been immobilised onto a chelating matrix. The amino acids (histidine, tryptophan, tyrosine and 
phenylalanine) act as electron donors on the surface of the proteins. Histidine is the most 
important of these amino acids as it has the highest affinity for the immobilised metal ions, and 
will bind selectively to them even in the presence of excess free-form metal ions in solution. 
Nickel and copper are the transition-metal ions which have the highest affinity for histidine 
(Yip et al., 1989). The initial application of MCAC used iminodiactic acid (IDA) as the 
chelating adsorbent and was found to be associated with problematic yields and purity. The 
development of nitrilotriacetic acid (NTA) significantly overcame these problems. IDA has 
only three metal-chelating sites compared to six metal-chelating sites in NTA. This means that 
NTA binds metal ions more stably thus allowing purification to be performed under more 
stringent conditions (Hochuli et al., 1987). A commonly used MCAC resin is Ni-NTA which 
consists of nickel ions immobilised onto a NTA solid support. Disassociation of the bound and 
washed proteins from the immobilised nickel ion can be achieved by lowering the buffer pH or 
using buffers containing high concentrations of a histidine analogue (imidazole) to displace the 
His6-tag.  
 
Production of recombinant proteins using E. coli expression systems have been achieved for a 
wide range of Gram-positive and Gram-negative bacteria. Cytoplasmic and membrane-  75
associated spirochaetal proteins have been produced in E. coli for Borrelia spp. (Dunn et al., 
1990; Hansson et al., 1995; Shang et al., 1997; Jauris-Heipke et al., 1999; Skare et al., 1999), 
Treponema spp. (Schouls et al., 1989; Blanco et al., 1996; Fenno et al., 1996; Gerber et al., 
1996; Champion et al., 1997; Xu et al., 2001), Leptospira spp. (Shang et al., 1995; Shang et 
al., 1996; Haake et al., 1999) and Brachyspira spp. (Koopman et al., 1992; Gabe et al., 1995; 
Dugourd et al., 1999; Hsu et al., 2001). Recombinant production of surface-exposed proteins 
has been of increased interest due to their potential as immuno-stimulating antigens for 
vaccination. Amongst the recombinant proteins from Brachyspira that have been studied, only 
three membrane proteins from Brachyspira species have been cloned and expressed. These 
include a 16 kDa outer membrane lipoprotein (SmpA) (Thomas and Sellwood, 1993) and a 39 
kDa surface-exposed protein (VspH) (McCaman et al., 2003; Witchell et al., 2006) for B. 
hyodysenteriae, and a 36 kDa glucose-galactose MglB lipoprotein of B. pilosicoli (Zhang et 
al., 2000).  
 
This chapter describes the cloning, over-expression and large-scale purification of the 29.7 
kDa outer-membrane lipoprotein (Bhlp29.7) of B. hyodysenteriae using an E. coli expression 
system. The ability to produce a sufficient quantity of the recombinant protein was an essential 
requirement for subsequent studies. The Bhlp29.7 gene was also sub-cloned and expressed in 
the same expression system in order to identify the approximate location of the epitope for the 
BJL/SH1 monoclonal antibody.   76
3.2. MATERIALS AND METHODS 
3.2.1. Cloning strategy 
Cloning of Bhlp29.7 into the pTrcHis Escherichia coli expression system had a two-fold 
purpose. Firstly, it allowed full-length Bhlp29.7 polypeptide to be expressed in E. coli and 
subsequently purified for further immunological studies. Secondly, it allowed portions of the 
Bhlp29.7 polypeptide to be sequentially truncated without the need to use protease digestion 
followed by complex fractionation procedures. The truncated Bhlp29.7 polypeptides were then 
used to determine the approximate binding location of the Mab BJL/SH1, which had initially 
allowed the Bhlp29.7 gene to be isolated.  
 
3.2.2. Plasmid Extraction 
E. coli JM109 clones harbouring the pTrcHisA plasmid (Invitrogen) were streaked out from 
glycerol stock storage onto LB agar plates supplemented with 100 mg/l ampicillin and 
incubated at 37°C for 16 h. A single colony was used to inoculate 10 ml of LB broth 
supplemented with 100 mg/l ampicillin and the broth culture was incubated at 37°C for 12 h 
with shaking.  The entire overnight culture was centrifuged at 5,000 × g for 10 min and the 
plasmid contained in the cells extracted using the QIAprep Spin Miniprep Kit (Qiagen) as 
described in Chapter 2 (Section 2.2.6). The purified plasmid was quantified using a Dynaquant 
DNA fluorometer (Hoefer), using pUC18 plasmid (Promega) as the standard, and the DNA 
concentration adjusted to 100 μg/ml by dilution with Tris-ethylenediaminetetraacetic acid (TE) 
buffer. The purified pTrcHisA plasmid was stored at -20°C. 
 
3.2.3. Vector Preparation 
One μg of the purified pTrcHisA plasmid was digested at 37°C overnight in a total volume of 
100μl containing 5 U of EcoR1 (Promega) and 5 U of Xho1 (Promega) in 100 mM Tris-HCl 
(pH 7.5), 50 mM NaCl, 10 mM MgCl2, dithiothreitol (DTT) and 100 μg/ml bovine serum 
albumin (BSA). The restricted vector was verified by electrophoresing 2 μl of the digestion   77
reaction through a 1% (w/v) agarose gel in 1× TAE buffer at 90V for 1 h. The electrophoresed 
DNA was stained with 1 μg/ml ethidium bromide and viewed over UV light. 
 
Linearised pTrcHisA vector was purified using the UltraClean PCR Clean-up Kit (Mo Bio 
Laboratories) as described in Chapter 2 (Section 2.2.12.2). Purified linear vector was 
quantified using the fluorometer (Hoefer), using calf thymus DNA (Hoefer) as the molecular 
mass standard, and the DNA concentration adjusted to 50 μg/ml by dilution with TE buffer. 
The purified restricted vector was stored at -20°C. 
 
3.2.4. Insert Preparation 
3.2.4.1. Primer design 
The primers used for PCR amplification and cloning in this chapter are listed in Table 3.1. All 
cloning primers included a restriction enzyme recognition site at the 5’-OH end to enable 
cohesive-end ligation of the resultant amplicon into the linearised pTrcHisA vector. All 
upstream (forward) primers contained a terminal Xho1 recognition site and all downstream 
(reverse) primers contained a terminal EcoR1 recognition site. The primers were tested in 
silico using Amplify 1.2 (University of Wisconsin) and the theoretical amplicon sequence was 
inserted into the appropriate position in the pTrcHisA vector sequence. Deduced translation of 
the chimeric pTrcHisA expression cassette was performed using Vector NTI version 6 
(InforMax) to determine the expected molecular mass of the recombinant polypeptides, and to 
confirm that the Bhlp29.7 inserts were in the correct reading frame. 
 
Two primers (Bhlp29.7-F13-Xho1 and Bhlp29.7-R809-EcoR1) were designed to amplify an 
internal 796 bp coding region of Bhlp29.7 such that upon translation, the lipoprotein signal 
peptide was modified in the polypeptide. Three reverse primers (Bhlp29.7-R195-Xho1, 
Bhlp29.7-R411-EcoR1, Bhlp29.7-R613-EcoR1) were designed which annealed to the 
Bhlp29.7 gene at approximately 25%, 50% and 75% of the gene, respectively.  The   78
combination of the Bhlp29.7-F13-Xho1 primer and each of the above reverse primers 
generated amplicons whereby the expressed Bhlp29.7 polypeptide would be sequentially 
truncated by 25% with each reverse primer. That is, Bhlp29.7-F13-Xho1 with Bhlp29.7-R195-
EcoR1 produced the N-terminal 25% portion of Bhlp29.7 (residues 5 to 65), Bhlp29.7-F13-
Xho1 with Bhlp29.7-R411-EcoR1 produced the N-terminal 50% portion of Bhlp29.7 (residues 
5 to 137), and Bhlp29.7-F13-Xho1 with Bhlp29.7-R613-EcoR1 produced the N-terminal 75% 
portion of Bhlp29.7 (residues 5 to 204). One forward primer (Bhlp29.7-F604-Xho1) was 
designed to anneal to the Bhlp29.7 gene at approximately 75% along the length of the gene. 
When used in combination with Bhlp29.7-R809-EcoR1, this allowed the C-terminal 25% 
(residue 202 to 269) to be cloned. All truncates of Bhlp29.7 overlapped such that every part of 
Bhlp29.7 was represented in at least one of the sub-clones. A schematic representation of the 
cloning and sub-cloning of Bhlp29.7 is shown in Fig. 3.1. 
 
 
Table 3.1.  Oligonucleotide primers used for the cloning of bhlp29.7 into pTrcHis. 
Primer name  TA (°C)  Sequence (5’-3’) 
Bhlp29.7-F13-Xho1 60  AAACTCGAGTTATTATTGGTATCATCAGC 
Bhlp29.7-R809-EcoR1 60 TATGAATTCCAAGTAGGAAGATAAGAACC 
Bhlp29.7-R195-EcoR1 58 TATGAATTCATCAGAGAAAGATACTAGCTC 
Bhlp29.7-R411-EcoR1 57 TCCGAATTCAGAAGGGTCATTAGGTATAGC 
Bhlp29.7-R613-EcoR1 60 GATGAATTCCGAAGTATATAGCATAGTTTC 
Bhlp29.7-F604-Xho1 57  AACCTCGAGATATACTTCGGTTTGAATCCTG 
pTrcHis-F 60 CAATTTATCAGACAATCTGTGTG 
pTrcHis-R 60 TGCCTGGCAGTTCCCTACTCTCG   79
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4.2. Amplification of the Bhlp29.7 inserts 
The Bhlp29.7 inserts were amplified by PCR in a 100 μl total volume using Taq DNA 
polymerase (Biotech International) and Pfu DNA polymerase (Promega). Briefly, the 
amplification mixture consisted of 1× PCR buffer (containing 1.5 mM of MgCl2), 1 U of Taq 
DNA polymerase, 0.1 U Pfu DNA polymerase, 0.2 mM of each deoxynucleotide triphosphate 
(dNTP; Promega), 0.5 μM of the primer pair (Bhlp29.7-F13-Xho1 and Bhlp29.7-R195-EcoR1; 
Bhlp29.7-F13-Xho1 and Bhlp29.7-R411-EcoR1; Bhlp29.7-F13-Xho1 and Bhlp29.7-R613-
EcoR1; Bhlp29.7-F13-Xho1 and Bhlp29.7-R809-EcoR1; Bhlp29.7-F604-Xho1 and Bhlp29.7-
R809-EcoR1), and 2.5 μl chromosomal template DNA from B. hyodysenteriae strain WA1 (a 
Figure 3.1. Schematic representation of the Bhlp29.7 truncated fragments 
which were cloned into pTrcHisA. Five clones were constructed corresponding 
to approximately 100% (A), 25% (B), 50% (C), 75% (D) and C-terminal 25% 
(E) of the native Bhlp29.7 protein. The numbers indicate the base positions of 
the native Bhlp29.7 gene at which the cloning primers annealed. 
native bhlp29.7 
1  813 
13  809 
rec. Bhlp29.7 
13 195 
Bhlp29.7-R195 
13 411 
Bhlp29.7-R411 
13 613 
Bhlp29.7-R613 
809  604 
Bhlp29.7-F604 
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Western Australian field strain isolated from a pig) that was prepared in Chapter 2 (section 
2.2.1). Cycling conditions involved an initial template denaturation step of 5 min at 94°C, 
followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 15 sec, and 
primer extension at 68°C for 2 min. The PCR products were subjected to electrophoresis in 
1.5% (w/v) agarose gels in 1× TAE buffer, stained with a 1 μg/ml ethidium bromide solution 
and viewed over UV light. After verifying the presence of the correct size PCR product, the 
PCR reaction was purified using the UltraClean PCR Clean-up Kit as described in Chapter 2 
(section 2.2.12.2). The purified PCR product was eluted from the clean-up column using 100 
μl of TE buffer. 
 
3.2.4.3. Restriction enzyme digestion of the Bhlp29.7 inserts 
Fifty μl of each purified PCR product was digested in a 100 μl total volume with 1 U of EcoR1 
and 1 U of Xho1 in 100 mM Tris-HCl (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT and 
100 μg/ml BSA at 37°C overnight. The digested insert DNA was purified using the UltraClean 
PCR Clean-up Kit (section 2.2.12.2). Purified digested insert DNA was eluted from the clean-
up column using 50μl of TE buffer and was quantified using a fluorometer (Hoefer), with calf 
thymus DNA (Hoefer) as the molecular mass standard. The DNA concentration was adjusted 
to 20 μg/ml by dilution with TE buffer. The purified restricted insert DNA was used 
immediately for vector ligation. 
 
3.2.4.4. Ligation of the Bhlp29.7 inserts into the pTrcHisA vector 
Ligation reactions were all performed in a total volume of 20 μl. One hundred ng of 
Xho1/EcoR1-linearised pTrcHisA was incubated with 20 ng of Xho1/EcoR1-restricted 
Bhlp29.7 insert at 14°C for 16 h in 30 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM DTT 
and 1 mM adenosine triphosphate (ATP) containing 1 U of T4 DNA ligase (Promega). An 
identical ligation reaction containing no Bhlp29.7 insert DNA was also included as a vector re-
circularisation negative control.   81
3.2.5. Transformation of pTrc-Bhlp29.7 into E. coli cells 
Competent E. coli BL21 Star™ (DE3) pLys One Shot
® (Invitrogen) cells were thawed from -
80°C storage on ice and then 50 μl of the cells were transferred into ice-cold 1.5 ml microfuge 
tubes containing 5 μl  of the overnight ligation reactions (equivalent to 25 ng of pTrcHisA 
vector). The tubes were mixed by gently tapping the bottom of each tube on the bench and left 
on ice for 30 min. The cells were then heat-shocked by placing the tubes into a 42°C water-
bath for 45s before returning the tube to ice for 2 min. The transformed cells were recovered in 
1 ml LB broth for 1 h at 37°C with gentle mixing. The recovered cells were harvested at 2,500 
× g for 5 min and the cells resuspended in 50 μl of fresh LB broth. The entire 50 μl of 
resuspended cells were spread evenly onto a LB agar plate containing 100 mg/l ampicillin 
using a sterile glass rod. Plates were incubated at 37°C for 16 h. 
 
3.2.6. Detection of the pTrc-Bhlp29.7 constructs in E. coli by PCR 
For each transformation reaction, 12 single transformant colonies were streaked onto fresh LB 
agar plates containing 100 mg/l ampicillin and incubated at 37°C for 16 h. A single colony 
from each transformation event was resuspended in 50 μl of TE buffer and boiled for 1 min. 
Two μl of boiled cells were used as template for PCR. The amplification mixture consisted of 
1× PCR buffer (containing 1.5 mM of MgCl2), 1 U of Taq DNA polymerase, 0.2 mM of each 
dNTP, 0.5 μM of the pTrcHis-F primer and 0.5 μM of the pTrcHis-R primer. Cycling 
conditions involved an initial template denaturation step of 5 min at 94°C, followed by 30 
cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 15 sec, and a primer extension 
at 72°C for 30s. The PCR products were subjected to electrophoresis in 1.5% (w/v) agarose 
gels in 1× TAE buffer, stained with a 1 μg/ml ethidium bromide solution and viewed over UV 
light. 
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3.2.7. Verification of the pTrc-Bhlp29.7 constructs by direct sequence analysis 
Two transformant clones which produced the correct sized PCR products for each construct 
were inoculated into 10 ml LB broth containing 100 mg/l ampicillin and incubated at 37°C for 
12 h with shaking. The overnight cultures were centrifuged at 5,000 × g for 10 min and the 
plasmid contained in the cells extracted using the QIAprep Spin Miniprep Kit as described in 
chapter 2 (section 2.2.6). The purified plasmid was quantified using a fluorometer (Hoefer), 
and pUC18 plasmid (Promega) as the standard. Both purified plasmids for each construct were 
subjected to automated direct sequencing of the pTrcHisA expression cassette using the 
pTrcHis-F and pTrcHis-R primers. Each sequencing reaction was performed in a 10 μl volume 
consisting of 200 ng of plasmid DNA, 2 pmol of primer, and 4 μl of the ABI PRISM™ Dye 
Terminator Cycle Sequencing Ready Reaction Mix (PE Applied Biosystems).  Cycling 
conditions involved a 2 min denaturing step at 96°C, followed by 25 cycles of denaturation at 
96°C for 10s and a combined primer annealing and extension step at 60°C for 4 min.  Residual 
dye terminators were removed from the sequencing products by precipitation with 95% (v/v) 
ethanol containing 120 mM sodium acetate (pH 4.6), and vacuum dried. The plasmids were 
sequenced in duplicate using each primer. Sequencing products were analysed using an ABI 
373A DNA Sequencer (PE Applied Biosystems). Successfully ligated plasmids were 
designated pTrc-Bhlp29.7, pTrc-Bhlp29.7-R195, pTrc-Bhlp29.7-R411, pTrc-Bhlp29.7-R613 
and pTrc-Bhlp29.7-F604. 
 
3.2.8. Pilot expression of recombinant Bhlp29.7 proteins 
A single colony of each Bhlp29.7 construct in E. coli BL21 was inoculated into 10 ml LB 
broth containing 100 mg/l ampicillin and incubated at 37°C for 16 h with shaking. Fifty ml of 
LB broth in a 250 ml conical flask containing 100 mg/l ampicillin was inoculated with 1 ml of 
the overnight culture and incubated at 37°C until the optical density of the cells at 600 nm was 
0.5 (approximately 3 h). IPTG was then added to the cells to a final concentration of 1 mM and 
the cells returned to 37°C with shaking for 6 h. The cells were harvested by centrifugation at   83
5,000 × g for 10 min before resuspending each cell pellet with 2 ml of nickel-nitrilotriacetic 
acid (Ni-NTA) denaturing lysis buffer. All cell lysates were incubated at -20°C overnight. Cell 
debris was clarified from the thawed lysates by centrifuging at 20,000 × g for 15 min at 4°C. 
The supernatant from each construct was individually collected and used for SDS-PAGE 
(chapter 2, section 2.2.4) and Western blotting (chapter 2, section 2.2.5) with Mab BJL/SH1 
diluted 10-fold. To confirm that the recombinant his-tagged proteins had been expressed, 
mouse anti-polyhistidine (Sigma Chemical Company) diluted 5,000-fold was also used for 
Western blotting. Goat anti-mouse IgG-HRP (Sigma Chemical Company) was used to detect 
antibody binding.  
 
3.2.9. Large-scale expression of recombinant His6-Bhlp29.7 
The His6-Bhlp29.7 protein was needed in high concentration for development of an indirect 
antibody test (see chapter 4) and for vaccination of pigs (see chapter 5). For these reason, His6-
Bhlp29.7 was expressed and purified in large-scale. A single colony of pTrc-Bhlp29.7 in E. 
coli BL21 was inoculated into 50 ml LB broth in a 250 ml conical flask containing 100 mg/l 
ampicillin and incubated at 37°C for 16 h with shaking. A 2 litre conical flask containing 1 l of 
LB broth supplemented with 100 mg/l ampicillin was then inoculated with 10 ml of the 
overnight culture and incubated at 37°C until the optical density of the cells at 600 nm was 0.5 
(approximately 3-4 h). Expression was induced by adding IPTG to a final concentration of 1 
mM and the cells returned to 37°C with shaking. After 6 h of induction, the culture was 
transferred to 250 ml centrifuge bottles and the bottles were centrifuged at 5,000 × g for 20 
min at 4°C. The supernatant was discarded and each pellet was resuspended with 10 ml Ni-
NTA denaturing lysis buffer (i.e. 40 ml lysis buffer per 1 l cell culture). The lysates were 
incubated at -20°C overnight. 
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3.2.10. Large-scale purification of recombinant His6-Bhlp29.7 
The cell lysates were removed from -20°C and thawed on ice. To reduce the viscosity of the 
lysate (due to E. coli DNA), the lysates were sonicated on ice three times for 30s with 2 min 
incubation on ice between sonication rounds. The lysed cells were clarified by centrifugation 
at 20,000 × g for 10 min at 4°C and the supernatants transferred to 15 ml columns containing a 
1 ml bed volume of Ni-NTA agarose resin (Qiagen). The columns were securely capped and 
the his-tagged proteins were allowed to bind to the resin for 1 h at 4°C with end-over-end 
mixing. The resin was then washed five times with 10 ml of Ni-NTA denaturing wash buffer 
before elution with Ni-NTA denaturing elution buffer. Three 10 ml fractions of the eluate were 
collected and stored at 4°C. The purified proteins were subjected to SDS-PAGE (chapter 2, 
section 2.2.4) and stained with Coomassie Brilliant Blue G250 (CBB-G250; Sigma Chemical 
Company). The electrophoresed proteins in the gel were fixed for 30 min in CBB-G250 fixing 
solution before being transferred to the CBB-G250 staining solution for 1 h. The staining 
solution was decanted and the gel was de-stained for 3 h with three changes of CBB-G250 
destaining solution. The de-stained gel was equilibrated in distilled water for 1 h and dried 
between two sheets of cellulose overnight at RT. 
 
3.2.11. Dialysis and lyophilisation of the purified recombinant His6-Bhlp29.7 
The eluted fractions containing purified his-tagged proteins were pooled and transferred into a 
hydrated dialysis tube (Spectrum Laboratories) with a molecular weight cut-off (MWCO) of 
3,500 Da. A 200 μl aliquot of the pooled eluate was taken and quantified using the Bio-Rad 
Protein Assay (Bio-rad Laboratories) (see below).  The proteins were dialysed against 2 l of 
distilled water at 4°C with stirring. The distilled water was changed eight times at 12-hourly 
intervals. The dialysed proteins were transferred from the dialysis tube into a 50 ml centrifuge 
tubes (40 ml maximum volume) and the tubes were placed at -80°C overnight before being 
transferred to a MAXI freeze-drier (Heto-Holten) and lyophilised to dryness. The lyophilised   85
protein was then re-hydrated with physiological saline to a concentration of 2 mg/ml and 
stored at -20°C in 1 ml aliquots. 
 
3.2.12. Western blot analysis of re-hydrated, purified His6-Bhlp29.7 with infected pig 
serum 
Ten μg of the purified His6-Bhlp29.7 antigen was loaded into a 7cm preparative well and 
subjected to SDS-PAGE (described in chapter 2, section 2.2.4) and Western blotting 
(described in chapter 2, section 2.2.5) using 6 pig serum samples obtained from a herd in 
which SD was observed. Serum from a pig hyper-immunised with a bacterin made with B. 
hyodysenteriae strain B78
T (see chapter 4, section 4.2.2) was used as a positive control. The 
pig serum was diluted 50-fold in TBST and goat anti-pig IgG-HRP conjugate (diluted 5,000-
fold) (Southern Biotechnology) was used for the blot. The hyper-immunised pig serum raised 
against B. hyodysenteriae strain B78
T (diluted 100-fold) was included as a positive control. 
 
3.2.13. Quantification of the purified recombinant His6-Bhlp29.7 
A commercial BSA protein standard (Sigma Chemical Company) was serially diluted with Ni-
NTA native elution buffer in 2-fold serial dilutions from 6.25 μg/ml to 100 μg/ml. The purified 
recombinant His6-Bhlp29.7 was also diluted with the same buffer in 2-fold serial dilutions 
from 2-fold to 32-fold. Twenty μl of the Protein Assay Reagent (Bio-rad Laboratories) was 
added to the wells of a 96-well microtitre plate. Eighty μl of the corresponding protein 
standards or purified protein was added to the appropriate wells and the microtitre plate was 
gently vortexed to mix. The BSA standards were assayed in triplicate and the diluted purified 
his-tagged proteins were tested in duplicate. The microtitre plate was then placed into a 
microtitre plate reader (Model 3550-UV; Bio-rad Laboratories) and the optical density at 600 
nm recorded. The standard curve generated from the optical density of the protein standards 
was used to interpolate the concentration of the His6-Bhlp29.7 sample and subsequently the 
yield of protein obtained from the 1 litre culture.   86
3.3. RESULTS 
3.3.1. Construction of the pTrc-Bhlp29.7 recombinant vector 
Cloning of the full-length bhlp29.7 insert into the pTrcHisA expression vector produced a 
recombinant construct, designated pTrc-Bhlp29.7, which was 5,168 bp in size. A complete 
plasmid map of pTrc-Bhlp29.7 expression vector is shown in Fig. 3.2. Sub-cloning of bhlp29.7 
to yield truncates of the gene produced four constructs. These constructs were essentially 
identical to pTrc-Bhlp29.7 but had shorter inserted sequences following the Xho1-EcoR1 
cloning site. The constructs were designated pTrc-Bhlp29.7-R195 (4,554 bp), pTrc-Bhlp29.7-
R411 (4,770 bp), pTrc-Bhlp29.7-R613 (4,972 bp) and pTrc-Bhlp29.7-F604 (5,577 bp). 
Nucleotide sequencing of the pTrc-Bhlp29.7 constructs verified that the expression cassette 
was in the correct frame for all five plasmids. Predicted translation of the pTrc-Bhlp29.7 
constructs indicated the recombinant Bhlp29.7 proteins were identical to the deduced amino 
acid sequence of corresponding portions of native Bhlp29.7. 
 
3.3.2. Expression and purification of recombinant His6-Bhlp29.7 
Expression of the pTrc-Bhlp29.7 construct produced a recombinant his-tagged Bhlp29.7 
protein with an apparent molecular mass of 34 kDa. The anti-histidine and BJL/SH1 
monoclonal antibodies reacted strongly with the recombinant His6-Bhlp29.7 (Fig. 3.3 and Fig. 
3.4). Purification of the His6-Bhlp29.7 recombinant protein by affinity chromatography under 
denaturing conditions successfully yielded his-tagged Bhlp29.7 at a level of purity at which 
CBB-G250 staining was unable to detect contaminating co-elution products (Fig. 3.5). 
Recombinant protein yields of 4 mg/L were consistently obtained. Following dialysis and 
lyophilisation, a stable recombinant His6-Bhlp29.7 antigen was successfully produced. 
Expression of Bhlp29.7 in E. coli as a his-tagged protein, and the purification of His6-Bhlp29.7 
under denaturing conditions did not alter its reactivity with infected pig serum and hyper-
immunised pig serum (Fig. 3.6). 
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Figure 3.2. Complete plasmid map of the pTrc-Bhlp29.7 expression vector 
showing features of the vector and the restriction sites used in its construction. 
The plasmid map for the truncated Bhlp29.7 constructs (pTrc-Bhlp29.7-R195, 
pTrc-Bhlp29.7-R411, pTrc-Bhlp29.7-R611 and pTrc-Bhlp29.7-F604) is 
essentially identical except for shorter coding sequences between the Xho1 and 
EcoR1 enzyme recognition sites.   88
Figure 3.3. Western blot analysis of recombinant his-tagged Bhlp29.7 
truncates expressed in E. coli. The expressed proteins were detected using the 
anti-histidine monoclonal antibody. Lane 1, “full-length” Bhlp29.7; lane 2, 
Bhlp29.7-R195 (N-terminal 25% portion); lane 3, Bhlp29.7-R411 (N-terminal 
50% portion); lane 4, Bhlp29.7-R613 (N-terminal 75% portion). The arrow 
indicates the position of the “full-length” his-tagged Bhlp29.7  protein. 
Figure 3.4. Western blot analysis of recombinant his-tagged Bhlp29.7 truncates 
expressed in E. coli. The expressed proteins were detected using the 
monoclonal antibody BJL/SH1. Lane 1, “full-length” Bhlp29.7; lane 2, 
Bhlp29.7-R195 (N-terminal 25% portion); lane 3, Bhlp29.7-R411 (N-terminal 
50% portion); lane 4, Bhlp29.7-R613 (N-terminal 75% portion). The arrow 
indicates the position of the “full-length his-tagged Bhlp29.7 protein.   89
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Coomassie Brilliant Blue G250 stain of recombinant his-tagged 
Bhlp29.7 purified by affinity chromatography using Ni-NTA agarose. Lane 1, 
first elution fraction; lane 2, second elution fraction; lane 3, third elution 
fraction. 
Figure 3.6. Reactivity of recombinant his-tagged Bhlp29.7 against 
convalescent pig serum. The pig serum was obtained from a herd in which SD 
had been observed. The anti-histidine monoclonal antibody was included as an 
internal control. Lane 1, hyper-immunised pig serum raised against B. 
hyodysenteriae strain B78
T; lanes 2-7, infected pig sera. The arrow indicates 
the position of the his-tagged Bhlp29.7 protein.   90
3.3.3. Reactivity of monoclonal antibody BJL/SH1 with truncated Bhlp29.7 proteins 
Expression of the pTrc-Bhlp29.7 sub-cloning constructs produced four recombinant his-tagged 
proteins with an apparent molecular mass of 11.6 kDa, 20.1 kDa, 26.7 kDa and 12 kDa for 
His6-Bhlp29.7-R195, His6-Bhlp29.7-R411, His6-Bhlp29.7-R613 and His6-Bhlp29.7-F604, 
respectively. The anti-histidine Mab reacted strongly with the all the recombinant Bhlp29.7 
truncates indicating that all these truncates were expressed with an intact his-tag (Fig. 3.3 and 
Fig. 3.7). However, only the His6-Bhlp29.7-F604 protein (C-terminal 25% polypeptide) 
reacted with Mab BJL/SH1 (Fig. 3.4 and Fig. 3.7). Nucleotide sequencing of all the sub-
cloning constructs indicated that there were no discrepancies between the deduced amino acid 
sequence of the recombinant truncates and the native Bhlp29.7 protein. The lack of reactivity 
of Mab BJL/SH1 with all Bhlp29.7 truncates except the Bhlp29.7-F604 truncate indicates that 
the epitope for Mab BJL/SH1 is located on the C-terminal 25% portion of Bhlp29.7 between 
residues 202 and 269. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Western blot analysis of recombinant his-tagged Bhlp29.7-F604 
(C-terminal 25% portion) using the anti-histidine and BJL/SH1 monoclonal 
antibodies. Lane 1, “full-length” his-tagged Bhlp29.7 protein reacting with 
Mab BJL/SH1; lane 2, his-tagged Bhlp29.7-F604 protein reacting with Mab 
BJL/SH1; lane 3, his-tagged Bhlp29.7-F604 protein reacting with the anti-
histidine Mab.   91
Comparative analysis of the translated amino acid sequence of Bhlp29.7 for the 11 B. 
hyodysenteriae strains and B. innocens strain B256
T (chapter 2, section 2.3.4) identified an 
amino acid dissimilarity at position 210 which occurred only in B. innocens strain B256
T, 
where the serine for B. hyodysenteriae was replaced by a tyrosine for B. innocens strain B256
T 
(Fig. 3.8). 
 
 
 
 
                  205        215        225        235 
               ....|....| ....|....| ....|....| ....|....|  
B78T           AIDFGLNPGS DYIFKDDPSI YSGKSFVNLI AARTKDKDNE  
P18A           AIDFGLNPGS DYIFRDDPSI YSGKSFVNLI AARTKDKDNE  
B169           AIDFGLNPGS DYIFKDDPSI YSGKSFVNLI AARTKDKDNE  
B204           AIDFGLNPGS DYIFRDDPSI YSGKSFVNLI AARTKDKDDE  
B/Q02          AIDFGLNPGS DYIFKDDPSI YSGKSFVNLI AARTKDKDNE  
WA4,5          AIDFGLNPGS DYIFKDDPSI YSGKSFVNLI AARTKDKDNE  
WA1,6,15,16    AIYFGLNPGS DYIFKDDPSI YSGKSFVNLI AARTKDKDNE  
B256T          AIDFGLNPGY DYIFKDDPSI YSGKSFVNLI AARTKDKDNE 
Figure 3.8. Comparative analysis of the translated amino acid sequence of 
Bhlp29.7 for the 11 B. hyodysenteriae strains and B. innocens strain B256
T. 
The polypeptide between residues 202 and 269 possibly contains the epitope 
for Mab BJL/SH1. The amino acid dissimilarity present only in B. innocens 
strain B256
T is indicated in bold type-face. Sequence between residues 202 to 
199, and 241 to 269 were identical for all strains. The bhlp29.7 sequence for 
WA4 and WA5 were identical, as were the sequences of WA1, WA6, WA15 
and WA16.   92
3.4. DISCUSSION 
The Bhlp29.7 gene of B. hyodysenteriae was amplified by PCR and cloned into the bacterial 
expression vector pTrcHis. Oligonucleotide primers were designed to replicate the Bhlp29.7 
ORF such that upon translation, the pro-lipoprotein would have amino acids 1 to 4 of the 
native Bhlp29.7 replaced with the His6-tag. The remaining amino acid sequence was left 
unchanged. PCR amplification was performed using Taq DNA polymerase and Pfu DNA 
polymerase.  Pfu DNA polymerase is responsible for DNA repair of mis-matched bases 
(Barnes, 1994). The use of the high-fidelity Pfu DNA polymerase for PCR reduces the high 
error rate characteristic of Taq DNA polymerase activity (Flaman et al., 1994; Cline et al., 
1996). In addition, the Bhlp29.7 gene was sequentially sub-cloned into the pTrcHis vector 
such that the expressed recombinant proteins represented four truncates of the Bhlp29.7 
protein. These included an N-terminal 25% portion (Bhlp29.7-R195), an N-terminal 50% 
portion (Bhlp29.7-R411), an N-terminal 75% portion (Bhlp29.7-R613) and a C-terminal 25% 
portion (Bhlp29.7-F604). Sequence analysis of the cloned Bhlp29.7 ORF indicated that no 
mutations were introduced by the DNA polymerase during PCR amplification for cloning. The 
PCR-amplified Bhlp29.7 products were ligated into the pTrcHis expression cassette in the 
correct reading frame and the deduced translation of the cloned inserts were identical to the 
deduced translation of the original Bhlp29.7 gene. 
 
The purpose for sub-cloning Bhlp29.7 was to determine the approximate location of the 
epitope for Mab BJL/SH1. Western blot analysis with an anti-histidine Mab indicated that all 
Bhlp29.7 truncates had been expressed. Western blotting with Mab BJL/SH1 showed 
reactivity with the full recombinant Bhlp29.7 protein and the Bhlp29.7-F604 truncate, but not 
with the other truncates. This indicated that the epitope for the Mab BJL/SH1 was located at 
the C-terminal end of Bhlp29.7 between amino acid residues 202 and 269. Comparative 
analysis of the amino acid sequence of Bhlp29.7 for 11 B. hyodysenteriae strains and B. 
innocens strain B256
T identified an amino acid substitution at residue 210 which occurred only 
in the B. innocens strain, where the serine for B. hyodysenteriae was replaced by a tyrosine for   93
B256
T. The Mab BJL/SH1 is specific for B. hyodysenteriae, and does not bind to B. innocens 
strain B256
T even though it possess a homologue of Bhlp29.7. Based on the presence of this 
single consistent difference in the amino acid sequences of Bhlp29.7 between the B. 
hyodysenteriae strains and B. innocens strain B256
T, it is likely that the binding site of Mab 
BJL/SH1 is localised around position 210 (serine) of Bhlp29.7, and that the tyrosine residue 
contained on the Bhlp29.7 of B. innocens B256
T at position 210 prevents cross-reactivity. 
Identification of the epitope for this antibody could provide a suitable peptide antigen for 
serological diagnosis of SD.  Although an estimation of the epitope location has been 
suggested, further work is needed to confirm this hypothesis. 
 
The remaining emphasis of this chapter was to generate recombinant Bhlp29.7 proteins in high 
concentration and purity without the need for complex methodologies such as high 
performance liquid chromatography and fast performance liquid chromatography. Following 
the outcome from sub-cloning bhlp29.7, His6-Bhlp29.7 and His6-Bhlp29.7-F604 were 
expressed and purified for subsequent studies. 
  
Over-expression of foreign proteins in E. coli frequently results in the sequestering of these 
proteins into insoluble inclusion bodies (Schein, 1989). The inclusion bodies can be solubilised 
easily with denaturants such as guanidine hydrochloride and urea, or with a variety of 
detergents, however, all tertiary structure is lost and refolding of the denatured protein can be 
complex with no guarantee of restoring the native structure.  In addition, proteins in inclusion 
bodies are usually resistant to proteolytic degradation. Unfortunately the solubilisation process 
results in denaturation of the recombinant protein which is a serious disadvantage for intended 
applications requiring correct conformation and presentation. For applications in which 
activity of the expressed protein is not essential (such as antibody production) inclusion body 
formation is the most common strategy for high-level expression of recombinant protein in E. 
coli (Coligan et al., 2002). In this project, the recombinant Bhlp29.7 protein was expressed at 
high levels in insoluble form and subsequently solubilised using 8 M urea. The   94
immunogenicity of the recombinant His6-Bhlp29.7 protein did not appear to affect by 
denaturation as six different sera taken from pigs from a herd with SD reacted strongly with 
the denatured form of the recombinant protein. 
 
The native Bhlp29.7 lipoprotein has been found to be membrane-associated and shares 
homology with the D-methionine transport proteins of various bacteria, including E. coli 
(Chapter 2). Expression of recombinant membrane proteins in E. coli can be toxic, resulting in 
the inhibition of cell growth following induction. This is most likely due to the association of 
hydrophobic regions of the protein with or incorporation into vital membrane systems of the 
host (Coligan et al., 2002). It seems likely that interference of the E. coli D-methionine 
transport system with a possible homologue from B. hyodysenteriae would hinder cell growth, 
and hence be toxic to E. coli during recombinant protein expression, but fortunately this did 
not occur. Although the signal peptidase cleavage site of Bhlp29.7 is similar to that of E. coli 
(Chapter 2), the cellular processes involved in post-translational modifications leading to the 
ultimate attachment of the lipoprotein to the cell membrane may be incompatible with the E. 
coli system - hence recombinant His6-Bhlp29.7 may not be recognised by E. coli as a 
membrane destined protein. In addition, amino acid residues 1 to 4 of the native Bhlp29.7 were 
replaced with the His6-tag during the cloning process. If the signal peptides of E. coli and B. 
hyodysenteriae were compatible, the modifications to the Bhlp29.7 signal peptide during 
cloning may have caused the signal peptide to be unrecognisable to the E. coli cellular 
machinery, hence accounting for the unexpected non-toxicity of recombinant His6-Bhlp29.7. 
Furthermore, the over-expression of recombinant His6-Bhlp29.7 as inclusion bodies renders 
the protein inactive, thus preventing it from associating with the membrane of the host. 
 
Purification of the His6-tagged proteins using nickel-nitrilotriacetic acid (Ni-NTA) metal-
affinity chromatography is independent of conformation, and exploits the high affinity of 
histidine for nickel ions (Ni
2+). Due to this characteristic, purification of the recombinant 
Bhlp29.7 proteins were performed under denaturing conditions allowing easy solubilisation of   95
inclusion bodies which had formed. The proteins after affinity purification were highly pure 
and any co-purification contaminants were of insufficient quantity to be detected by 
Coomassie Brilliant Blue staining. The pooled fractions containing the purified His6-Bhlp29.7 
and His6-Bhlp29.7-F604 were dialysed against distilled water to remove the urea present in the 
eluate. Re-folding of the purified protein was not considered worthwhile as the activity and 
conformation of His6-Bhlp29.7 was not believed to be essential for downstream applications.  
 
In this study, the expression conditions for His6-Bhlp29.7 were chosen to favour high-yield 
over solubility. Following solubilisation and purification by Ni-NTA metal-affinity 
chromatography under denaturing conditions, yields of at least 4 mg per litre of culture were 
consistently achieved. This high-level expression and purification of the Bhlp29.7 protein in 
recombinant form was a crucial component of the subsequent studies described in this thesis. 
The recombinant Bhlp29.7 protein produced was used for serological analysis of blood 
samples taken from pigs in Australian herds, and for vaccination of experimentally challenged 
pigs, as described in the following chapters. 
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CHAPTER 4: EVALUATION OF RECOMBINANT BHLP29.7 
AS AN ELISA ANTIGEN FOR SD SEROLOGY 
 
4.1. INTRODUCTION 
In the field, diagnosis of SD primarily relies on the herd history and observation of typical 
clinical signs including the presence of diarrhoea containing fresh blood and/or mucus, usually 
restricted to pigs in the grower/finisher phase. However, these clinical signs can be similar to 
those of other diseases including salmonellosis, swine fever and colibacillosis (Harris et al., 
1999). Furthermore, in some herds typical signs may not be observed – particularly if the herd 
is receiving routine antimicrobial therapy. A definitive diagnosis of SD still requires the 
isolation and identification of the causative agent. For many years, the identification of B. 
hyodysenteriae has been dependant on observing its phenotypic characteristics, however, the 
development of PCR now allows a molecular-based approach to B. hyodysenteriae-specific 
diagnosis, supplementing microbiological culture and biochemical testing. Antigen-based 
detection methods also have been used to help identify B. hyodysenteriae, however these 
methods have a tendency to lack sensitivity and specificity. To date, reliable serological assay 
to detect antibody to B. hyodysenteriae, and hence provide indirect evidence of exposure, are 
not available. 
 
Enzyme immunoassays (such as enzyme-linked immunosorbent assay or ELISA) are based on 
two important biological phenomena: (i) the extraordinary discriminatory power of antibodies, 
based on the ability of the immune system of vertebrates to produce a virtually unlimited array 
of antibodies, each with an affinity for a specific foreign antigen; and (ii) the extremely high 
catalytic power and specificity of enzymes, which quite often may be detectable with great 
ease. ELISA consists of a two-pronged strategy: the reaction between the immuno-reactants 
(antibody with the corresponding antigen) and the detection of that reaction using enzymes,   97
labelled to the reactants, as indicators. The specificity of the assay resides with the particular 
antigen molecule used to capture reactive antibody. 
 
Colonisation by B. hyodysenteriae elicits a strong immunological response against the 
spirochaete (Harris et al., 1999), and hence indirect evidence of exposure to B. hyodysenteriae 
can be obtained by measuring circulating antibody titres in the blood of infected animals.  
Several serological tests have been developed that detect antibodies to B. hyodysenteriae in the 
serum of infected pigs (reviewed in chapter 1). These tests have not been based on species-
specific antigens, and, as a consequence, lack specificity and/or sensitivity. Of the serological 
tests available, ELISA appears to be the most promising, potentially providing the greatest 
sensitivity and the ability to analyse large numbers of samples simultaneously. Although 
classical ELISA tests for SD (based on lipopolysaccharides or sonicated cells) have shown 
some potential, there is an underlying need for a more specific plate-coating antigen which is 
applicable to all serogroups of B. hyodysenteriae. A number of proteins associated with the 
outer surface of B. hyodysenteriae have already been identified and characterised (reviewed in 
chapter 1), however the suitability of these components for serological detection remains 
unclear. Ideally, a suitable assay component would involve a single, cell membrane-associated 
protein, preferably recombinant, which is specific for all strains of B. hyodysenteriae and is 
known to be highly immunogenic in experimentally and naturally infected pigs. 
 
This chapter describes the development and evaluation of an ELISA test for the serological 
detection of SD using recombinant His6-Bhlp29.7 as the discriminatory antigen. The test was 
aimed at detection of SD at the herd level, and used sera collected from pigs at slaughter in 
abbottoirs – since this is a convenient source of sera for screening the health status of herds. 
The practical limitations of obtaining well-defined serum precluded a thorough evaluation of 
the usefulness of the test for detecting individual infected animals, although a set of sera from 
a group of acutely affected animals was examined.   98
4.2. MATERIALS AND METHODS 
4.2.1. Preparation of ELISA antigen 
Purified recombinant His6-Bhlp29.7 antigen was prepared as described in Chapter 3 (section 
3.2.10). The lyophilised antigen was re-hydrated and diluted to a working concentration of 200 
μg/ml using sterile PBS. 
 
4.2.2. Preparation of reference sera 
The reference sera used for the development of the Bhlp29.7-ELISA were obtained from pigs 
which had been hyper-immunised with bacterin preparations of B. hyodysenteriae strain B78
T 
and B. pilosicoli strain 1648. The hyper-immunised pig sera were prepared by I.W.M. Tenaya 
(Tenaya, 1997), as described below. 
 
Spirochaete cells were grown in 500 ml of modified pre-reduced Kunkle’s broth at 37°C as 
described in chapter 2 (section 2.2.9) The mid-log phase cultures were harvested at 10,000 × g 
at 4°C and washing twice in PBS. The washed cells were resuspended in 0.3% formaldehyde 
in PBS and inactivated for 24 h with constant stirring at room temperature. The bacterin 
suspension was adjusted to a cell density of approximately 10
9 cells/ml and stored in aliquots 
at -20°C. 
 
Two Large White pigs of approximately 5 weeks of age were obtained from an SD-free herd in 
Western Australia. These pigs were housed in a pen in an isolation house, and offered an 
antibiotic-free weaner diet and water on an ad libitum basis. The pigs were injected 
intramuscularly in the neck with 3 ml of a 1:1 emulsion of Freunds’ Incomplete Adjuvant 
(FIA; Sigma Chemical Company) and thawed bacterin. Each pig was vaccinated with a 
different spirochaete bacterin. After two weeks, the intramuscular injection was repeated 
weekly for four weeks using the same vaccine. Finally, 1.5 ml of bacterin without adjuvant 
was given intravenously twice at weekly intervals. Blood was collected by jugular puncture   99
one week after the final immunisation and the sera was separated and stored at -20°C until 
required. 
 
4.2.3. ELISA conditions 
Assaying conditions involved overnight antigen coating in 100 μl carbonate buffer at 4°C onto 
96-well microtitre plates (Immulon 4HBX, Dynex Technologies) followed by blocking of 
unbound sites with 150 μl PBS containing 1% (w/v) BSA (Sigma Chemical Company). The 
wells were washed three times with 150 μl of PBST before the addition of diluted pig serum 
(200-fold) and incubation for 2 h. The wells were washed (as above) and the bound serum 
antibodies were detected with goat anti-swine IgG-HRP (Southern Biotechnology) diluted 
5,000-fold. All antibodies were diluted in 100 μl of PBST containing 0.1% (w/v) BSA and 
incubations occurred at RT with mixing for 1 h unless stated otherwise. Colour development 
occurred after the addition of 100 μl of the K-Blue Tetramethylbenzidine (TMB) substrate 
(ELISA Systems) and was allowed to intensify for 15 minutes at RT. The colour reaction was 
stopped by the addition of 50 μl of 1 M sulphuric acid and the absorbance of the coloured 
substrate reaction was recorded at 450 nm using a microtitre plate reader (Bio-Rad Model 
3550-UV).  
 
4.2.4. Optimisation of the immunoassay 
To optimise the Bhlp29.7-ELISA, a checkerboard titration involving serial dilutions of plate 
coating antigen and primary antibody (reference sera) was performed under the ELISA 
conditions described above. A checkerboard titration of plate coating antigen and primary 
antibody dilution was performed with a constant 5,000-fold dilution of the HRP-conjugated 
goat anti-pig IgG antibody. The procedure was optimised to give the greatest distinction 
between the positive signal (absorbance) and the background noise. Immunoassay plates were 
coated with serial 2-fold dilutions of antigen from 750 ng/ml to 6,000 ng/ml. Reference sera 
were serially diluted in 2-fold increments from 50-fold to 800-fold. The optimal concentration   100
for antigen coating was chosen as the concentration that gave a signal greater than 1.0 and 
allowed the highest signal-to-noise ratio. The optimal coating concentration of His6-Bhlp29.7 
was used for all subsequent ELISA tests. 
 
4.2.5. Collection of pig serum 
Sera from 1121 finisher pigs were obtained from 19 Australian piggeries with differing health-
status located in Queensland, Victoria and Western Australia (see Tables 4.2 to 4.4 in Results 
section). These samples were provided by consultant veterinarians who were familiar with the 
health-status of the herds, and were collected at slaughter from the abattoir. These herds 
included five in which SD had never been observed (group A, n=464), six in which SD was 
confirmed to be present (group B, n=337), and eight herds with a history of diarrhoea and 
where it was thought that SD might be present (group C, n=320), although it had not been 
confirmed by laboratory testing. In addition, 25 sera from 12 to 13 week old pigs with acute 
signs of SD in a 20
th herd (group D, n=25) were also tested. Apart from the pigs in group D, 
the health status of the individual pigs from which the serum was obtained in the other herds 
was not known. 
 
4.2.6. Strategy used for the development and evaluation of the ELISA test 
The approach taken for the standardisation of the ELISA test consisted of three steps. In the 
first step, the 464 serum samples from the five herds in which SD had never been observed 
(group A) were used to set a suitable cut-off value for the test. The threshold value was set as 
three standard deviations above the mean of all individuals in this population in order to have 
the ELISA result of all individuals in this group below the cut-off value. Using this criterion, a 
confidence level of greater than 99% was achieved for this test. Due to the stringency of the 
threshold value, herds were considered to be diseased when one or more individuals returned 
an ELISA value greater than the set cut-off. A moderate stringency cut-off calculated as two 
standard deviations above the mean was also determined for comparison. 
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In the second step, the ELISA test was then applied to 337 serum samples from six herds in 
which SD had been confirmed (group B), to check that it was capable of detecting infected 
herds. Using the outcomes of the assay from the healthy and SD affected herds, the sensitivity 
and specificity of the assay was determined. The sensitivity was defined as the proportion of 
diseased herds identified by the test as having at least one serum sample with an ELISA value 
above the set cut-off. Sensitivity provides an indication of the ability of the test to correctly 
identify herds containing animals with SD. The specificity was defined as the proportion of 
healthy herds identified by the test as having all 40 animals with an ELISA value below the set 
cut-off. Specificity provides an indication of the ability of the test to correctly identify herds 
containing animals which are healthy. 
 
The third step of the ELISA test development involved the application of the assay to 320 
serum samples from pigs in eight herds in which diarrhoea had been observed but SD had not 
been confirmed. For the analysis of these herds, a sample size of 40 was chosen since it would 
give a confidence level of approximately 95% of determining that SD was present in the herds 
tested. This sample size was selected in accordance with a similar study in Australia which 
evaluated the use of a LPS-based ELISA test for the diagnosis of SD, where it was assumed 
that the minimum prevalence of disease in most infected herds was 10% (Mhoma, 1992).  
 
In addition, the opportunity was taken to apply the ELISA to sera from a group of pigs with 
acute SD (group D) in another herd. This would test whether the time of sample collection, in 
relation to the progression of disease, would affect the outcome of the test. These pigs were 
ear-tagged with the intention to obtain convalescent sera when the pigs were sent to the 
abattoir. Unfortunately, these pigs were sent to slaughter without informing the investigator, 
and the second set of samples was missed.  
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4.2.7. Application of immunoassay to field samples 
Microtitre plates were coated with the optimal concentration of His6-Bhlp29.7 determined in 
section 4.2.4 and assayed in triplicate according to section 4.2.3. Immunised pig sera raised 
against B. hyodysenteriae strain B78
T was used as the positive control reference (A
P) and 
immunised pig sera raised against B. pilosicoli strain 1648 was used as the negative control 
reference (A
N). These controls were included in all tests. The raw absorbance values measured 
at 450 nm (A
X) were manipulated by the equation below to attain cross-plate standardisation 
and normalisation. 
 
 
 
 
 
4.2.8. Analysis of B. hyodysenteriae isolates from group D 
The Bhlp29.7-ELISA detects antibody directed against the Bhlp29.7 protein. One Western 
Australian farm (group D) gave negative ELISA results using serum samples obtained from 25 
pigs of 12 to 13 weeks of age that were showing acute signs of SD. Since B. hyodysenteriae 
isolates were cultured from pigs kept on this farm at the time of blood collection, it was 
possible to investigate the presence and expression of the Bhlp29.7 gene in these isolates. 
 
4.2.8.1. Western blot analysis of pig serum reactivity to the ELISA antigen 
Ten μg of the purified His6-Bhlp29.7 antigen was loaded into a 7cm preparative well and 
subjected to SDS-PAGE (described in chapter 2, section 2.2.4) and Western blotting 
(described in chapter 2, section 2.2.5) using six pig serum samples from herd B1 and 14 pig 
sera from group D. Each pig serum was diluted 50-fold in TBST and the same goat anti-pig 
IgG-HRP conjugate (diluted 5,000-fold) (Southern Biotechnology) as used in the ELISA was 
used for the blot. The hyper-immunised pig serum raised against B. hyodysenteriae strain B78
T 
(diluted 100-fold) was included as a positive control.  
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4.2.8.2. PCR and sequencing of the B. hyodysenteriae isolates for the Bhlp29.7 gene 
Three B. hyodysenteriae isolates were obtained from pigs in group D. Bacteriology swabs 
taken from the pigs were streaked onto selective agar plates consisting of TSA (Becton 
Dickinson Microbiology Systems) containing 5% (v/v) defibrinated sheep blood, 400 μg/ml 
spectinomycin and 25 μg/ml each of colistin and vancomycin (Sigma Chemical Company). 
The plates were incubated for 7 days at 37°C in an anaerobic environment of 94% H2 and 6% 
CO2, generated using anaerobic Gaspak plus sachets (Becton Dickinson Microbiology 
Systems), before being examined. The presence of low flat spreading growth of spirochaetes 
on the plate, and any haemolysis around the growth was recorded. Spirochaetes were 
confirmed by picking off areas of suspected growth and sub-culturing until a pure culture of 
the isolate was obtained. The isolate was re-suspended in PBS, used as template in a PCR for 
the Bhlp29.7 gene, and the amplified gene was subsequently sequenced (described in chapter 
2, section 2.2.12). 
 
4.2.8.3. Western blot analysis of the B. hyodysenteriae isolates for Bhlp29.7 expression 
The three isolates obtained from group D were grown in 10 ml broth culture as described in 
chapter 2 (section 2.2.9). The cells were harvested by centrifugation at 10,000 × g for 20 min 
and the pellet resuspended with 100 μl of PBS. The resuspended cells were subjected to SDS-
PAGE (described in chapter 2, section 2.2.4) and Western blotting (described in section 2.2.5) 
using the Mab BJL/SH1. 
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4.3. RESULTS 
4.3.1. Immunoassay development 
Optimised results were obtained with a 200-fold dilution of positive serum and 300 ng/ml of 
antigen (Table 4.1). The reactivity of the serum from the pig immunised against B. 
hyodysenteriae B78
T gave an ELISA value of 94.1, which was approximately 2.6-fold greater 
than the serum raised against B. pilosicoli 1648 (ELISA value of 36.3). 
 
 
 
Table 4.1. Ratio of SD-positive (B. hyodysenteriae immunised pig) serum to SD-
negative (B. pilosicoli immunised pig) serum for the optimisation of assay 
conditions for ELISA against recombinant His6-Bhlp29.7 antigen. Optimum values 
with the best signal-to-noise ratio are highlighted. 
 
Reciprocal of serum dilution 
Antigen concentration  
(ng/ml)  50  100 200 400 
75  5.8  6.4 6.8 5.7 
150 5.9  7.0  7.2 5.6 
300 5.9  7.5  7.6 6.5 
600  4.6  6.4 6.9 6.0 
   105
4.3.2. Determination of the cut-off value for the ELISA test 
The mean and standard deviation of the normalised ELISA absorbance value of sera from pigs 
in group A (SD not observed) were 16.9 and 9.4, respectively. The cut-off value for the assay 
was determined to be 45.0 (mean + three standard deviations) for high stringency, and 35.7 
(mean + two standard deviations) for moderate stringency. 
 
4.3.3. Specificity and sensitivity of the ELISA test 
Diagrammatic representations of the ELISA results for pigs in groups A and B are shown in 
Fig. 4.1 and 4.2, respectively. The mean ELISA values for the serum from the five healthy 
herds (group A) and six infected herds (group B) are shown in Tables 4.2 and 4.3. Using the 
criterion that any serum from a herd that exceeded the cut-off value indicated that the herd was 
infected, and using the two standard deviations cut-off, the test had zero specificity (all five 
negative herds scored positive) and a sensitivity of 100% (detecting all 6 positive herds 
correctly; group B). Using a cut-off value of three standard deviations above the mean, the 
ELISA test had a specificity of 100% (correctly identifying 5 of 5 negative herds; group A) 
and the specificity remained unchanged at 100 % (detecting all 6 positive herds, group B). 
Since the ELISA test showed zero sensitivity using a cut-off value two standard deviations 
above the mean, use of this value was not continued for the remainder of the study. 
 
4.3.4. Application of the Bhlp29.7-ELISA to field samples 
Four of the eight (50%) herds in the farms where SD was suspected (group C) were 
determined to be diseased according to the test.  Prevalence within these four confirmed 
diseased herds ranged from 2.5% (1 of 40 samples) to 15% (6 of 40 samples), with a mean of 
8.75%. The remaining four herds in this group did not contain any individuals with ELISA 
values above the three standard deviation cut-off criterion (Table 4.4). The actual disease 
status of these four herds was unclear, as there was no laboratory evidence to show that SD 
was present on these farms. The consulting veterinarians had only suspected that it would be 
present.   106
Figure 4.1. Serological reactivity of pigs (n=464) from five herds where SD was not present (group A). Immunological response towards 
recombinant His6-Bhlp29.7 was determined by ELISA. The different symbols correspond to different pig herds: -z- herd A1 and -{- herd 
A2, -d- herd A3, -V- herd A4, and -- herd A5. The dotted line indicates the cut-off value (P<0.05) for the immunoassay, two standard 
deviations above the mean. The dashed line indicates the cut-off value (P<0.01) three standard deviations above the mean. 
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Figure 4.2. Serological reactivity of pigs (n=337) from six herds where SD was present (group B) and confirmed by laboratory-based methods. 
Immunological response towards recombinant His6-Bhlp29.7 was determined by ELISA. The different symbols correspond to different pig 
herds (n=2): -z- herd B1 and -{- herd B2, -d- herd B3, -V- herd B4, and -- herd B5, -- herd B6. The dotted line indicates the cut-off value 
(P<0.05) for the immunoassay, two standard deviations above the mean. The dashed line indicates the cut-off value (P<0.01) three standard 
deviations above the mean. Both cut-off values were set using sera from uninfected farms (Fig. 4.1). 
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Table 4.2. Summary of normalised ELISA absorbance values for the detection of 
specific antibody against recombinant His6-Bhlp29.7 in sera taken from five 
Australian pig herds in which SD was not present (group A). The two cut-off values 
were obtained from the means and standard deviations of the serum samples from 
this group. Qld, Queensland; Vic, Victoria; WA, Western Australia. 
 
Seropositive pigs (%) 
Herd Origin 
No. of 
samples 
Mean ± standard 
deviation  Cut-off 1*  Cut-off 2** 
A1  WA  132  13.5 ± 9.4  4 (3.0)  0 (0) 
A2  Vic  236  18.0 ± 8.7  4 (1.7)  0 (0) 
A3  WA  55  12.6 ± 6.9  1 (1.8)  0 (0) 
A4  Vic  20  24.5 ± 5.3  1 (5.0)  0 (0) 
A5  Vic  21  29.9 ± 5.7  1 (4.8)  0 (0) 
Total    464  16.9 ± 9.4  11 (2.4)  0 (0) 
* mean plus two standard deviations 
** mean plus three standard deviations   109
 
Table 4.3. Summary of normalised ELISA absorbance values for the detection of 
specific antibody against recombinant His6-Bhlp29.7 in sera taken from six 
Australian pig herds which were confirmed to have SD present (group B). The two 
cut-off values were obtained from the mean and standard deviation of the serum 
samples obtained for five uninfected herds (group A). Qld, Queensland; Vic, 
Victoria. 
 
Seropositive pigs (%) 
Herd Origin 
No. of 
samples 
Mean ± standard 
deviation  Cut-off 1*  Cut-off 2** 
B1  Vic  140  24.6 ± 13.2  22 (15.7)  10 (7.1) 
B2  Vic  38  32.5 ± 11.1  11 (28.9)  4 (10.5) 
B3  Qld  39  31.1 ± 6.7  8 (20.5)  1 (2.6) 
B4  Qld  40  29.9 ± .5  9 (22.5)  1 (2.5) 
B5  Q1d  40  34.4 ± 5.8  17 (42.5)  2 (5.0) 
B6  Qld  40  17.7 ± 8.8  3 (7.5)  1 (2.5) 
Total    337  27.2 ± 11.6  70 (20.8)  19 (5.6) 
* mean plus two standard deviations 
** mean plus three standard deviations   110
Table 4.4. Summary of normalised ELISA absorbance values for the detection of 
specific antibody against recombinant His6-Bhlp29.7 in sera taken from eight pig 
herds obtained from different farms in Queensland, Australia (group C). All herds 
were suspected to have SD, but had not been confirmed positive by laboratory 
methods. 
 
Herd 
No. of 
samples 
Mean ± standard 
deviation 
Seropositive pigs* (%) 
C1  40  33.2 ± 11.9  6 (15.0) 
C2  40  30.6 ± 8.9  4 (10.0) 
C3  40  24.2 ± 6.3  0 (0) 
C4  40  18.9 ± 9.4  0 (0) 
C5  40  27.9 ± 7.3  3 (7.5) 
C6  40  32.5 ± 6.6  0 (0) 
C7  40  20.4 ± 6.9  0 (0) 
C8  40  14.3 ± 5.5  1 (2.5) 
Total  320  25.3 ± 10.3  17 (4.7)   111
4.3.5. Application of the Bhlp29.7-ELISA to samples from group D 
The ELISA result of all 25 pigs from group D (acute SD observed) did not exceed the mean 
plus two standard deviations cut-off value or the mean plus three standard deviations value 
(Fig. 4.3). The mean and standard deviation of the samples in this group were 18.8 and 5.5, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.6. Analysis of Bhlp29.7 expression in B. hyodysenteriae isolates from group D 
PCR and sequencing of the three B. hyodysenteriae isolates cultured from faeces obtained 
from the same farm which housed group D indicated that the Bhlp29.7 gene was present in all 
Figure 4.3. Serological reactivity of 25 pigs from the herd where acute SD was observed 
(group D). Immunological response towards recombinant His6-Bhlp29.7 was determined by 
ELISA. The dashed line indicates the cut-off value (p<0.01) for the immunoassay and the 
dotted line indicates the cut-off value (P<0.01) three standard deviations above the mean. 
Both cut-off values were set using sera from uninfected farms (Fig. 4.1). 
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three isolates and that they shared 97.4 to 99.2% homology to the protein in the WA1 strain of 
B. hyodysenteriae.  
 
Western blotting of whole-cell extracts prepared from the three isolates showed strong 
reactivity with the Mab BJL/SH1 (Fig. 4.4). When 14 serum samples from group D were  used 
in a Western blot against the recombinant Bhlp29.7 antigen, weak or no reactivity was seen 
(Fig. 4.5). This was compared to the strong reactivity exhibited by serum taken from a pig 
hyper-immunised with a bacterin prepared with B. hyodysenteriae strain B78
T, and by six 
serum samples taken from herd B1 (chapter 3, Fig. 3.6). 
Figure 4.4. Western blot reactivity of three B. hyodysenteriae isolates with Mab 
BJL/SH1. The isolates were cultured from faeces obtained from pigs in group D 
(acute SD observed). Lane 1, isolate 1; lane 2, isolate 2; lane 3, isolate 3. The arrow 
indicates the position of the Bhlp29.7 protein.   113
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 4.5. Reactivity of pig serum from group D (acute SD observed) against the 
recombinant His6-Bhlp29.7 protein that was used as plate-coating antigen for the 
Bhlp29.7-ELISA. Serum from a pig hyper-immunised with a bacterin preparation of 
B. hyodysenteriae strain B78
T was used as a positive control. Lane 1, hyper-
immunised pig serum raised against B. hyodysenteriae strain B78
T; lane 2-15, 
individual serum samples of 14 pigs from group D. The arrow indicates the position 
of the His6-Bhlp29.7 protein.   114
4.4. DISCUSSION 
Since its first description in 1971 (Engvall and Perlman, 1971), ELISA has become the system 
of choice when assaying soluble antigens and antibodies. Factors which have contributed to 
the success of the method include high sensitivity, long shelf-life of the reagents, ease of 
reagent preparation, and the speed and reproducibility of the assay.  
 
In this chapter, an indirect ELISA test was established and standardised for the detection of 
antibodies to Bhlp29.7, an outer membrane lipoprotein of B. hyodysenteriae. This lipoprotein 
is believed to be surface exposed and immunogenic in infected pigs. In order to evaluate the 
usefulness of the ELISA test, sera from herds of pigs observed to be SD-free (group A) were 
used to determine a cut-off value for the assay. The cut-off value was then applied to sera from 
herds which had been observed to have SD (group B) to determine the sensitivity and 
specificity of the test. The ELISA then was used on “test” sera from herds in which diarrhoea 
had been observed, but had not been confirmed to be SD by laboratory methods (group C). 
Finally the ELISA was used on sera from younger pigs with acute SD at the time of sampling 
(group D). 
 
4.4.1. Sensitivity and specificity of the ELISA 
The criterion used for determining the disease status of the different herds according to the 
current ELISA was determined statistically using the mean and distribution of the serum 
reactivity of pigs from the healthy farms (group A). The actual cut-off value that was selected 
for use can be easily manipulated to either increase the sensitivity of the assay at the expense 
of the specificity, or vice-versa. In this study, two stringency levels were applied in 
establishing the cut-off value – one value which was two standard deviations above the mean 
of the healthy herds, and another which was three standard deviations above the mean. When 
the lower stringency cut-off value was applied to the healthy and diseased herds, the test 
lacked any sensitivity and so this clearly was not appropriate. False-positive diagnosis would   115
lead to the implementation of costly antibiotic treatment of an entire herd, or implementation 
of other control or quarantine measures. 
 
When the higher stringency cut-off value was applied, all samples from the five healthy herds 
scored below the cut-off values, indicating the test was 100% sensitive. Relatively large 
numbers of sera were used in this step (464), which increased confidence in the results. 
Subsequently, all six diseased herds (group B) were successfully confirmed by the ELISA as 
being infected (100% specificity), although 94.4% of the animals (318 out of 337) had ELISA 
values below the cut-off value. Pigs in these herds were of slaughter age (22 weeks) and some 
had suffered clinical SD approximately four to six weeks prior to sampling. In a study using 
LPS as the plate-coating antigen for ELISA, it was reported that within infected herds, only a 
minority of individuals have antibody levels exceeding the cut-off value at a given time of 
sampling (Mhoma et al., 1992). Since only 19 of the 337 (5.6%) serum samples tested gave an 
ELISA result above the cut-off value, and a herd is considered infected when one sample 
returns a positive ELISA result, the number of samples assayed per herd is critical to the test. 
A sample size of 40 was chosen for testing of herds with unconfirmed health status, since this 
would give a confidence level of approximately 95% of identifying SD in an infected herd. In 
choosing the sample size, a within-herd prevalence of 10% was assumed in accordance with a 
previous Australian serological study (Mhoma, 1992). Based on the current ELISA test using 
the serum samples for group C, the within-herd serological prevalence of the infected herds 
was found to be between 2.5 (1 out of 40 pigs) and 15% (6 out of 40 pigs). Although the true 
prevalence would need to be confirmed by culture and PCR on individual pigs, it nevertheless 
indicates that a sample size of 40 would be appropriate for the ELISA test. 
 
4.4.2. Application of the ELISA to samples from herds with uncertain health status 
The use of the ELISA test on serum samples from the eight herds with a history of diarrhoea 
but which had not been confirmed to have SD indicated that, according to the criterion of the 
test, 50% (4 out of 8 herds) were seropositive. Within these herds, the seroprevalence ranged   116
from 2.5% (1 out of 40 samples) to 15% (6 out of 40 samples). When SD first enters a herd, 
the pigs are usually exposed to only low infectious doses of B. hyodysenteriae and, as a 
consequence, the disease is generally observed in only a few pigs. As infectious faeces 
accumulate, SD spreads to other animals in the exposed herd. The rate of its spread within the 
herd depends on the level of contact, and may take several weeks (Hampson et al., 1997). 
Since the ELISA test was intended for detecting SD at the herd level and not at the individual 
animal level, all samples did not necessarily need to be seropositive for the herd to be 
diagnosed as diseased. During the standardisation of the ELISA test, a within-herd prevalence 
of 10% was assumed, hence with 40 serum samples tested for each herd, it would be expected 
that up to four samples would be seropositive. Consistent with this, for the herds in which SD 
was present (group B), 2.5% (1 out of 40 samples) to 10.5% (4 out of 38 samples) of the 
animals tested were seropositive. 
 
Infection with B. hyodysenteriae induces a systemic immune response which can last up to 17 
weeks after the initial exposure (Fisher and Olander, 1981; Fernie et al., 1983; Joens et al., 
1981b). For many of the herds in which SD had been observed (group B) or was suspected 
(group C), there was a high standard deviation in the ELISA test values (Table 4.3 and 4.4). 
Since the pigs in these herds were of a similar age, and SD had been observed four to six 
weeks prior to collection of serum, the scatter seen in the ELISA values for a herd suggests 
that some pigs had been more recently exposed to the spirochaete than others. If this was the 
case, investigation of different antibody subclasses, such as IgM, which is induced during the 
primary response following exposure, may provide more information. 
 
4.4.3. Antibody response in acutely affected pigs 
When the ELISA was applied to the samples obtained from pigs suffering acute disease, the 
ELISA values did not exceed the cut-off value, despite the observation of clinical SD in these 
pigs at the time of sampling. When a subset of these samples was tested in a Western blot 
using the plate-coating antigen, little or no reactivity was seen. In contrast, serum samples   117
from another infected herd (herd B1) reacted strongly in a Western blot using the same 
antigen. This indicated that the lack of reactivity seen in this herd was due to serum-specificity 
and not due to problems with the ELISA test. The lack of systemic response may have been 
because these acutely affected pigs had insufficient time to mount an antibody response. It is 
also possible, although not likely, that the younger age of these pigs meant that they were less 
able to mount an immune response. Had these animals been sampled after a few weeks, they 
may have become seropositive – although seroconversion has been detected in the pigs as 
early as four to seven days after the onset of clinical SD (Joens et al., 1985). This 
seroconversion was directed towards the whole cell of B. hyodysenteriae, which also includes 
cellular components and LPS. The current ELISA only detects antibodies against Bhlp29.7 and 
it is possible that the antibody response towards Bhlp29.7 occurs some time after the 
appearance of clinical signs of SD. As will be seen in the following chapter (chapter 5), 
experimentally infected pigs with acute signs of disease also do not have significant antibody 
titres towards Bhlp29.7, compared to the good local antibody titres seen in the colon. 
Nevertheless, on the basis of these results, it is recommended that the ELISA test only be used 
on pigs of slaughter age – since it has been standardised for these animals. More work is 
needed to investigate the dynamics of the systemic immune response to Bhlp29.7 before the 
test can be applied to serum samples collected in acutely affected pigs, or in animals tested 
before slaughter age. 
 
To further investigate the lack of ELISA reactivity in the pigs of group D, isolates of B. 
hyodysenteriae from this farm were examined. They were shown to possess the Bhlp29.7 gene, 
and it was expressed in vitro, hence there was nothing unusual about the strain of B. 
hyodysenteriae present on the farm. Cullen et al. (2003) looked at the genome sequence 
surrounding Bhlp29.7 and found that the bhlp29.7 locus (referred to as blpGFEA) contained a 
number of paralogous genes which were not expressed simultaneously. In their work, they 
further substantiated that Bhlp29.7 (referred to by them as BlpA) was the gene member which 
was expressed in the strain they studied. It is possible that in different B. hyodysenteriae   118
isolates, different members of the Bhlp29.7 gene set are expressed under different 
environmental conditions, as may be the case for the B. hyodysenteriae variable surface 
exposed protein Bhmp39 (Witchell et al., 2006). In the current work, the presence of the 
Bhlp29.7 gene in a large number of B. hyodysenteriae strains has been examined, but the 
expression of Bhlp29.7 in these strains has not been studied. Future work is required to analyse 
in vitro and in vivo expression of Bhlp29.7, and the other paralogous genes, in different B. 
hyodysenteriae strains. 
 
4.4.4. False-positives 
Early ELISA tests developed for SD using crude whole cell preparations of B. hyodysenteriae 
were hampered by false-positive readings associated with the cross-reactivity of antibodies 
produced against intestinal spirochaetes other than B. hyodysenteriae. The use of a 
recombinant protein, purified by affinity chromatography, as the coating antigen in the current 
ELISA test reduces the possibility of cross-reactivity by providing only one B. hyodysenteriae 
protein for antibodies to interact with. In this ELISA test, the wide distribution of ELISA 
values (indicated by the standard deviations from the means) seen for the healthy herds (group 
A), suggest that cross-reactivities probably still occurred. These cross-reactivities could have 
been due to E. coli proteins which co-purified with the His6-Bhlp29.7 and were subsequently 
coated onto the ELISA plate. Another source of cross-reactivity may have been with the six 
histidine fusion present at the N-terminal of the recombinant Bhlp29.7 protein, however this 
was unlikely since histidine-tags show low immunogenicity (Coligan et al., 1995). Other 
sources of cross-reactivity could reside with the Bhlp29.7 protein itself. It was shown in 
chapter 2 that Bhlp29.7 probably belongs to the family of methionine substrate-binding 
proteins (MetQ), which are found in a wide range of Gram-negative bacteria. As such, there 
are possibly epitopes present on Bhlp29.7 which would be similar to those of MetQ proteins in 
other bacteria. Exposure of pigs to these bacteria could induce antibody responses which 
would result in cross-reactivity with His6-Bhlp29.7. Another possible source of cross-reactivity 
would be due to exposure of the pigs to certain strains of B. innocens, a common commensal   119
species colonising the pig colon (Stanton et al., 1991). In chapter 3, PCR and sequencing of 
different strains of Brachyspira species revealed that the Bhlp29.7 gene was present in B. 
innocens strain B256
T. This gene was nearly identical to that of all the B. hyodysenteriae 
strains tested. Although in this study Bhlp29.7 was only found in one of the four B. innocens 
strains tested, it is possible that other B. innocens strains may possess the gene, and hence be a 
source of cross-reactivity if this is expressed.  
 
Despite the possibility of cross-reactivities associated with the His6-Bhlp29.7 antigen, the 
standardised ELISA test showed a good sensitivity and specificity at the herd level. Reducing 
the likelihood of cross-reactivities, and hence false-positives, may enable a better 
discrimination between positive and negative samples, and especially samples with titres close 
to the cut-off value.  
 
4.4.5. Practical limitations 
The major limitation in the development of this ELISA test was the practical problems 
associated with obtaining a reliable well-defined set of sera from pigs/herds with confirmed 
health status. The definitive diagnosis of SD in herds requires a combination of clinical 
observation and microbiological culture and PCR of B. hyodysenteriae from a large number of 
clinical samples.  For most of the herds in this study, the health status was determined from the 
clinical history of the herd, and the sera from these herds were collected from slaughter-aged 
animals at the abattoir. Although this method of collection does not provide a truly random 
representation of the pigs in a herd, and misidentification of herds or individuals is possible, it 
was far less difficult than collecting blood directly from the pigs – especially since most of the 
farms in this study were located in a different State. Additionally, obtaining diagnostic samples 
for follow-up studies on certain herds (such as those in groups C and D) was virtually 
impossible due to the herds having been depopulated or sold, or the consulting veterinarian 
having relocated. Moreover, issues concerning confidentiality also hindered the 
communication of information. Besides the limitations associated with sample collection,   120
estimation of the prevalence of SD in the herds being tested may be problematic. Prevalence 
studies are labour intensive and require the co-ordination of a large number of professionals. 
Due to this, prevalence studies are infrequently performed, even though the internal prevalence 
is an important parameter required to establish the necessary number of test samples. All these 
practical problems were encountered in this study, and made a definitive evaluation of the 
ELISA test difficult.  
 
4.4.5. Future improvements 
It remains unclear why the pigs in group D did not show seroconversion, even though clinical 
SD was observed at the time of serum collection and B. hyodysenteriae was present on the 
farm. An obvious difference between the pigs in this herd and the pigs in the remaining herds 
was the age of the pigs and the acuteness of the clinical signs. Further investigation may be 
necessary to ascertain whether parameters such as age and disease progression will affect the 
effectiveness of the ELISA test. In addition, it is not known whether Bhlp29.7 is expressed in 
vivo in all strains of B. hyodysenteriae. Although the presence of Bhlp29.7-specific antibody 
titres produced in response to B. hyodysenteriae exposure has been confirmed in a number of 
Australian herds, it is still unclear whether this response is universal for all strains/serogroups. 
Application of the ELISA test to serum samples collected from a larger number of herds of 
known disease status in the major pig producing countries would be desirable, however this 
may be difficult given the current state of international biosecurity. 
 
It is possible that the use of the entire Bhlp29.7 protein as the ELISA antigen may lead to 
cross-reactivities which reduce the capacity of the assay to discriminate between seropositive 
and seronegative samples. The in silico analyses revealed that the most antigenic epitopes of 
the Bhlp29.7 protein lie at the C-terminal portion (Chapter 2, section 2.3.3.2). It is also within 
this C-terminal region that the epitope for the B. hyodysenteriae-specific monoclonal antibody 
(BJL/SH1) is found. Knowing this, it may be possible to use the monoclonal antibody as a 
blocking agent in a competitive ELISA test. In such an assay, the Bhlp29.7 antigen is bound to   121
the microtitre plate and the test serum allowed to bind. The HRP-labelled monoclonal antibody 
is then applied and allowed to bind and an ELISA reading is obtained after washing away all 
unbound material after. The ELISA reading for the blocked antigen is compared with that for 
the unblocked antigen. A sample with a lower reading for the blocked antigen compared to the 
unblocked antigen indicates a seropositive sample. Unfortunately the hybridoma cell-line 
producing the monoclonal antibody BJL/SH1 has expired, and the remaining BJL/SHI stocks 
were insufficient to evaluate this modification. It would be useful to raise new hybridomas 
expressing monoclonal antibodies reacting with the C-terminal of Bhlp29.7, and to test these in 
blocking ELISAs. 
 
Another alternative method of utilising the C-terminal region of Bhlp29.7 would be to use this 
polypeptide as the ELISA coating antigen. A polypeptide (Bhlp29.7-F604) containing residues 
202 to 271 of the 271 amino acid Bhlp29.7 protein has been cloned and expressed in E. coli 
(chapter 3). Due to the possible hydrophilicity and small size of Bhlp29.7-F604, expression 
levels of this protein in E. coli were extremely low, making it difficult to generate sufficient 
protein for use in the ELISA test. The Bhlp29.7-F604 gene region was subsequently cloned 
and expressed as a MBP fusion-protein (MBP-Bhlp29.7-F604) for vaccination of pigs (chapter 
5). The MBP fusion-tag allows the Bhlp29.7-F604 polypeptide to be expressed abundantly, 
however the MBP component is highly immunogenic in pigs. Cleavage and purification of the 
MBP fusion would be necessary to further explore the possibility of using the Bhlp29.7-F604 
protein as the basis for an alternative ELISA test.   
 
4.4.6. Conclusions 
Overall, the ELISA that was developed and standardised appears useful as an indirect test for 
determining exposure of herds to B. hyodysenteriae. It does not appear to be particularly useful 
at the individual pig level, but this was not properly investigated in this study since, in nearly 
all cases, the disease history of individual animals was not recorded. The timing of sample 
collection appeared to be important, and it is recommended that the ELISA should be used for   122
slaughter-age pigs to avoid possible false-negative results. Although it may require follow-up 
culture and PCR to confirm the test result, the ELISA still provides another convenient method 
of diagnosis other than directly isolating the causative agent. The ELISA test was 100% 
specific and 100% sensitive at the herd level – although it was recognised that relatively few 
herds were tested. In a previous assessment of an ELISA test for Australian herds using LPS as 
the plate-coating antigen, a specificity of 81.8% and a sensitivity of 77.3% were achieved 
(Mhoma et al., 1992). Compared to this LPS-ELISA, the current ELISA shows both better 
specificity and sensitivity. Furthermore, in the event that a subunit vaccine using recombinant 
His6-Bhlp29.7 becomes available (Chapter 5), this ELISA test should prove useful for 
monitoring the efficacy of vaccination during its development and application in the field. 
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CHAPTER 5: EVALUATION OF IMMUNISATION WITH 
RECOMBINANT BHLP29.7 FOR PROTECTION AGAINST 
BRACHYSPIRA HYODYSENTERIAE COLONISATION 
IN MICE AND PIGS 
 
5.1. INTRODUCTION 
In infected herds SD can be controlled using antimicrobials, although strains of Brachyspira 
hyodysenteriae with reduced antimicrobial susceptibility are increasingly being encountered 
(Karlsson et al., 2002; Karlsson et al., 2003; Karlsson et al., 2004). Pigs with SD show a 
strong circulating antibody response to B. hyodysenteriae, and a proportion of recovered 
animals are protected from re-infection (Olson, 1974; Joens et al., 1979). Past attempts to 
develop bacterin and live vaccines to control SD have met with limited success (reviewed in 
chapter 1). The use of recombinant subunit vaccines for the control of SD is highly appealing, 
since the products would be well-defined (essential for registration purposes), and relatively 
easy to produce on a large scale. Several attempts have been made to identify outer envelope 
proteins from B. hyodysenteriae that could be used as vaccine components (reviewed in 
chapter 1), but to date attempts to use recombinant proteins from B. hyodysenteriae as vaccine 
subunits have failed to prevent colonisation in pigs or mice (Gabe et al., 1995; Davis et al., 
2005).  
 
Earlier chapters have described the identification and recombinant production of the 29.7 kDa 
outer membrane lipoprotein of B. hyodysenteriae, designated Bhlp29.7. Mice and pigs 
immunised with an E. coli clone expressing recombinant Bhlp29.7 generated antibodies 
recognising the native lipoprotein of B. hyodysenteriae, and pigs naturally infected with B. 
hyodysenteriae also recognise both recombinant and native Bhlp29.7.  
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This chapter contains two sections. The first section primarily evaluates the immunogenicity of 
recombinant histidine-tagged Bhlp29.7 in mice. To achieve this, a recombinant lipidated 
histidine-tagged homologue of Bhlp29.7 was cloned and expressed in E. coli. The lipidated 
and non-lipidated recombinant histidine-tagged Bhlp29.7 were used to immunise mice and the 
effect of the lipidation on immunogenicity was evaluated. The more immunogenic 
recombinant Bhlp29.7 homologue was subsequently evaluated for its ability to provide 
protection against B. hyodysenteriae colonisation in experimentally challenged mice. 
 
The second section of this chapter describes production in E. coli of recombinant histidine-
tagged Bhlp29.7 and an approximately 8 kDa polypeptide from the carboxy-terminal end of 
Bhlp29.7, fused to maltose binding protein, and designated MBP-Bhlp29.7-F604, and the use 
of these purified proteins to vaccinate pigs. The carboxy-terminal portion of Bhlp29.7 was 
chosen for use as a vaccine component since computer-assisted immunogenicity analysis of 
the Bhlp29.7 amino acid sequence indicated that the most antigenic portion of the lipoprotein 
was at the carboxy-terminal end (chapter 2). Hence it was considered that it would be useful to 
compare protection achieved with the carboxy-terminal end and the whole molecule.  
 
The aim of the studies in this chapter was to investigate whether immunisation with these 
recombinant Bhlp29.7 proteins would protect mice and pigs from SD following experimental 
challenge with B. hyodysenteriae.   125
5.2. MATERIALS AND METHODS 
5.2.1. Preparation of recombinant His6-Bhlp29.7 
Recombinant histidine-tagged Bhlp29.7 was expressed and purified using the methods outlined 
in chapter 3. Purified, dialysed and concentrated His6-Bhlp29.7 protein (2 mg/ml) was 
prepared as described in chapter 3 (sections 3.2.9-3.2.11) and stored at -20°C. 
 
5.2.2. Preparation of recombinant lipidated His6-Bhlp29.7 
5.2.2.1. Construction of the pLIP-Bhlp29.7 expression vector 
The lipidation cassette containing the conserved E. coli lipoprotein signal peptidase 
recognition site [L, V, I][A, S, T, G][G, A]C (von Heijne, 1989) followed by a six histidine 
motif was constructed and used to replace the six histidine expression cassette of the pTrc-
Bhlp29.7. The lipidation cassette was constructed by directional ligation of three synthetic 
linkers (lpp1-3). The lpp-1 linker was generated with oligonucleotides lpp-1A and lpp-1B, the 
lpp-2 linker was generated with oligonucleotides lpp-2A and lpp-2B, and the lpp-3 linker was 
generated with oligonucleotides lpp-3A and lpp-3B (Table 5.1). All the linkers were 
individually generated by combining 50 µM of each oligonucleotide in a 0.2 ml PCR tube and 
heating the tube to 96°C for 5 min in a thermocycler. The tubes were removed from the 
thermocycler and cooled slowly at RT to allow the oligonucleotides to anneal. The three 
linkers were combined with 5 U of T4 DNA ligase (Promega) in 30 mM Tris-HCl (pH 7.8), 10 
mM MgCl2, 10 mM DTT and 1 mM ATP. Ligation was allowed to occur at 14°C for 16 h. 
Following ligation, the resulting DNA fragment was purified using the UltraClean PCR Clean-
up kit as described in chapter 2, section 2.2.12.2.  
  
Cloning of the lipidation cassette into pTrc-Bhlp29.7 was carried out in a similar manner to 
that described for the initial construction of pTrc-Bhlp29.7 (chapter 3, sections 3.2.4-3.2.7). 
The pTrc-Bhlp29.7 plasmid was restricted with 1 U of NcoI (Promega) and 1 U of BamHI 
(Promega) in 6 mM Tris-HCl (pH 7.5), 100 mM NaCl, 6 mM MgCl2, 1 mM DTT and 100 
μg/ml BSA at 37°C overnight. The restricted plasmid was purified using the UltraClean PCR   126
Clean-up kit. Since the DNA fragment comprising the lipidation cassette was designed with 
terminal  Nco1- and BamHI-compatible cohesive ends, equimolar amounts of this DNA 
fragment and the linearised pTrc-Bhlp29.7 plasmid were ligated at 14°C for 16 h in 30 mM 
Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM DTT and 1 mM ATP containing 1 U of T4 DNA 
ligase (Promega). The ligation products were transformed into chemically competent E. coli 
BL21 Star (DE3) pLys One Shot (Invitrogen) cells by heat-shock. Transformed cells were 
plated onto LB agar plates containing 100 mg/l ampicillin and incubated at 37°C for 16 h. 
 
 
Ten single transformant colonies were streaked onto fresh LB agar plates containing 100 mg/l 
ampicillin and incubated at 37°C for 16 h. A single colony from each transformation event was 
resuspended in 50 μl of TE buffer and boiled for 1 min. Two μl of boiled cells were used as 
template for PCR with the pTrcHis-F and pTrcHis-R primers. Two transformant clones which 
produced the correct sized PCR products were inoculated into 10 ml LB broth containing 100 
mg/l ampicillin and incubated at 37°C for 12 h with shaking. The entire overnight cultures 
were centrifuged at 5,000 × g for 10 min and the plasmid contained in the cells extracted using 
Table 5.1. Oligonucleotide sequences used to produce synthetic linkers for the generation 
of the lipidation cassette for expression in E. coli. 
 
Oligonucleotide 
name 
Sequence (5’-3’) 
lpp-1A  CATGAAAGCTACTAAACTGGTACTGGGCGCGGTAATCCTGGGTTCTACTCTGCTGG 
lpp-1B  AGAGTAGAACCCAGGATTACCGCGCCCAGTACCAGTTTAGTAGCTTT 
lpp-2A  CAGGTTGCTCCAGCAACCATCATCATCATCATCATGGTATGGCTAGCATGACTGG 
lpp-2B  CATGCTAGCCATACCATGATGATGATGATGATGGTTGCTGGAGCAACCTGCCAGC 
lpp-3A  TGGACAGCAAATGGGTGACGATGACGATAAGGATCGATGGGGATC 
lpp-3B  CCCATCGATCCTTATCGTCATCGTCACCCATTTGCTGTCCACCAGT   127
the QIAprep Spin Miniprep Kit as described previously (chapter 2, section 2.2.6). Both 
purified plasmids were subjected to automated direct sequencing of the cloned lipidation 
cassette using the pTrcHis-F primer. Successfully ligated plasmids were designated pLIP-
Bhlp29.7. 
 
5.2.2.2. Verification of His6-Bhlp29.7 lipidation 
A single colony of the pLIP-Bhlp29.7 construct in E. coli BL21 was inoculated into 10 ml LB 
broth containing 100 mg/l ampicillin and incubated at 37°C for 16 h with shaking. Fifty ml of 
LB broth in a 250 ml conical flask containing 100 mg/l ampicillin was inoculated with 1 ml of 
the overnight culture and incubated at 37°C until the optical density of the cells at 600 nm was 
0.5 (approximately 3 h). The culture was spiked with 200 μCi of 
3[H] palmitic acid 
(Amersham Pharmacia Biotech) and IPTG was added to a final concentration of 1 mM. The 
cells were returned to 37°C with shaking for 6 h. The cells were harvested by centrifugation at 
5,000 × g for 10 min before resuspending the pellet with 1 ml of Ni-NTA denaturing lysis 
buffer. The cell lysate was incubated at -20°C overnight. Cell debris was clarified from the 
thawed lysate by centrifuging at 20,000 × g for 15 min at 4°C. SDS-PAGE (chapter 2, section 
2.2.4) was used to separate 15µl of the purified lipidated His6-Bhlp29.7 in two duplicate gels. 
One polyacrylamide gel containing the separated proteins was stained with Coomassie 
Brilliant Blue G250 (chapter 3, section 3.2.10). The other polyacrylamide gel was equilibrated 
in Amplify solution (Amersham Pharmacia Biotech) for 15 min before the gel was placed into 
a plastic bag and heat sealed. An autoradiograph was obtained by incubating the sealed gel 
with pre-flashed Hyperfilm-MP (Amersham Pharmacia Biotech) in a film cassette at –80°C for 
14 days. The autoradiograph was developed and compared with the stained gel to identify 
corresponding bands. Both autoradiograph and stained gel were scanned for comparative 
presentation. 
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5.2.2.3. Expression and purification of recombinant lipidated His6-Bhlp29.7  
Recombinant lipidated His6-Bhlp29.7 was expressed and purified using the methods outlined 
in chapter 3 (sections 3.2.9-3.2.10). Purified, dialysed and concentrated His6-Bhlp29.7 protein 
(2 mg/ml) was prepared as described in chapter 3 (sections 3.2.11 and 3.2.13) and stored at -
20°C. 
 
5.2.3. Preparation of recombinant MBP-Bhlp29.7-F604 
The pMAL-c2x Expression System (New England Biolabs) was chosen for the recombinant 
expression of the carboxy-terminal portion of Bhlp29.7 in E. coli, as the pTrcHis Expression 
System was unable to express proteins smaller than 12 kDa at high levels (Coligan et al., 
2002).  
 
5.2.3.1. Cloning of the carboxyl-terminus of Bhlp29.7 for recombinant expression 
Cloning of the carboxyl-terminus of Bhlp29.7 into the pMAL-c2x Expression System (New 
England Biolabs) was carried out in a similar manner to that described for pTrc-Bhlp29.7 
(chapter 3, sections 3.2.4-3.2.5). The gene sequence encoding the carboxyl-terminus of the 
Bhlp29.7 polypeptide between amino acid residues 201 to 271 was amplified from B. 
hyodysenteriae strain WA1 (Western Australian field strain isolated from a pig) chromosomal 
DNA that was prepared in the work described in chapter 2 (section 2.2.1) using 
oligonucleotide primers Bhlp29.7-F604-BamH1 (5’-GTAGGATCCATATACTTCGGTTTGA 
ATCCTG-3’) and Bhlp29.7-R809-HinDIII (5’- TATAAGCTTCAAGTAGGAAGATAAGA 
ACC-3’). The pMAL-c2x vector and the amplified PCR product was restricted separately with 
1 U of BamH1 (Promega) and 1 U of HinDIII (Promega) in 6 mM Tris-HCl (pH 7.5), 100 mM 
NaCl, 6 mM MgCl2, 1 mM DTT and 100 μg/ml BSA at 37°C overnight. Restricted DNA was 
purified and equimolar amounts of the linearised pMAL-c2x vector and the Bhlp29.7-F604 
insert was ligated at 14°C for 16 h in 30 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM DTT 
and 1 mM ATP containing 1 U of T4 DNA ligase (Promega). Ligation products were 
transformed into chemically competent E. coli BL21 Star (DE3) pLys One Shot (Invitrogen)   129
cells by heat-shock. Transformed cells were plated onto LB agar plates containing 100 mg/l 
ampicillin and incubated at 37°C for 16 h. 
 
5.2.3.2. Detection and verification of pMAL-Bhlp29.7-F604 transformants 
Twelve single transformant colonies were streaked onto fresh LB agar plates containing 100 
mg/l ampicillin and incubated at 37°C for 16 h. A single colony from each transformation 
event was resuspended in 50 μl of TE buffer and boiled for 1 min. Two μl of boiled cells were 
used as template for PCR. The amplification mixture consisted of 1× PCR buffer (containing 
1.5 mM of MgCl2), 1 U of Taq DNA polymerase, 0.2 mM of each dNTP (Promega), 0.5 μM of 
the pMAL-F primer (5’-GGTCGTCAGACTGTCGATGAAGCC-3’) and 0.5 μM of the 
pMAL-R primer (5’-CGCCAGGGTTTTCCCAGTCACGAC-3’). Cycling conditions involved 
an initial template denaturation step of 5 min at 94°C, followed by 30 cycles of denaturation at 
94°C for 30 sec, annealing at 55°C for 15 sec, and a primer extension at 72°C for 30 s. The 
PCR products were subjected to electrophoresis in 1% (w/v) agarose gels in 1× TAE buffer, 
stained by emersion in 1 μg/ml ethidium bromide solution for 15 min and viewed over UV 
light. 
 
Two transformant clones which produced the correct sized PCR products were inoculated into 
10 ml LB broth containing 100 mg/l ampicillin and incubated at 37°C for 12 h with shaking. 
The entire overnight cultures were centrifuged at 5,000 ×  g for 10 min and the plasmid 
contained in the cells was extracted using the QIAprep Spin Miniprep Kit as described 
previously (chapter 2, section 2.2.6). The purified plasmid was quantified with a Dynaquant 
DNA fluorometer (Hoefer), using pUC18 plasmid (Promega) as the standard, and the DNA 
concentration adjusted to 100 μg/ml by dilution with TE buffer. Both purified plasmids were 
subjected to automated direct sequencing of the pMAL-c2x expression cassette using the 
pMAL-F and pMAL-R primers. Each sequencing reaction was performed in a 10 μl volume 
consisting of 200 ng of plasmid DNA, 2 pmol of primer, and 4 μl of the ABI PRISM Dye   130
Terminator Cycle Sequencing Ready Reaction Mix (PE Applied Biosystems). Cycling 
conditions involved a 2 min denaturing step at 96°C, followed by 25 cycles of denaturation at 
96°C for 10 s, annealing at 55°C for 5 s and extension at 60°C for 4 min. Residual dye 
terminators were removed from the sequencing products by precipitation with 95% (v/v) 
ethanol containing 120 mM sodium acetate (pH 4.6), and vacuum dried. The plasmids were 
sequenced in duplicate with each primer, using an ABI 373A DNA Sequencer (PE Applied 
Biosystems). The successfully ligated plasmid was designated pMAL-Bhlp29.7-F604. 
 
5.2.3.3. Expression and purification of recombinant MBP-Bhlp29.7-F604 
A single colony of pMAL-Bhlp29.7-F604 in E. coli BL21 was inoculated into 50 ml LB broth 
in a 250 ml conical flask containing 100 mg/l ampicillin and incubated at 37°C for 16 h with 
shaking. A 2 litre conical flask containing 1 l of LB broth supplemented with 2 g/l glucose and 
100 mg/l ampicillin was inoculated with 10 ml of the overnight culture and incubated at 37°C 
until the optical density of the cells at 600 nm was approximately 0.5. The culture was then 
induced by adding IPTG to a final concentration of 0.3 mM and the cells returned to 37°C with 
shaking. After 3 h of induction, the culture was transferred to 250 ml centrifuge bottles and the 
bottles were centrifuged at 5,000 × g for 10 min at 4°C. The cell pellets were combined and 
resuspended with 50 ml of MBP column buffer. All subsequent protein purification was 
performed at 4°C. The resuspended cells were frozen in liquid nitrogen and immediately 
thawed in ice-water. The cell lysate was then sonicated on ice three times for 30 s with 1 min 
incubation on ice between sonication rounds. The lysed cells were cleared by centrifugation at 
20,000 × g for 15 min at 4°C and the supernatant diluted by adding 150 ml of MBP column 
buffer. A 100 ml syringe containing glass wool at the bottom was loaded with 15 ml of 
amylose resin (New England Biolabs) and equilibrated by washing with 400 ml of MBP 
column buffer. The diluted cell lysate was then applied to the amylose column in 100 ml 
amounts and the protein allowed to bind at a flow rate of approximately 2 ml/min. The column 
was washed 10 times with 100 ml of MBP column buffer before eluting with 200 ml of MBP   131
column buffer containing 10 mM maltose. Twenty 10 ml fractions of the eluate were collected 
and stored at 4°C. The samples were subjected to SDS-PAGE (chapter 2, section 2.2.4) and 
stained with Coomassie Brilliant Blue G250 (chapter 3, section 3.2.10). The fractions 
containing the purified MBP-Bhlp29.7-F604 protein were pooled, quantified, dialysed and 
lyophilised to dryness (chapter 2, section 3.2.11). The lyophilised protein was resuspended 
with PBS to a concentration of 2 mg/ml and stored at -20°C.  
 
5.2.4. Preparation of spirochaete inoculum 
A full description of spirochaete growth is provided in Chapter 2 (section 2.2.9).  A pure 
culture of Australian B. hyodysenteriae strain B/Q02 was obtained as frozen stock from the 
culture collection held at the Reference Centre for Intestinal Spirochaetes, Murdoch 
University. The cells were propagated on a rocking platform at 37°C in Kunkle's pre-reduced 
anaerobic broth containing 2% (v/v) FBS and a 1% (v/v) ethanolic cholesterol solution. Once 
cultures reached approximately 10
9 cells per ml (after approximately 3-5 days), as determined 
by counting in a haemocytometer chamber under a phase-contrast microscope, they were 
removed from 37°C and used immediately for oral challenge. 
 
5.2.5. Animals and experimental protocols 
Four animal experiments were conducted to evaluate the usefulness of recombinant His6-
Bhlp29.7 as a vaccine subunit for SD. Two mouse experiments were carried out, the first of 
which was performed to compare the immunogenicity of non-lipidated and lipidated forms of 
His6-Bhlp29.7. The second mouse experiment evaluated the usefulness of His6-Bhlp29.7 as a 
vaccine subunit for SD in mice. Two pig experiments were then conducted to evaluate the 
efficacy of vaccination with recombinant His6-Bhlp29.7 and MBP-Bhlp29.7-F604 (C-terminal 
portion of Bhlp29.7) in pigs experimentally challenged with B. hyodysenteriae.  
 
All animal experiments were performed with the permission of the Animal Ethics Committee 
of Murdoch University.   132
5.2.5.1. Experiment 1 – immunogenicity of lipidated His6-Bhlp29.7 in mice 
Twenty C3H/HeJARC weanling female mice (5 weeks of age) were purchased from a specific 
pathogen free (SPF) facility. The mice were randomly assigned to two groups of 10, numbered 
by punching the ears and blood taken from the tail vein. Each group of mice was housed in a 
separate cage kept in the same room of the animal house. The mice were fed ad libidum on a 
standard balanced mouse diet that did not contain antibiotics. Mice in group M1 were 
vaccinated with non-lipidated recombinant His6-Bhlp29.7 and mice in group M2 were 
vaccinated with lipidated recombinant His6-Bhlp29.7. 
 
Both groups of mice initially received either 100 µg recombinant His6-Bhlp29.7 or 100 µg 
recombinant lipidated His6-Bhlp29.7 emulsified with VSA3 adjuvant (MVP Laboratories) in a 
50 µl volume administered intramuscularly (im) into the quadriceps muscle of the right hind 
leg. Three weeks later, the mice received a similar im vaccination. Two weeks after the second 
vaccination, all mice were removed for post-mortem examination. Euthanasia was by gassing 
in methoxyfluorane followed by cervical dislocation. Blood was collected from the heart of 
each mouse and the serum was collected following overnight coagulation at 14°C. 
 
5.2.5.2. Experiment 2 – His6-Bhlp29.7 vaccination of mice 
Twenty C3H/HeJARC weanling female mice of the same age and from the same source as 
those in experiment 1 were used. The mice were randomly assigned to two groups of 10 
(groups M3 and M4), numbered by punching the ears and blood taken from the tail vein. The 
mice were fed ad libidum on a standard balance mouse diet that did not contain antibiotics. 
Mice in group M3 acted as unvaccinated controls, whilst mice in group M4 were vaccinated 
with 100 µg recombinant His6-Bhlp29.7 emulsified with VSA3 adjuvant (MVP Laboratories) 
in a 50 µl volume administered intramuscularly (im) into the quadriceps muscle of the right 
hind leg. Three weeks later, mice in group M4 received 100 µg recombinant His6-Bhlp29.7 in 
PBS administered by gastric intubation. Ten days prior to challenge with B. hyodysenteriae, all 
mice were placed on a diet formulation which contained approximately 63% (w/w) glucose   133
(Glen Forrest Stockfeeds). This diet composition has been shown to improve B. 
hyodysenteriae colonisation in mice (Nibbelink and Wannemuehler 1992). Two weeks after 
the second vaccination, all mice in both groups were given 0.8 ml of exponential log-phase B. 
hyodysenteriae strain B/Q02 culture (approximately 10
9 cells/ml) by gastric intubation. 
Experimental challenge was repeated over three consecutive days using freshly cultured 
inoculum for each day. Faeces were collected from individual mice twice weekly and cultured 
for spirochaetes. All mice were removed for necropsy 13 days after the last day of 
experimental challenge. Euthanasia was as in experiment 1. The presence and nature of lesions 
in the caecum and large intestine were recorded, and swabs were taken from the wall of the 
caecum for spirochaete culture. Blood was collected from the heart of each mouse and the 
serum was collected following overnight coagulation at 14°C. 
 
5.2.5.3. Experiment 3 – His6-Bhlp29.7 vaccination of pigs 
Thirty female pigs (Large White x Landrace x Duroc) which had just been weaned at 21 days 
of age were purchased from a commercial piggery that was regularly monitored to ensure it 
remained SD-free. The animals were weighed and ear-tagged, then randomly assigned to three 
groups of ten, with each group housed in a single pen with open wire-mesh partitions. The 
three pens were adjacent to each other, and were located in one room of an isolation animal 
house. The animals were fed ad libidum on a commercial pelleted weaner diet that did not 
contain antibiotics (20% crude protein, 14.7% MJ/kg digestible energy, Wesfeeds Ltd). The 
animals were weighed weekly throughout the experiment. Group 1A acted as unvaccinated 
controls, whilst groups 1B and 1C were vaccinated with His6-Bhlp29.7 by different routes.  
 
Both vaccinated groups (1B and 1C) initially received 1 mg recombinant His6-Bhlp29.7 
emulsified in FIA (Sigma Chemical Company), in a 2 ml volume administered intramuscularly 
(im) into the neck muscles behind the left ear. Three weeks later, pigs in group 1B received a 
solution containing 1 mg recombinant His6-Bhlp29.7 (without adjuvant) in 10 ml PBS by 
gastric intubation, whilst pigs in group 1C received their second vaccination with adjuvant im   134
behind the right ear. Two weeks after the second vaccination, all 30 pigs were given 50 ml of 
exponential log-phase B. hyodysenteriae strain B/Q02 culture (approximately 10
9 cells/ml) by 
gastric intubation. Experimental challenge was repeated over five consecutive days using 
freshly cultured inoculum for each day. Serum was obtained by bleeding from the anterior 
vena cava prior to the first vaccination (“pre-bleed”), just prior to the second vaccination (“pre-
boost”), prior to the first day of challenge (“pre-infection”), and at post-mortem. Rectal swabs 
for spirochaete culture were taken from all pigs at arrival to the facility, just prior to 
inoculation, and thereafter three times per week. The pigs were examined daily, and were 
removed for post-mortem examination within 24 h of diarrhoea containing mucus and/or fresh 
blood being observed. Such pigs were recorded as having clinical signs of SD. All other pigs 
were removed for necropsy between 20 and 23 days after the last day of experimental 
challenge. Euthanasia was by captive bolt stunning, followed by exsanguination. The presence, 
distribution and nature of gross lesions in the large intestine were recorded, and swabs were 
taken from the wall of the proximal colon for spirochaete culture. Ten centimetre long sections 
of the proximal colon were collected and the mucosa scraped off as described in section 
5.2.7.2. This was subsequently used to test for specific immunoglobulin content by ELISA and 
Western blot analysis. Sections of the colon also were removed and fixed in 10% formalin for 
subsequent histological examination. 
 
5.2.5.4. Experiment 4 – MBP-Bhlp29.7-F604 vaccination of pigs 
Thirty six female weaner pigs of the same age and from the same source as in experiment 4 
were used. They were randomly assigned to three groups of twelve. Group 2A acted as 
unvaccinated controls. Group 2B received 1 mg recombinant His6-Bhlp29.7 emulsified with 
VSA3 adjuvant (MVP Laboratories) administered im in a 2ml volume, followed 3 weeks later 
by 1 mg recombinant His6-Bhlp29.7 in 10 ml PBS by gastric intubation. Group 2C received 1 
mg recombinant MBP-Bhlp29.7-F604 with VSA3 adjuvant im, followed 3 weeks later by 1 
mg recombinant MBP-Bhlp29.7-F604 in 10 ml PBS by gastric intubation. The control pigs in 
group 2A were housed in a pen in a separate room from the two pens of vaccinated pigs   135
(groups 2B and 2C). The pigs were observed and sampled exactly as in experiment 1, except 
that animals that did not develop disease were not removed for post-mortem examination until 
51 days after experimental challenge. The same strain of B. hyodysenteriae was used for oral 
challenge. 
 
5.2.6. Microbiological analysis 
5.2.6.1. Culture of faecal swabs 
Bacteriology swabs taken from rectal faeces or the colonic walls of experimentally infected 
mice and pigs were streaked onto selective agar plates (Jenkinson and Wingar, 1981), 
consisting of TSA (Becton Dickinson Microbiology Systems) containing 5% (v/v) defibrinated 
sheep blood, 400 μg/ml spectinomycin and 25 μg/ml each of colistin and vancomycin (Sigma 
Chemical Company). The plates were incubated for 5 to 7 days at 37°C in an anaerobic 
environment of 94% H2 and 6% CO2, generated using anaerobic Gaspak plus sachets (Becton 
Dickinson Microbiology Systems), before being examined. The presence of low flat spreading 
growth of spirochaetes on the plate, and any haemolysis around the growth was recorded. 
Spirochaetes were confirmed by picking off areas of suspected growth, re-suspending this in 
PBS, and examining the suspension under a phase contrast microscope at 400× magnification.  
 
5.2.6.2. Detection of B. hyodysenteriae by PCR 
Spirochaetes were identified as B. hyodysenteriae on the basis of strong β-haemolysis, 
microscopic morphology and results of a NADH oxidase (nox) PCR of cell growth on the 
plates. The PCR primers and conditions used have been described previously (chapter 2, 
section 2.2.13.1). A cell-pick method was used to obtain spirochaetal DNA from the plates. 
The tip of a sterile wooden toothpick was used to stab through the area of strong haemolysis, 
and the material adhering to the tip was resuspended in 50 μL of ultra-pure water before being 
boiled for 30 s. A 2.5 μL volume of boiled cells was used as template for the nox PCR. The   136
PCR products were subjected to electrophoresis through a 1% (w/v) agarose gel in 1× TAE 
buffer, stained with ethidium bromide and viewed over UV light. 
 
5.2.7. Serological analysis 
5.2.7.1. ELISA for systemic antibodies in pigs and mice 
Ninety-six well microtitre plates (Immulon 4HBX, Dynex Technologies) were coated with 100 
μl per well of purified lipidated His6-Bhlp29.7 (0.5 μg/ml), His6-Bhlp29.7 (0.5 μg/ml), MBP-
Bhlp29.7-F604 (0.5 μg/ml) or a whole-cell preparation of B. hyodysenteriae strain Q/B02 (1 
μg/ml) in 0.1 M carbonate buffer (pH 9.6). The whole-cell preparation was prepared by 
harvesting 50 ml of mid-log phase B. hyodysenteriae strain Q/B02 cells at 5,000 × g for 15 min 
and resuspending the pellet in 15 ml PBS. The cells were sonicated three times for 30 s with 1 
min incubation on ice between sonication rounds. The lysed cells were cleared by 
centrifugation at 20,000 × g for 15 min at 4°C and the proteins in the supernatant quantified 
using the Bio-Rad Protein Assay (Bio-Rad Laboratories) (chapter 2, section 3.2.13).  Plate 
coating was allowed to occur at 4°C overnight. Plates were blocked with 150 μl of PBS 
containing 1% (w/v) BSA for 1 h at 25°C with mixing, and then washed three times with 150 
μl of PBST. Mice and pig sera were diluted 200-fold in 100 μl of PBST containing 0.1% (w/v) 
BSA and incubated at 25
oC for 2 h with mixing. Plates were washed as above before adding 
100 μl of goat anti-mouse IgG-HRP (Sigma Chemical Company) or goat anti-swine IgG-HRP 
(Southern Biotechnology) diluted 2,000-fold in PBST containing 0.1% (w/v) BSA. After 
incubating for 1 h at 25
oC, the plates were washed and 100 μl of K-Blue substrate (ELISA 
Systems) added. Colour development was allowed to occur for 10 min before being stopped 
with the addition of 50 μl of 1 M sulphuric acid. The optical density of each well was read at 
450 nm using a microtitre plate reader (Bio-Rad Model 3550-UV). For experiment 1, only 
His6-Bhlp29.7 and whole cell ELISAs were undertaken on mouse sera whilst for experiment 2, 
His6-Bhlp29.7 and whole cell ELISAs were undertaken on mouse sera and colonic extracts. 
Only His6-Bhlp29.7 and whole cell ELISAs were undertaken on pig sera and colonic extracts   137
from experiment 3, whilst His6-Bhlp29.7, MBP-Bhlp29.7-F604 and whole cell ELISAs were 
used on samples from experiment 4. 
 
5.2.7.2. ELISA for porcine colonic IgA 
Pig colonic extracts were made from a 15 cm
2 section of the proximal colon. The epithelium 
was briefly rinsed with sterile PBS to remove digesta, stripped off with a scalpel blade and 
resuspended in PBS containing 1% (w/v) BSA, 2 mM PMSF, 1 mM EDTA and 0.2% (w/v) 
sodium azide to a concentration of approximately 250 mg/ml. The suspensions were vortexed 
thoroughly and centrifuged at 20,000 × g for 10 min at 4°C to remove the particulate material. 
The supernatant was removed and 100 μl used directly for the ELISA. The mucosal ELISA 
was performed as for the serum ELISA (chapter 4, section 4.2.3), except goat anti-swine IgA-
HRP (Southern Biotechnology) was used to detect the reactive mucosal antibody. 
 
5.2.7.3. Western blot analysis of porcine antibodies 
Fifteen μg of the B. hyodysenteriae strain Q/B02 whole-cell preparation was loaded into a 7cm 
preparative well and subjected to SDS-PAGE (chapter 2, section 2.2.4) and the separated 
proteins electro-transferred to nitrocellulose membrane (chapter 2, section 2.2.5). After 
transfer, the membrane was removed from the transfer apparatus, washed briefly with distilled 
water and blocked with TBS containing 5% (w/v) skim milk powder. The membrane was then 
assembled into a Multi-Screen Apparatus (Bio-Rad Laboratories) that allowed the 
simultaneous analysis of 20 samples using the identical antigen. Each well of the Multi-Screen 
Apparatus was loaded with 100 μl of diluted serum pooled from two pigs (100-fold) or 
mucosal supernatant (2-fold) and incubated for 2 h at 25°C with gently mixing. Serum from a 
pig hyperimmunised with formalinised B. hyodysenteriae strain B78
T (chapter 4, section 4.2.2) 
was diluted 500-fold and used as a reaction control. The wells were washed three times with 
TBST then incubated for 1 h at 25°C with gentle mixing with 100 μl of either goat anti-swine 
IgG-HRP (Southern Biotechnology) for serum samples, or goat anti-swine IgA-HRP (Southern   138
Biotechnology) for colon samples. Both secondary antibodies were diluted 2,000-fold. The 
membrane was removed and washed three times with TBST and twice with distilled water. 
Colour development occurred with the addition of 10 ml of DAB substrate (Sigma Chemical 
Company), and the membrane was washed with tap water when sufficient development had 
occurred. 
 
5.2.8. Statistical Analysis 
In the two experiments using mice, serological titres between corresponding groups of mice 
were compared using either Student’s paired or unpaired t-tests, as appropriate, and statistical 
significance was accepted at the P≥0.05 level. Within each of the two pig experiments, 
comparisons were made between the groups. The data were analysed using GraphPad InStat, 
version 3.0 for Macintosh (GraphPad Software Inc.). For faecal excretion of B. hyodysenteriae, 
for each group, the number of faecal samples taken that were positive and the number negative 
over the experimental period were recorded. Ratios for each group were then compared using a 
Chi-squared test for independence. Where a significant value was obtained, the results for 
sequential pairs of groups were compared using Fisher’s exact test. The disease incidence over 
the experiment (number developing SD/number remaining healthy) was similarly examined. 
For the purposes of measuring and comparing disease incidence, animals were only recorded 
as having SD if they had both clinical signs of SD and lesions of SD in their colons (whether 
mild or severe). Pigs that had lesions in the colon at post-mortem, but remained healthy and 
did not have clinical SD, were scored as being healthy for the purpose of this analysis. Weekly 
body weights and ELISA titres were compared using one-way ANOVA, with the Tukey-
Kramer Multiple Comparisons Test used to identify significant between-group differences. 
Where only two sets of data were available, these were compared using Student’s unpaired t-
tests.   139
5.3. RESULTS 
5.3.1. Recombinant proteins 
5.3.1.1. Lipidated His6-Bhlp29.7 
Cloning of the lipidation cassette, containing the conserved E. coli lipoprotein signal peptidase 
recognition site (L-A-G-C) and the six histidine fusion, into the pTrc-Bhlp29.7 plasmid 
produced a recombinant construct, designated pLIP-Bhlp29.7, which was 5,150 bp in size. A 
complete plasmid map of pTrc-Bhlp29.7 expression vector is shown in Fig. 5.1. Nucleotide 
sequencing of the pLIP-Bhlp29.7 construct verified that the lipidation cassette was in the 
correct frame for protein translation. Predicted translation of the pLIP-Bhlp29.7 construct 
indicated the recombinant His6-Bhlp29.7 lipoprotein was identical to the deduced amino acid 
sequence of the corresponding portion of native Bhlp29.7. Expression of the pLIP-Bhlp29.7 
construct produced a recombinant his-tagged Bhlp29.7 lipoprotein with an apparent molecular 
mass of 34.1 kDa (Fig. 5.2, lane 3). The radioactive palmitate incorporation assay indicated 
that recombinant His6-Bhlp29.7 was expressed as a lipoprotein in E. coli (Fig. 5.2, lane 1). 
Purification of the His6-Bhlp29.7 recombinant lipoprotein by affinity chromatography under 
denaturing conditions successfully yielded his-tagged Bhlp29.7 without affecting its lipidation 
(Fig. 5.2, lane 2). Following dialysis and lyophilisation, a stable recombinant His6-Bhlp29.7 
lipoprotein was successfully produced. 
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Figure 5.1. Complete plasmid map of the pLIP-Bhlp29.7 expression vector showing 
features of the vector and the restriction sites used in its construction. SP, conserved E. 
coli signal peptidase recognition site; HIS, six histidine tag. 
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5.3.1.2. MBP-Bhlp29.7-F604 
Analysis of the E. coli expressed and purified recombinant His6-Bhlp29.7 was shown in 
chapter 3 (section 3.3.2). The His6-Bhlp29.7 protein had an apparent molecular mass of 34 kDa 
(chapter 3, Fig. 3.5). The gene region encoding the carboxyl-terminal portion (Bhlp29.7-F604) 
of the Bhlp29.7 lipoprotein was successfully cloned into the pMAL-c2x Expression System. 
Sequencing of the pMAL-c2x expression cassette indicated that the cloned insert DNA was in-
frame with the pMAL-c2x start codon and that the expressed Bhlp29.7 protein fragment had an 
amino acid sequence identical to the B. hyodysenteriae Bhlp29.7 lipoprotein. The carboxyl-
Figure 5.2. Autoradiograph and Coomassie Brilliant Blue staining of lipidated his-tagged 
Bhlp29.7 produced by the expression of the pLIP-Bhlp29.7 plasmid in E. coli. Lanes 1 and 
2 indicate radioactively labelled lipoproteins; lane 3 indicates Coomassie Brilliant Blue 
G250 stained protein. Lane 1, lysate of E. coli cells before purification by affinity 
chromatography using Ni-NTA agarose; lanes 2 and 3, purified lipidated his-tagged 
Bhlp29.7. The arrow indicates the position of the lipidated his-tagged Bhlp29.7 protein. 
Molecular weight marker is indicated as kDa.   142
terminal portion was expressed in E. coli BL21 as a maltose-binding protein fusion (MBP-
Bhlp29.7-F604) and purified by amylose-facilitated chromatography to produce a protein with 
an apparent molecular mass of 50 kDa of which approximately 42 kDa was contributed by the 
fusion with maltose binding protein (Fig. 5.3). Both recombinant His6-Bhlp29.7 and MBP-
Bhlp29.7-F604 remained stable following dialysis and lyophilisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2. Mouse experiments 
5.3.2.1. Experiment 1 
The mean serum antibody responses of the mice to recombinant His6-Bhlp29.7 and to whole 
cell antigen of B. hyodysenteriae are shown in Table 5.2a and Table 5.2b, respectively. In this 
experiment, vaccination with both non-lipidated and lipidated His6-Bhlp29.7 resulted in 
significant increases in serum antibody titres to both Bhlp29.7 and B. hyodysenteriae whole 
cell antigens. No significant differences (P>0.05) were observed between the immunogenicity 
of the two vaccine antigens in either ELISA. 
Figure 5.3. SDS-PAGE of the amylose-facilitated affinity chromatography 
purified recombinant maltose-binding protein fusion of the carboxy-terminal 
portion of the Bhlp29.7 lipoprotein (MBP-Bhlp29.7-F604) used for the 
vaccination of pigs. Lanes 1-2, MBP-Bhlp29.7-F604.    143
  
 
Table 5.2a. Means ± standard deviation of group ELISA titres before and after vaccination 
with non-lipidated and lipidated recombinant His6-Bhlp29.7 in experiment 1. Mouse serum 
was used in ELISA using His6-Bhlp29.7 as the plate coating antigen. 
 
Vaccine antigen 
Sample time  Non-lipidated 
His6-Bhlp29.7 
Lipidated 
His6-Bhlp29.7 
P-value 
Pre-vaccination 0.041  ± 0.028  0.052 ± 0.025  P=0.1021 
Post-vaccination  0.876 ± 0.118  0.799 ± 0.083  P=0.2886 
P-value  P=0.0011  P<0.0001  
 
Table 5.2b. Means ± standard deviation of group ELISA titres before and after vaccination 
with non-lipidated and lipidated recombinant His6-Bhlp29.7 in experiment 1. Mouse serum 
was used in ELISA using a sonicated whole cell preparation of B. hyodysenteriae as the 
plate coating antigen.  
 
Vaccine antigen 
Sample time  Non-lipidated 
His6-Bhlp29.7 
Lipidated 
His6-Bhlp29.7 
P-value 
Pre-vaccination 0.073  ± 0.059  0.049 ± 0.044  P=0.5966 
Post-vaccination  0.832 ± 0.124  0.816 ± 0.089  P=0.4113 
P-value  P=0.0008  P<0.0001  
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5.3.2.2. Experiment 2 
5.3.2.2.1. Colonisation of mice with B. hyodysenteriae 
The summarised results for microbiological culture of B. hyodysenteriae from the faeces of 
unvaccinated mice (group M3) and the His6-Bhlp29.7 vaccinated mice (group M4) are shown 
in Table 5.3. Apart from the first sampling four days post infection, when four of the 
vaccinated mice (group M4) were excreting B. hyodysenteriae in the faeces, none of the 
vaccinated animals showed evidence of colonisation up to 13 days post-infection. At necropsy 
(13 days post-infection), B. hyodysenteriae was not detected in the caecum of any vaccinated 
mice. Four of the remaining seven (57%) unvaccinated mice were excreting B. hyodysenteriae 
in their faeces on sampling days four, six and 11 post-infection. At the time of necropsy, three 
of these unvaccinated mice were positive for B. hyodysenteriae in their faeces, however B. 
hyodysenteriae was detected in the caecum of all seven (100%). Three of the 10 unvaccinated 
mice died prior to experimental infection. The cause of death was not established. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3. Number and percentage of unvaccinated and His6-Bhlp29.7 vaccinated mice that 
were orally challenged with strain Q/01 having B. hyodysenteriae in their faeces, or in their 
caecum at post-mortem. Each challenge regime initially consisted of 10 mice. Three 
unvaccinated mice died of unknown causes unrelated to vaccination prior to experimental 
challenge. 
 
Days post-infection  -3  4  6  11  13 * 
Site for culture  Faeces  Faeces  Faeces  Faeces  Faeces  Caecum 
Non-vaccinated  0/7 (0%)  4/7 (57%)  4/7 (57%)  4/7 (57%)  3/7 (43%)  7/7 (100%) 
His6-Bhlp29.7 vaccinated  0/10 (0%)  4/10 (40%)  0/10 (0%)  0/10 (0%)  0/10 (0%)  0/10 (0%) 
  * samples taken at necropsy   145
5.3.2.2.2. Antibody response 
The systemic antibody response of the mice at necropsy, 13 days after experimental challenge 
with B. hyodysenteriae, is shown in Fig. 5.4 for the ELISA using His6-Bhlp29.7 as the antigen, 
and Fig. 5.5 for the ELISA using B. hyodysenteriae whole cells as the antigen. In the non-
vaccinated mice (group M3), little or no systemic antibody response to recombinant His6-
Bhlp29.7 was detected before or after challenge with B. hyodysenteriae (Fig. 5.4). All the mice 
in this group showed some response to the B. hyodysenteriae whole-cell preparation, although 
the response of some mice (mice 1, 3 and 4) was higher than others (Fig. 5.5).  
 
All vaccinated mice (group M4) showed a strong systemic antibody response to both the 
recombinant His6-Bhlp29.7 protein (Fig. 5.4) and the B. hyodysenteriae whole-cell preparation 
(Fig. 5.5). In some mice (mice 8, 9, 10 and 12), a higher systemic response was directed at the 
B. hyodysenteriae whole-cell compared to the recombinant His6-Bhlp29.7. 
 
5.3.2.2.3. Macroscopic lesions 
No macroscopic lesions were observed in the caecum or colon of mice in either group.   146
 
 
 
 
 
 
 
 
Figure 5.4. Systemic antibody titres against recombinant His6-Bhlp29.7 following 
vaccination with recombinant His6-Bhlp29.7 and experimental challenge of the mice with 
B. hyodysenteriae. Mice 1-7 were not vaccinated and mice 8-17 were vaccinated prior to 
challenge with B. hyodysenteriae. Circulating antibodies prior to vaccination and at 
necropsy were detected by ELISA using recombinant His6-Bhlp29.7 as the coating antigen. 
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Figure 5.5. Systemic antibody titres against B. hyodysenteriae whole cells following 
vaccination with recombinant His6-Bhlp29.7 and experimental challenge of the mice with 
B. hyodysenteriae. Mice 1-7 were not vaccinated and mice 8-17 were vaccinated prior to 
challenge with B. hyodysenteriae. Circulating antibodies prior to vaccination and at 
necropsy were detected by ELISA using a whole cell preparation of B. hyodysenteriae as 
the coating antigen. 
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5.3.3. Pig experiments 
5.3.3.1. Body weights 
In both pig experiments no significant differences were found in body weights of the groups of 
pigs at any weighing (Table 5.4 and 5.5). Individual pigs rapidly lost weight when they 
developed clinical signs of SD, but because they were then removed from the experiment, their 
weights were not subsequently recorded in the group data.  
 
 
Table 5.4. Mean ± standard deviations of body weights (kg) of the pigs in experiment 3 
recorded at the start of the experiment before the first vaccination (pre-vaccination), prior to 
spirochaetal challenge after the second vaccination (pre-infection) and at necropsy (post-
mortem). Post-mortem weights were calculated on the day when most of the non-vaccinated 
pigs were taken for necropsy. im, intramuscularly vaccinated. 
 
Group 
Time of sampling  Non-vaccinated 
(1A, n=10) 
im/oral  
(1B, n=10) 
im/im  
(1C, n=10) 
Pre-vaccination  6.1 ± 0.6  6.3 ± 0.8  6.3 ± 0.6 
Pre-infection  19.6 ± 3.6  20.3 ± 1.6  20.1 ± 2.8 
Post-mortem  38.5 ± 5.2  43.6 ± 2.8  43.7 ± 4.5 
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5.3.4. Experiment 3 
5.3.4.1. Antibody response 
The serum and colonic antibody responses of the pigs in experiment 3 to recombinant His6-
Bhlp29.7 and whole cell antigen are summarised in Table 5.6. In this experiment, vaccination 
by the im/oral (group 1B) and im/im (group 1C) routes both resulted in good primary and 
secondary serum antibody responses to Bhlp29.7, with the im/im route resulting in the highest 
titres. Infection of the unvaccinated control pigs did not result in an increase in serum 
antibody. No differences were observed between the three groups in colonic IgA titres. Using a 
whole cell preparation as ELISA antigen, neither vaccination with His6-Bhlp29.7 nor 
experimental infection with B. hyodysenteriae resulted in increases in serum antibodies, and no 
differences were observed between any of the groups in the colon. Western blot analysis of 
serum from the vaccinated pigs confirmed that the systemic antibody response induced by both 
the vaccination regimens was primarily directed against the native Bhlp29.7 protein of B. 
hyodysenteriae (Fig. 5.6 and 5.7). The non-vaccinated pigs failed to show any significant 
Table 5.5. Mean ± standard deviation of body weights (kg) of the pigs in experiment 4 
recorded at the start of the experiment before the first vaccination (pre-vaccination), prior 
to spirochaetal challenge after the second vaccination (pre-infection) and at necropsy 
(post-mortem). 
 
 Group 
Time of sampling Non-vaccinated 
(2A, n=12) 
His6-Bhlp29.7  
(2B, n=12) 
MBP-Bhlp29.7-F604  
(2C, n=12) 
Pre-vaccination  5.8 ± 0.4  5.9 ± 0.6  5.7 ± 0.6 
Pre-infection  12.0 ± 1.5  10.8 ± 1.5  10.5 ± 1.5 
Post-mortem  28.9 ± 3.9  27.6 ± 4.0  23.4 ± 6.7 
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antibody titres specific for Bhlp29.7 following infection and at necropsy (when acute SD was 
observed), although they did recognise other proteins in the B. hyodysenteriae whole-cell 
extract. Western blot analysis of the colonic IgA indicated that the local response in 
experiment 3 was directed at the native Bhlp29.7 lipoprotein (Fig. 5.8). 
 
Table 5.6. Means ± standard deviation of group ELISA titres at four sampling times in 
experiment 3. Each pig was sampled prior to the first vaccination (pre-bleed), prior to the 
second vaccination (pre-boost), prior to spirochaetal challenge (pre-infection) and at 
necropsy (post-mortem). Within a row, mean values with different superscripts differ at least 
at the 5% level of significance. ND denotes sample not taken. 
 
Experimental group 
ELISA 
antigen 
Sample type* 
and time 
Control 
(1A) 
im/oral 
(1B) 
im/im 
(1C) 
P-value 
Bhlp29.7  S: pre-bleed  0.039 ± 0.040  0.048 ± 0.021  0.034 ± 0.028  0.570 
Bhlp29.7 S:  pre-boost  ND  0.932 ± 0.271  0.863 ± 0.435  0.428 
Bhlp29.7 S:  pre-infection 0.038
a ± 0.016  1.280
b ± 0.396  1.595
b ± 0.370  < 0.0001 
Bhlp29.7 S:  post-mortem 0.069
a ± 0.022  1.152
b ± 0.283  1.467
c ± 0.251  < 0.0001 
Bhlp29.7 C:  post-mortem 0.315  ± 0.304  0.382 ± 0.200  0.444 ± 0.201  0.493 
Whole cell  S: pre-bleed  0.051 ± 0.038  0.040 ± 0.034  0.040 ± 0.040  0.742 
Whole cell  S: pre-boost  ND  0.083 ± 0.030  0.085 ± 0.033  0.883 
Whole cell  S: pre-infection  0.101 ± 0.054  0.131 ± 0.042  0.142 ± 0.060  0.212 
Whole cell  S: post-mortem  0.307 ± 0.130  0.392 ± 0.134  0.368 ± 0.126  0.338 
Whole cell  C: post-mortem  0.231 ± 0.300  0.157 ± 0.230  0.108 ± 0.108  0.458 
* S, serum IgG; C, colonic IgA   151
  
Figure 5.6. Western blot analysis of pooled serum from the pigs in experiment 
3 vaccinated intramuscularly and orally with recombinant His6-Bhlp29.7 (group 
1B). Sera from two pigs were pooled for each sampling time. The antigen used 
was a whole-cell extract of the homologous B. hyodysenteriae strain used for 
challenge. Lane 1, serum from a pig hyper-immunised with a B. hyodysenteriae 
B78
T (positive control), lanes 2-6, serum taken pre-vaccination; lanes 7-11, 
serum taken pre-challenge, lanes 12-16, serum taken at post-mortem. Each set 
of three sampling times includes serum taken from pigs 21-22 (lanes 2, 7 and 
12), pigs 23-24 (lanes 3, 8 and 13), pigs 25-26 (lanes 4, 9 and 14), pigs 27-28 
(lanes 5, 10 and 15) and pigs 29-30 (lanes 6, 11 and 16). The native Bhlp29.7 
protein of B. hyodysenteriae is indicated with the arrow.   152
  
Figure 5.7. Western blot analysis of pooled serum from the pigs in 
experiment 3 vaccinated twice intramuscularly with recombinant His6-
Bhlp29.7 (group 1C). Sera from two pigs were pooled for each sampling 
time. The antigen used was a whole-cell extract of the homologous B. 
hyodysenteriae strain used for challenge. Lane 1, serum from a pig hyper-
immunised with a B. hyodysenteriae B78
T (positive control), lanes 2-6, serum 
taken pre-vaccination; lanes 7-11, serum taken pre-challenge, lanes 12-16, 
serum taken at post-mortem. Each set of three sampling times includes serum 
taken from pigs 31-32 (lanes 2, 7 and 12), pigs 33-34 (lanes 3, 8 and 13), pigs 
35-36 (lanes 4, 9 and 14), pigs 37-38 (lanes 5, 10 and 15) and pigs 39-40 
(lanes 6, 11 and 16). The native Bhlp29.7 protein of B. hyodysenteriae is 
indicated with the arrow.   153
  
Figure 5.8. Western blot analysis of mucosal IgA in the colon of selected pigs in 
experiment 3 which showed reactivity to recombinant His6-Bhlp29.7 in ELISA. 
The antigen used was a whole-cell extract of the B. hyodysenteriae strain used for 
challenge. Lane 1, pig 1; lane 2, pig 7; lane 3, pig 8; lane 4, pig 12; lane 5, pig 13; 
lane 6, pig 19; lane 7, pig 20; lane 8, pig 21; lane 9, pig 23; lane 10, pig 24; lane 
11, pig 29. Lanes 1-3 were from the non-vaccinated pigs (group 1A). Lanes 4-7 
were from the group of pigs vaccinated intramuscularly and orally with 
recombinant His6-Bhlp29.7 (group 1B). Lanes 8-11 were from the pigs vaccinated 
intramuscularly with recombinant His6-Bhlp29.7 (group 1C). The position of the 
native Bhlp29.7 protein is indicated with the arrow.   154
5.3.4.2. Faecal excretion of B. hyodysenteriae 
For the non-vaccinated control pigs (group 1A), excretion of B. hyodysenteriae was first 
detected in two pigs six days after the end of experimental infection (Table 5.7). Pig number 4 
was killed before the end of the experiment, when diarrhoea was observed, although it was 
culture negative and did not have lesions consistent with SD at post-mortem. Eight of the 
remaining nine pigs excreted B. hyodysenteriae in their faeces prior to development of clinical 
signs. In contrast, the first faecal sample positive for B. hyodysenteriae in pigs vaccinated 
im/oral (group 1B) was 14 days after experimental infection (Table 5.8). One pig was removed 
due to lameness. Five of the remaining nine pigs were faecal positive at some point during the 
experimental period. For the pigs vaccinated im/im (Group 1C), the first pig became culture 
positive six days after experimental infection (Table 5.9). Overall, seven of the ten pigs were 
faecal culture positive at some point during the experiment. The number of positive faecal 
samples compared to the total number of faecal samples examined for the three groups were 
19/73, 9/87 and 14/82 (groups 1A, 1B and 1C, respectively). Overall there was a significant 
difference in these rates (χ
2=6.813; df=2; P=0.033), but the only significant difference between 
individual pairs of groups was between the unvaccinated animals (group 1A) and the pigs 
vaccinated im/oral (group 1B), with the faeces of the latter being less commonly positive 
(χ
2=6.762; df=1; P=0.009). 
 
5.3.4.3. Development of clinical signs, and lesions at post-mortem 
A summary of the clinical signs and severity of colonic lesions in the pigs at post-mortem is 
presented in Table 5.10. The appearance of clinical signs of SD was always preceded by the 
presence of positive faecal cultures, although amongst vaccinates positive cultures were not 
always followed by disease. Seven of the ten non-vaccinated pigs (70%) developed clinical 
signs of SD and had lesions of severe mucohaemorrhagic colitis at post-mortem examination 
(Fig. 5.9). Three of the ten pigs (30%) that were vaccinated im/oral (group 1B) developed 
diarrhoea. Two had severe lesions of mucohaemorrhagic colitis at post-mortem, whilst the   155
 
 
Table 5.7. Culture results for faecal swabs taken from individual pigs in the non-vaccinated group of experiment 3 (group 1A) after experimental challenge 
with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD was observed, or else at the end of the experimental period. Culture at post-
mortem was taken from the caecum. Dpi denotes days post-infection. The arrow indicates that no culture result was available as the pig had been removed 
for post-mortem. Positive (+) and negative (-) culture for B. hyodysenteriae are indicated. 
 
dpi  -9  3  6  8  10 14 16 20 22 23 
Pig 11  -  -  + + + ↓  ↓  ↓  ↓  ↓ 
Pig  12 - - - - - - - - - + 
Pig  13 - - - + + + + ↓  ↓  ↓ 
Pig  14 - - - - - - - ↓  ↓  ↓ 
Pig  15 - - - - - - +  + + ↓ 
Pig  16 - - - - +  ↓  ↓  ↓  ↓  ↓ 
Pig  17 - - - - - - + + ↓  ↓ 
Pig 18  -  -  + + + ↓  ↓  ↓  ↓  ↓ 
Pig  19 - - - - - + + ↓  ↓  ↓ 
Pig  20 - - - - - - - - - - 
    156
 
Table 5.8. Culture results for faecal swabs taken from individual pigs in experiment 3 which were vaccinated intramuscularly and orally with His6-
Bhlp29.7 (group 1B). The swabs were taken after the experimental challenge with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD 
was observed, or else at the end of the experimental period. Culture at post-mortem was taken from the caecum. Dpi denotes days post-infection. The 
arrow indicates that no culture result was available as the pig had been removed for post-mortem. Pig 30 was taken to PM due to physical injury unrelated 
to SD. Positive (+) and negative (-) culture for B. hyodysenteriae are indicated. 
 
dpi  -9  3  6  8  10 14 16 20 22 23 
Pig  21 - - - - - - - - +  ↓ 
Pig  22 - - - - - - - - - - 
Pig  23 - - - - - - - - + - 
Pig  24 - - - - - - - - - ↓ 
Pig  25 - - - - - - - - - ↓ 
Pig  26 - - - - - - - - - ↓ 
Pig  27 - - - - - - - +  +  ↓ 
Pig  28 - - - - - +  +  +  ↓  ↓ 
Pig  29 - - - - - - - +  +  ↓ 
Pig  30 - - - - - ↓  ↓  ↓  ↓  ↓ 
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Table 5.9. Culture results for faecal swabs taken from individual pigs in experiment 3 which were vaccinated twice intramuscularly with His6-Bhlp29.7 
(group 1C). The swabs were taken after the experimental challenge with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD was 
observed, or else at the end of the experimental period. Culture at post-mortem was taken from the caecum. Dpi denotes days post-infection. The arrow 
indicates that no culture result was available as the pig had been removed for post-mortem. Positive (+) and negative (-) culture for B. hyodysenteriae are 
indicated. 
 
dpi  -9  3  6  8  10 14 16 20 22 23 
Pig 31  -  -  + + + ↓  ↓  ↓  ↓  ↓ 
Pig  32 - - - - - - - - - - 
Pig  33 - - - - - - - - - + 
Pig  34 - - - - - - - +  ↓  ↓ 
Pig  35 - - - - - - - +  ↓  ↓ 
Pig  36 - - - - - - - - ↓  ↓ 
Pig  37 - - - - + + + + ↓  ↓ 
Pig  38 - - - - - - - - - ↓ 
Pig  39 - - - - - - - + + ↓ 
Pig  40 - - - - - +  -  +  ↓  ↓ 
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Table 5.10. Occurrence of clinical SD, presence of B. hyodysenteriae in the colon and severity of colonic lesions in the pigs of experiment 3, 
including controls and two groups vaccinated with His6-Bhlp29.7 by different routes. Pig 4 had watery diarrhoea which was not caused by SD. 
 
Non-vaccinated pigs (group 1A)  im/oral vaccinated pigs (group 1B)  im/im vaccinated pigs (group 1C) 
Pig  Clinical SD  PM Culture 
Lesion 
severity 
Pig Clinical  SD PM  Culture 
Lesion 
severity 
Pig  Clinical SD  PM Culture 
Lesion 
severity 
1 yes  +  severe  11  yes  +  severe  21  yes  +  mild 
2 no  +  --  12  no  -  -  22  no  -  -- 
3 yes  +  severe  13 no  -  mild  23 no  +  -- 
4 no  -  --  14  no  -  -  24  yes  +  mild 
5 yes  +  severe  15 no  -  -  25 no  +  -- 
6 yes  +  severe  16 no  -  -  26 no  -  -- 
7 yes  +  severe  17 no  +  mild  27  yes  +  mild 
8 yes  +  severe  18  yes  +  mild  28 no  -  -- 
9 yes  +  severe  19  yes  +  severe  29  yes  +  severe 
10 no  -  --  20 no  -  -  30 no  +  -- 
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third only had mild localised lesions (Fig. 5.10). One pig (10%) was removed due to physical 
injury, and had no lesions in the colon. The remaining six pigs (60%) stayed healthy 
throughout the experimental period, and did not develop diarrhoea. Two of these healthy pigs 
had mild lesions limited to the proximal colon at post-mortem. One of these two pigs was 
culture negative from the colon, although previously it had been culture positive from the 
faeces. The other pig was culture positive from the colon, and had been faecal positive on 
several samplings before post-mortem. For the pigs that were vaccinated im/im (group 1C), 
four (40%) developed diarrhoea and were culture positive from the colon at post-mortem 
examination. One of these four pigs had severe mucohaemorrhagic lesions in the colon, whilst 
the other three had mild and/or localised lesions. The other six pigs (60%) remained healthy. 
Three of these six were culture positive from the colon and also were faecal culture positive 
prior to slaughter, although none had colonic lesions at post-mortem. The incidences of disease 
in the three groups 1A, 1B and 1C were 7/10, 3/9 and 4/10 respectively, and these differences 
were not significant (χ
2=2.97; df=2; P=0.227). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Colon showing the severe lesions of mucohaemorrhagic colitis seen in seven 
out of ten non-vaccinated pigs.   160
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.5. Experiment 4 
5.3.5.1. Antibody response 
The serum and colonic antibody responses of the pigs in experiment 4 to recombinant His6-
Bhlp29.7, whole cell antigen and MBP-Bhlp29.7-F604 are summarised in Table 5.11. 
Vaccination with His6-Bhlp29.7 (group 2B) induced good primary and secondary serum 
antibody responses to His6-Bhlp29.7. Titres also tended to be higher in the colon of these 
vaccinated pigs than in the other pigs. Pigs vaccinated with MBP-Bhlp29.7-F604 (group 2C) 
showed little or no reactivity to His6-Bhlp29.7. Using a whole cell preparation as ELISA 
antigen, the pigs vaccinated with His6-Bhlp29.7 did show a slight increase in serum titres 
compared to the control pigs. With the MBP-Bhlp29.7-F604 antigen, serum titres were 
significantly elevated in the animals vaccinated with this antigen (group 2C), but not in the 
other groups. Little colonic antibody was detected. The results of Western Blot analysis of the 
serum from the vaccinated pigs, using whole-cell preparations as antigen, were similar to those 
in experiment 3. The systemic response induced by vaccination with recombinant
Figure 5.10. Colon showing the mild localised lesions seen in some of the vaccinated pigs.   161
His6-Bhlp29.7 was directed predominately at the native Bhlp29.7 lipoprotein of B. 
hyodysenteriae, although reactivity with other spirochaetal proteins also was observed.  
 
Table 5.11. Mean ± standard deviation of group ELISA titres at four sampling times in 
experiment 4. Each pig was sampled prior to the first vaccination (pre-bleed), prior to second 
vaccination (pre-boost), prior to spirochaetal challenge (pre-infection) and at necropsy (post-
mortem). Within a row, mean values with different superscripts differ at least at the 5% level 
of significance. ND denotes sample not taken. 
 
Experimental group  P-value 
ELISA 
antigen
¥ 
Sample type* 
and time  Control (2A) 
His6-Bhlp29.7 
vaccine (2B) 
MBP-Bhlp29.7-F604 
vaccine (2C) 
 
Bhlp29.7  S: pre-bleed  ND  0.036 ± 0.021  0.042 ± 0.038  0.659 
Bhlp29.7 S:  pre-boost  0.036
a ± 0.014  0.725
b ± 0.313  0.033
a ± 0.020  < 0.0001 
Bhlp29.7 S:  pre-infection  0.091
a ± 0.035  1.879
b ± 0.260  0.102
a ± 0.031  < 0.0001 
Bhlp29.7 S:  post-mortem  0.118
a ± 0.090  1.710
b ± 0.545  0.169
a ± 0.143  < 0.0001 
Bhlp29.7 C:  post-mortem  1.264
ab ± 0.414  1.837
a ± 0.451  0.819
b ± 0.994  0.003 
Whole cell  S: pre-bleed  ND  0.151 ± 0.122  0.174 ± 0.266  0.790 
Whole cell  S: pre-boost  ND  ND  ND  ND 
Whole cell  S: pre-infection  0.333
ab ± 0.437  0.578
a ± 0.406  0.200
b ± 0.111  0.039 
Whole cell  S: post-mortem  0.361 ± 0.302  0.687 ± 0.400  0.406 ± 0.441  0.096 
Whole cell  C: post-mortem  0.140 ± 0.156  0.135 ± 0.171  0.132 ± 0.184  0.993 
F604 S:  pre-bleed  ND  0.116 ± 0.095  0.143 ± 0.062  0.414 
F604 S:  pre-boost  0.071
a ± 0.087  0.101
a ± 0.097  1.302
b ± 0.332  < 0.0001 
F604 S:  pre-infection  0.049
a ± 0.033  0.091
a ± 0.029  2.277
b ± 0.346  < 0.0001 
F604 S:  post-mortem  0.027
a ± 0.030  0.039
a ± 0.028  1.994
b ± 0.046  < 0.0001 
F604 C:  post-mortem  0.440
ab ± 0.269  0.606
a ± 0.243  0.200
b ± 0.345  0.007 
* S, serum IgG; C, colonic IgA 
¥ F604=MBP-Bhlp29.7-F604
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5.3.5.2. Faecal excretion of B. hyodysenteriae  
For the non-vaccinated control pigs (group 2A), excretion of B. hyodysenteriae was first 
detected in the faeces eight days after the last day of experimental infection (Table 5.12). All 
the non-vaccinated pigs were culture positive from the faeces at some point during the 
experimental period. For the pigs vaccinated with recombinant His6-Bhlp29.7 (group 2B), the 
first faecal positive pig was detected ten days after experimental infection (Table 5.13). Eleven 
of these 12 pigs were culture positive from the faeces at some point in the experiment. For the 
pigs vaccinated with MBP-Bhlp29.7-F604 (group 2C), the first pig became culture positive six 
days after experimental infection (Table 5.14). All but one of these vaccinated pigs was culture 
positive from the faeces at some point during the experimental period. One pig died due to an 
unknown cause not related to SD (as established at post-mortem examination by a veterinary 
pathologist). The number of positive faecal samples compared to the total number of faecal 
samples examined for the three groups were 30/174, 51/191 and 32/129 (groups 2A, 2B and 
2C, respectively). Overall there were no significant differences in these rates, but a trend was 
present (χ
2=4.99; df=2; P=0.083). Pairwise comparisons revealed that the control pigs had a 
significantly smaller proportion of faecal positive days than the vaccinated pigs in group 2B 
(χ
2=4.72; df=1; P=0.030). 
 
5.3.5.3. Development of clinical signs, and lesions at post-mortem 
The clinical signs and lesions in the colon obtained from the pigs in experiment 4 are 
summarised in Table 5.15. For the unvaccinated pigs (group 2A), six (50%) developed clinical 
signs of SD. Five of these had severe mucohaemorrhagic colitis at post-mortem, whilst only 
one had mild localised lesions. Two of the 12 pigs (17%) did not develop clinical signs of SD, 
however they had severe lesions in the colon at post-mortem. The remaining four pigs (33%) 
stayed healthy and were culture negative at post-mortem. For the 12 pigs vaccinated with 
recombinant His6-Bhlp29.7, two (17%) developed clinical signs of SD and both had mild 
localised lesions in the colon at post- mortem. The remaining ten pigs (83%) remained healthy, 
and did not have diarrhoea, but two had severe mucohaemorrhagic lesions in the colon at post-  163
 
Table 5.12. Culture results for faecal swabs taken from individual pigs in the non-vaccinated group of experiment 4 (group 2A) after experimental 
challenge with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD was observed, or else at the end of the experimental period. 
Culture at post-mortem was taken from the caecum. Dpi denotes days post-infection. The arrow indicates that no culture result was available as the pig had 
been removed for post-mortem. Positive (+) and negative (-) culture for B. hyodysenteriae are indicated. 
 
dpi  -4  3  6  8  10 14 17 21 22 24 27 29 31 34 37 42 44 51 
Pig  1  - - - - - - - - - - - - - - + - +  + 
Pig 2  - - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 3  - - - - - - - - - - - - +  +  +  ↓  ↓  ↓ 
Pig  4  - - - - - - - - - - - - + - - - - + 
Pig 5  - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig  6  - - - - - - - - - - - - - - + - + - 
Pig  7  - - - - - - - - - + - - - - - - - - 
Pig  8  - - - - - - - - - - - - - - - - + - 
Pig  9  - - - - - - - - - - - - - - - +  +  + 
Pig 10  - - - - +  +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 11  - - - - - - - + - - + - +  +  +  ↓  ↓  ↓ 
Pig  12  - - - - - - - - - - - - - - +  + - + 
   164
Table 5.13. Culture results for faecal swabs taken from individual pigs in experiment 4 which were vaccinated His6-Bhlp29.7 (group 2B). The swabs were 
taken after the experimental challenge with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD was observed, or else at the end of the 
experimental period. Culture at post-mortem was taken from the caecum. Dpi denotes days post-infection. The arrow indicates that no culture result was 
available as the pig had been removed for post-mortem. Positive (+) and negative (-) culture for B. hyodysenteriae are indicated.  
 
dpi  -4  3  6  8  10 14 17 21 22 24 27 29 31 34 37 42 44 51 
Pig  13  - - - - - - - +  +  +  +  +  + - + - - - 
Pig  14  - - - - - - - - +  +  +  +  + - - - + - 
Pig  15  - - - - - - - - - - - - - - - - - - 
Pig  16  - - - - - - - - - - - - - - - - +  + 
Pig  17  - - - - - - - - - - - - - - +  +  + - 
Pig 18  - - - - - - - +  + - - +  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig  19  - - - - - - - - +  + - +  + - - - +  + 
Pig  20  - - - - - - - - + - - - + - +  +  + - 
Pig  21  - - - - - - - - - - - - - - + - - - 
Pig 22  - - - - - - - - +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig  23  - - - - +  + - - - - - - + - - - - - 
Pig  24  - - - - - +  +  + - - + - - - +  +  + - 
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Table 5.14. Culture results for faecal swabs taken from individual pigs in experiment 4 which were vaccinated MBP-Bhlp29.7-F604 (group 2C). The 
swabs were taken after the experimental challenge with B. hyodysenteriae. Pigs were removed for post-mortem when clinical SD was observed, or else at 
the end of the experimental period. Culture at post-mortem was taken from the caecum. Dpi denotes days post-infection. The arrow indicates that no 
culture result was available as the pig had been removed for post-mortem. Pig 33 was taken to PM due an unknown cause unrelated to SD. Positive (+) and 
negative (-) culture for B. hyodysenteriae are indicated.  
 
dpi  -4  3  6  8  10 14 17 21 22 24 27 29 31 34 37 42 44 51 
Pig 25  -  - + + + ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 26  - - - - - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 27  - - - - - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 28  - - - - - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 29  - - - - - - - - - - - +  +  +  +  ↓  ↓  ↓ 
Pig 30  - - - - - - +  +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig  31  - - - - - + + + - + - + + - + - - - 
Pig 32  - - - - - - - - +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 33  - - - - - - - - ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig 34  - - - - - - - +  +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
Pig  35  - - - - - - - - - - - - - - - - - - 
Pig 36  - - - - - - - +  +  +  ↓  ↓  ↓  ↓  ↓  ↓  ↓  ↓ 
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Table 5.15. Clinical signs and severity of colonic lesions in the pigs of experiment 4. Pig 63 died of an unknown cause not related to SD. 
Non-vaccinated pigs (group 2A)  His6-Bhlp29.7 vaccinated pigs (group 2B)  MBP-Bhlp29.7-F604 vaccinated pigs (group 2C) 
Pig  Clinical SD  PM Culture 
Lesion 
severity 
Pig  Clinical SD  PM Culture 
Lesion 
severity 
Pig  Clinical SD  PM Culture 
Lesion 
severity 
31 no  -  severe  43 no  -  --  55  yes  +  severe 
32 yes  +  mild  44 no  -  severe  56  yes  +  severe 
33 yes  +  severe  45 no  -  --  57  yes  +  severe 
34 no  -  --  46 no  +  mild  58  yes  +  severe 
35 yes  +  severe  47 no  -  --  59  yes  +  severe 
36 no  -  --  48  yes  +  mild  60  yes  +  severe 
37 no  -  --  49 no  +  severe  61  no  -  severe 
38 no  -  --  50 no  +  --  62  yes  +  severe 
39 no  +  severe  51 no  -  --  63  na  na  na 
40 yes  +  severe  52 yes  -  mild 64  yes  +  severe 
41 yes  -  severe  53 no  -  --  65  no  -  -- 
42 yes  +  severe  54 no  +  --  66  yes  +  severe 
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mortem, and one had mild localised lesions limited to the proximal colon. The other seven pigs 
did not show any evidence of colitis, although six of them had been culture positive some time 
during the experimental period. Two of the six pigs also were culture positive from the caecum 
at post-mortem. For the 12 pigs vaccinated with MBP-Bhlp29.7-F604 (group 2C), nine (75%) 
developed clinical signs of SD and had severe mucohaemorrhagic lesions in the colon. These 
pigs were culture positive from the colon. One pig (8%) died during the experimental period 
due to an unknown cause not related to SD. The remaining two pigs stayed healthy throughout 
the experiment, although one had severe mucohaemorrhagic colitis in the distal colon at post-
mortem. The other pig remained culture negative from the faeces for the duration of the 
experiment. Both pigs were culture negative at post-mortem. Disease incidence in the three 
groups (6/12, 2/12 and 9/11 respectively for groups 2A, 2B and 2C) showed a significant effect 
(χ
2=10.167; df=2; P=0.006). Pair-wise comparisons showed a significantly lower incidence in 
the group vaccinated with His6-Bhlp29.7 compared to those vaccinated with MBP-Bhlp29.7-
F604 (P=0.003). 
 
When results for the three groups vaccinated with His6-Bhlp29.7 in the two experiments (3 and 
4) were combined, regardless of route of vaccination, 9/31 developed SD. In comparison 13/22 
pigs in the two unvaccinated control groups developed SD. This difference, equivalent to a 
51% reduction in disease incidence attributable to vaccination, was statistically significant 
(P=0.047). 
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5.4. DISCUSSION 
In this chapter, murine and porcine models for SD were used to evaluate the efficacy of 
vaccination with recombinant his-tagged Bhlp29.7. The outcomes for these models will be 
discussed here, with the key focus being on the experiments in pigs, the target animal species. 
 
5.4.1. Mouse experiments 
Immunisation of mice with non-lipidated and lipidated His6-Bhlp29.7 in experiment 1 induced 
good systemic antibody titres which were not significantly different. These antibodies were 
cross-reactive with both the recombinant non-lipidated His6-Bhlp29.7 as well as with the 
native Bhlp29.7 lipoprotein represented in the whole cell preparation of B. hyodysenteriae. 
Since lipidation did not appear to affect the immunogenicity of His6-Bhlp29.7, the non-
lipidated variant was chosen as the vaccine subunit for the subsequent protection study in 
mice. 
 
In the second mouse experiment, good systemic antibody titres were induced in all the 
vaccinated mice and these titres were similar to those seen in the immunogenicity experiment. 
In this experiment, all mice were fed a defined diet (consisting of 63% w/w glucose) 10 days 
before experimental challenge. This diet has been shown to increase the susceptibility of the 
mice to B. hyodysenteriae, possibly by altering the microflora in the caecum (Suenaga and 
Yamazaki, 1984; Nibbelink and Wannemuehler, 1992; Hutto et al., 1998). Oral inoculation 
with B. hyodysenteriae resulted in reasonably good levels of B. hyodysenteriae excretion in the 
faeces of the unvaccinated mice, although it was apparent that examining the caecum at post-
mortem was a better measure of colonisation than was faecal culture. At necropsy, all the 
unvaccinated mice were colonised at the caecum whilst none of the vaccinated mice were 
colonised. This represents clear evidence that His6-Bhlp29.7 has potential as a vaccine 
component for SD.  
   169
Gross lesions were not observed in the caecum of any of the infected mice, even though other 
authors have reported mouse experiments reported that gross lesions occur in the murine 
model (Suenaga and Yamazaki, 1984; Mysore et al., 1992; Nibbelink and Wannemuehler, 
1992; Hutto et al., 1998). The reason for this discrepancy remains unknown since both the 
C3H/HeJ and C3H/HeN mouse strains have been shown to display lesions in the caecum 
(Nibbelink and Wannemuehler, 1992), and the C3H/HeJARC mouse strain used in this study 
was a subline of the C3H/HeJ strain with a LPS responsiveness reversion to the same level as 
its predecessor C3H/HeJ (Silvia and Urosevic, 1999). It is possible that the lack of lesions seen 
in the infected mice was due to the particular B. hyodysenteriae strain used for inoculation.  
 
The mechanism(s) that provided the vaccinated mice with protection from colonisation with B. 
hyodysenteriae was not determined. Unfortunately, local antibody and/or cell-mediated 
responses were not investigated. In pigs, neither systemic nor local antibody responses have 
strong correlation with protection from the development of SD (Joens et al. 1982; Fernie et al. 
1983; Rees et al. 1989). Limited information is available about the systemic and local immune 
responses of mice colonised with B. hyodysenterieae. One study in mice found that antigen-
specific IgG1 and IgG2 responses to commensal microflora increased following colonisation 
with  B. hyodysenteriae (Jergens et al., 2006). Also, no significant changes in T-cell 
populations in the murine lamina propria have been observed following infection, and changes 
in the mucosal mast cell population numbers have not correlated with the development of 
lesions associated with B. hyodysenteriae infection (Nibbelink and Wannemuehler, 1992). 
Further interogation of these aspects of immunity would be beneficial for future protection 
studies in mice.  
 
Nevertheless, vaccination with recombinant Bhlp29.7 induced serum antibody titres and 
reduced and/or prevented B. hyodysenteriae colonisation in mice. These findings reinforce the 
likelihood that recombinant Bhlp29.7 is a good vaccine candidate for controlling B.   170
hyodysenteriae infections, and also demonstrated its potential usefulness as a subunit vaccine 
for protection of pigs from SD. 
 
5.4.2. Pig experiments 
5.4.2.1. The infection model used 
The two pig experiments conducted in this study followed a somewhat simple infection model 
for inducing SD. In both experiments, pigs were inoculated by gastric intubation with 
approximately 10
10 cfu of B. hyodysenteriae at exponential log-phase on five consecutive days. 
The inoculum was cultured from a low-passaged isolate which showed strong β-haemolysis on 
blood agar plates and high motility under phase contract microscopy. The pigs were 
approximately nine weeks of age at the time of inoculation and were confirmed to be free of B. 
hyodysenteriae based on faecal culture and PCR. During the experiment, pigs receiving the 
same vaccination regime were housed in group pens with open wire-mesh partitions and raised 
wire-mesh floors. In experiment 3, all three groups were housed in adjacent pens in the same 
room of the isolation house. In experiment 4, pigs in the two vaccinated groups were housed in 
adjacent pens in one room of the isolation house, and unvaccinated control pigs were housed in 
another room. The walls and ceilings of the rooms were made of solid concrete and the only 
form of supplementary heating provided was a heat-lamp in each pen.  
 
Using this infection model, the incidence of disease in the unvaccinated groups was 70% 
(7/10) for experiment 3 and 50% (6/12) for experiment 4. Due to the larger group sizes used in 
experiment 4, the unvaccinated control pigs were housed in a separate room from the 
vaccinated pigs. The reduced density of pigs in this separate room may help explain the lower 
incidence of disease seen in the control group compared to experiment 3, since circulation of 
faeces from diseased animals has been shown to be a major predisposing factor for SD 
(Jacobson  et al., 2004). However, in the room which housed two groups of 12 pigs, the 
incidence of disease in the pigs vaccinated with MBP-Bhlp29.7-F604 was 75% (9/12), 
indicating that a good level of colonisation could be achieved. Previous experiments using   171
similar infection models have reported incidences of 82-94% in control groups (Hampson et 
al., 1993; Joens et al., 1979; Rees et al., 1989), suggesting that the incidence in the first 
experiment was acceptable. Although an incidence of 100% would be desirable, this may not 
be achievable since it has been reported that some experimentally challenged pigs may be 
recalcitrant to clinical SD even after exposure to large numbers of B. hyodysenteriae 
(Albassam et al., 1985; Jacobson et al., 2004).  
 
Factors such as the age of the animal being challenged, the B. hyodysenteriae strain used for 
inoculation, the method of inoculation, the number of consecutive doses, the housing 
temperatures, types of flooring used in pens, stocking density, and stress levels of the pigs 
have been suggested to influence the development of disease in SD models (Hampson et al., 
2006a). More recently, interest has been focused on the influence of feed composition on the 
incidence of disease. A highly-digestible diet was found to confer pigs with a better protection 
from developing SD than a highly-fermentable diet (Pluske et al, 1996; Siba et al., 1996; 
Durmic et al., 1998; Pluske et al., 1998). A recent study investigating the influence of factors 
such as age, diet, housing and administration of stress-inducing drugs on the development of 
SD in experimental pigs concluded that a diet based on soybean meal and group-housing of 
pigs were the major factors influencing the experimental induction of SD (Jacobson et al., 
2004). Using this infection model, nine out of nine pigs developed SD compared with four out 
of nine when the pigs were individually housed. 
 
In future experiments, feeding of large quantities of soybean meal may improve the incidence 
of SD in experimental animals. Where possible, pigs should be group-housed with all 
experimental groups in the same room. In experiments requiring larger group numbers, 
representative subsets of each group should be housed together in an attempt to reduce room 
effects. 
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5.4.2.2. Monitoring and defining disease 
In the present study, daily examination of the experimental animals mainly focused on 
observation of the consistency and colour of faeces on the pen floor. SD was defined as the 
occurrence of mucous-containing haemorrhagic diarrhoea connected with consistent shedding 
of  B. hyodysenteriae over several sampling times. Pens in which SD was observed were 
further monitored to identify the diseased pig(s). Although this method of monitoring was 
somewhat accurate, suggested by the fact near all pigs taken to necropsy due to the observation 
of suspected SD presented severe lesions upon post-mortem examination, it was only 
qualitative and was subjective. An earlier study by Stanton and Jensen (1993) used a 
commercial faecal occult blood test kit to monitor individual pigs which had been 
experimentally infected with B. hyodysenteriae. The study concluded that the faecal occult 
blood test was a reliable adjunct to bacteriology for monitoring individual animals with 
experimental SD. Another study looked at the dynamics of acute-phase protein (APP) levels in 
response to experimental SD (Jacobsen et al., 2004). This study found that there was a several-
fold increase in the levels of haptoglobin and serum acute amyloid (SAA) in response to 
haemorrhagic diarrhoea in infected pigs, but no associated response in pigs with non-
haemorrhagic diarrhoea. Both studies indicate that quantitative methods may be applicable for 
the objective monitoring of experimental SD in individual pigs. A foreseeable problem could 
be the misrepresentation of occult blood or APP levels caused by inflammatory effects 
associated with other intestinal disorders of swine, such as proliferative enteritis, 
salmonellosis, trichuriasis and gastric ulcers (Hampson et al., 2006). However, since pigs are 
normally kept in controlled conditions during the experimental period, treatment with 
antibiotics at the time of acquiring the animals may prevent the occurrence of inflammations 
associated with bacterial infections other than SD. 
 
In future experiments, assaying for these disease biomarkers may enable the quantitative 
assessment of the dynamics of disease development to be performed, and hence provide a 
clearer judgement of the animal’s health.    173
5.4.2.3. Vaccination regimes 
The vaccination regimes examined in this study included both parenteral (intramuscular) and 
parenteral/mucosal (oral) routes of immunisation. Both routes are known to be capable of 
stimulating systemic and local antibody responses (Galvin et al., 1997). In both pig 
experiments, an antigen load of 1 mg of protein per pig was given, both for the intramuscular 
and oral routes. This amount of antigen successfully induced good antibody titres in all 
individuals (section 5.4.2.4), although it is possible that the antigen load could have been 
reduced without affecting the antibody response. Given more time and resources, a titration of 
antigen load in pigs would have provided this information. For the intramuscular vaccinations, 
the His6-Bhlp29.7 antigen was prepared using Freunds’ Incomplete Adjuvant (FIA) for 
experiment 3, and another oil-based adjuvant (VSA3) in experiment 4. FIA is commonly used 
in vaccine preparation and has been shown to induce strong antibody titres in a large range of 
animals, including pigs (Bennett et al., 1992). Since the vaccine experiments were supported 
by a commercial partner, in-house efficacy experiments indicated that subunit vaccines 
prepared using the VSA3 adjuvant generated antibody responses superior to FIA. For this 
reason the VSA3 adjuvant was used in experiment 4. 
 
In the oral vaccinations, the vaccine antigen was solublised in PBS and administered to the 
back of the pig’s palate using a syringe. Since the antigen was not administered with any form 
of protection, exposure to the acidic conditions of the stomach may potentially have resulted in 
the proteolysis of the antigen before it arrived at the intestinal mucosa. Although this did not 
appear to have occurred, as determined by the fact that antibody levels increased after the oral 
boost, the effect of this gastric exposure on the stability of the vaccine antigen is not known. 
Various strategies using alternative means for the mucosal delivery of vaccines, such as the use 
of bacterial vectors, DNA vaccines, plant vector delivery systems, immune stimulating 
complexes (ISCOMs) and liposomes, are all available. In addition, mucosal adjuvants, such as 
bacterial toxins and CpG oligonucleotides, have also been shown to enhance immunity at the 
mucosal surfaces. These strategies for improved mucosal delivery will be discussed in more   174
detail in chapter 6. Adaptation of vaccination regimes to deliver antigens to the mucosal 
surfaces may be useful for future studies involving oral vaccination of animals with Bhlp29.7.  
 
5.4.2.4. Experimental outcomes 
5.4.2.4.1. Serological response in experiment 3 
In experiment 3, the im/im vaccination route induced slightly higher serum antibody titres to 
Bhlp29.7 than the im/oral route. In the unvaccinated control pigs, infection with B. 
hyodysenteriae failed to induce a systemic immune response to His6-Bhlp29.7 even though the 
pigs presented acute signs of SD, although an increase in systemic titres against the B. 
hyodysenteriae whole cell preparation was seen. As suggested in chapter 4, the lack of 
systemic response against His6-Bhlp29.7 may have been because these acutely affected pigs 
had insufficient time to mount an antibody response, and the increased systemic response 
detected against the B. hyodysenteriae whole cell was due to cumulative antibody titres 
induced towards all components of the spirochaete, including other lipoproteins and LPS. 
Neither vaccination route enhanced colonic IgA responses over that seen in the infected 
control pigs, but it was unclear to what extent the experimental infection contributed to the 
colonic IgA levels. To get a better understanding of the capacity of the vaccines to induce local 
colonic antibody, it would have been necessary to include a group of uninfected and non-
vaccinated control animals for comparison. The results of the whole cell ELISA and Western 
blots confirmed the specificity of the vaccine-induced response towards Bhlp29.7. The im/oral 
route also significantly reduced the amount of faecal excretion of B. hyodysenteriae compared 
to the control group. The explanation for this is not known, but it could reside with the 
activation of CD4+ T-cells present in the colonic lymph nodes as a result of the antigen 
exposure due to the oral immunisation (Waters et al., 2000; Hontecillas et al., 2005). Further 
studies are required to elucidate the mechanisms involved. Both vaccination routes similarly 
reduced the incidence of disease compared to the controls, but the difference was not 
significantly, probably due to the small group sizes and the fact that the incidence of disease 
amongst the control group was only 70%. Increased disease incidence, possibly using methods   175
discussed earlier (section 5.4.2.1), or larger group sizes may have resulted in statistically 
significant differences. 
 
5.4.2.4.2. Serological response in experiment 4 
As a result of the lower faecal excretion of B. hyodysenteriae and the marginally lower 
incidence of disease in the pigs vaccinated im/oral compared to im/im in the first experiment, 
the im/oral route was used for His6-Bhlp29.7 immunisation in experiment 4. A difference was 
the use of another oil-based adjuvant (VSA3 rather than FIA) for the primary immunisation in 
the second experiment. The im/oral vaccination regimen again produced good primary and 
secondary serum antibody responses directed at Bhlp29.7. A local colonic IgA response to 
Bhlp29.7 that was significantly greater than that of the group immunised with the carboxy-
terminal fusion of Bhlp29.7 also was generated. Again, fewer of the His6-Bhlp29.7 immunised 
pigs developed disease than did the controls (2/12 compared to 6/12), although, unexpectedly, 
the immunised pigs shed B. hyodysenteriae in their faeces significantly more frequently than 
did the control animals. This may be explained by the fact that more samples were taken from 
the vaccinated pigs because, unlike the control pigs, they remained healthy and were not 
removed even though they were excreting B. hyodysenteriae in their faeces. The immunised 
pigs were housed in a separate room from the control animals, and the level of environmental 
challenge in the room containing vaccinated pigs was much higher than in the control room. 
Only 50% of control pigs developed SD, whereas 82% (9/11) of the pigs in group 2C 
(immunised with MBP-Bhlp29.7-F604), housed in the room with the pigs vaccinated with 
His6-Bhlp29.7, developed SD. Hence this greater exposure may also have lead to the increased 
duration of faecal excretion compared to the control pigs. 
 
The MBP-Bhlp29.7-F604 protein was immunogenic, inducing good serum antibody titres, but 
there was no cross-reactivity with the native or his-tagged Bhlp29.7. Pig serum taken from 
animals vaccinated with MBP-Bhlp2.7-F604 reacted strongly with the immunising antigen but 
not with the whole cell of B. hyodysenteriae or with the his-tagged Bhlp29.7. This indicated   176
that most of the immune response generated towards MBP-Bhlp29.7-F604 was directed at the 
dominant 42 kDa MBP portion of the fusion. In addition, this vaccine offered no protection 
against SD, and, indeed, significantly more pigs vaccinated with MBP-Bhlp29.7-F604 than 
pigs in the same room vaccinated with His6-Bhlp29.7 developed SD. The failure of MBP-
Bhlp29.7-F604 to protect pigs may relate to the relatively large size of MBP compared to the 
carboxy-terminal end of Bhlp29.7. In future work it would be instructive to try other fusions to 
determine whether a protective immune response could be generated using the carboxy-
terminal end of the protein. 
 
Generally there was no clear relationship between the titres of serum or colonic antibodies 
present and the occurrence or severity of SD. Colonic IgA has been shown to be produced in 
pigs resistant to SD, but is believed to indicate recent exposure of the animal to B. 
hyodysenteriae rather than protective immunity (Rees et al., 1989). Besides antibodies, it is 
likely that the His6-Bhlp29.7 vaccine induced other cell-mediated immune mechanisms that 
may contributed to the protection observed (Waters et al., 1999a; Hontecillas et al., 2005). 
These cellular responses may involve monocytes, neutrophils, CD8α+ CD8β- CD4- 
lymphocytes and CD45RA- lymphocytes, which have been observed at elevated levels during 
SD, and neutrophils and γδ T-cells, which have been seen in increased levels during recovery 
(Jonasson et al., 2006). Unfortunately, cellular responses were not investigated in the present 
study. 
 
5.4.2.4.3. Gross lesions 
Most pigs that developed mucoid or haemorrhagic diarrhoea had severe and extensive lesions 
in their large intestines at post-mortem. Furthermore, these clinically affected animals tended 
to excrete spirochaetes in their faeces between two to four sampling times prior to the 
development of clinical signs of disease. This was consistent with there being a slow 
accumulation of spirochaete numbers in the large intestine, and progressive development of 
lesions along the colon to a point where diarrhoea and SD developed. Other situations also   177
occurred. In group 1A, control pig 2 did not have diarrhoea or colonic lesions, but spirochaetes 
were isolated from its colon. It is possible that this pig may have gone on to develop SD if it 
had been kept for longer. In most cases where vaccinated pigs developed diarrhoea, their 
colonic lesions were milder and less extensive than in control animals. The mild lesions seen 
in these pigs were localised in the proximal colon and entended only one-third of the way 
down towards the distal colon. It is believed that disease development involves a synergistic 
effect between B. hyodysenteriae and certain members of the normal intestinal microflora of 
the pig (Neef et al., 1994; Whipp et al., 1979). The development of lesions is thought to be 
accompanied by the translocation of luminal bacteria into the lamina propria following 
exposure to the heamolysin of B. hyodysenteriae. It has been proposed that this loss of an 
epithelial cell barrier causes exposure of the underlying mucosa to antigen in the lumen and 
triggers a severe inflammatory response which manifests as gross lesions (Hutto and 
Wannemuehler, 1999). The reduced faecal shedding observed in the im/oral vaccinated pigs 
may indicate lower B. hyodysenteriae numbers in the colon, thus exposing the mucosa to less 
haemolysin and consequently reducing epithelial damage. In vaccinated group 1B, of three 
pigs with mild colitis, pig 13 had no diarrhoea and was spirochaete negative, pig 17 was 
culture positive but did not have diarrhoea, and pig 18 was culture positive and did have 
diarrhoea. Even in these pigs, some degree of vaccine-induced protection seemed to be 
occurring.  
 
In experiment 4, pigs 31 and 39 in control group 2A, pigs 44 and 49 in vaccinated group 2B 
and pig 61 in vaccinated group 2C did not have diarrhoea, but had severe colonic lesions. In 
these animals it would appear that colonic function was still sufficient to maintain a normal 
stool consistency, although it is likely that they would have gone on to develop SD. 
Surprisingly, animals 31 and 61 were also culture negative at post-mortem. Animals that have 
colonic lesions but appear healthy are particularly problematic from a diagnostic perspective. 
Their growth performance would also probably be affected. Unfortunately the small group 
sizes and the need to remove animals from the groups as SD appeared meant that no   178
meaningful data on body weights could be collected. Larger scale field trials would be required 
to obtain this sort of production data. 
 
In experiment 4, all pigs were kept for 51 days after infection, compared to 20-23 days in the 
experiment 3. The purpose of this was to determine whether asymptomatic vaccinated animals 
would ultimately develop disease. By 24 days after infection, one pig vaccinated with His6-
Bhlp29.7 had developed SD, and it had mild localised lesions in the colon. Only one additional 
vaccinated pig developed diarrhoea between 25 days after infection and the end of the 
experiment, and this animal also only had mild lesions in the colon. Other pigs had colonic 
lesions at post-mortem, but no diarrhoea. These results suggest that the protection provided by 
vaccination lasts at least two months, and generally may be sufficient both to prevent the 
development of severe and/or extensive colonic lesions, and keep the pig asymptomatic. 
Vaccination also tended to delay the onset of faecal excretion of spirochaetes, but did not 
necessarily stop it occurring. It is not clear whether the presence of low-grade exposure to B. 
hyodysenteriae on naturally infected piggeries would provide sufficient immunological 
boosting to maintain protection through the grower phase.  
 
5.4.2.4.4. Efficacy of the vaccination 
Taken together, the results of the mouse and pig experiments indicate that Bhlp29.7 has 
promise as a candidate for use in vaccines for SD. The vaccination of mice with His6-Bhlp29.7 
provided complete protection from B. hyodysenteriae colonisation of the caecum, and this 
prompted the subsequent experiments in pigs. Although the complete protection seen in the 
mice was not achieved in either of the two pig experiments, a significant level of protection 
was seen. This level of protection was generally better than that achieved with whole-cell B. 
hyodysenteriae bacterins (Glock et al., 1978; Fernie et al., 1983; Diego et al., 1995; Waters et 
al., 1999a, Waters et al., 1999b), and in addition bacterins may exacerbate the disease in some 
animals (Olsen et al., 1994). This is the first time that a recombinant protein has been shown to 
have promise as a potential subunit vaccine component for the control of SD in pigs.    179
5.4.4. Conclusions 
In an earlier study it was demonstrated that immunisation of pigs with formalinised E. coli 
expressing recombinant Bhlp29.7 induced antibodies to the native Bhlp29.7 lipoprotein of B. 
hyodysenteriae (Lee, 1996). The present study aimed to assess the protection afforded by a 
recombinant Bhlp29.7 subunit vaccine and to investigate the effect of the immunisation on 
colonisation and SD development. Although microbiological sterility would be the best long-
term approach for the control of SD, an economically produced vaccine capable of reducing 
disease incidence and severity, coupled with proper management practices, should prove an 
attractive means of control for many herds with SD. The results of the experiments described 
in this chapter confirmed the immunogenicity of recombinant His6-Bhlp29.7, which induced 
good primary and secondary serum antibody responses, and demonstrated that pigs immunised 
with His6-Bhlp29.7 show a reduced susceptibility to SD. Although some pigs vaccinated with 
Bhlp29.7 did develop SD (17-40%), this was significantly less than amongst the unvaccinated 
control pigs (50-70%) when results for the two experiments were pooled. A similar 
approximately 50% reduction in incidence of SD in infected vaccinated herds would confer a 
considerable cost-benefit. The level of protection achieved was broadly similar to that reported 
for B. hyodysenteriae bacterin vaccines in some pen trials (Parizek et al., 1985; Hampson et 
al., 1993). Unlike bacterins, recombinant Bhlp29.7 should provide protection across all 
serovars of B. hyodysenteriae, although this requires further investigation. The vaccine also 
should be cheaper and easier to produce and standardise on a commercial scale than B. 
hyodysenteriae bacterins. 
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSIONS 
 
6.1. INTRODUCTION 
SD is one of the major economic diseases of pigs worldwide. There is currently no subunit 
vaccine available for SD and those based on LPS or sonicated cells have provided partial 
protection at best. Detection of the causative agent of SD has become more accurate partly due 
to the use of molecular methods, although indirect detection of exposure to B. hyodysenteriae 
within herds by serological means still remain undeveloped. The aims of this PhD was to 
interrogate the properties of a 29.7 kDa outer membrane protein previously described as being 
reactive with a monoclonal antibody specific for B. hyodysenteriae, and investigate the 
efficacy of the recombinant protein as a reagent for serological assays, and as a subunit for 
vaccination against SD.  The aims were successfully achieved, and the data generated suggest 
that the protein has potential applications in serology and vaccination. Nevertheless, more 
work is required to develop these areas to the point where commercial products become 
available. 
 
6.2. CHARACTERISATION OF BHLP29.7 
When the study began little was known about the properties of the 29.7 kDa protein of B. 
hyodysenteriae, except that it was possibly surface-exposed; it reacted with a monoclonal 
antibody which was specific for B. hyodysenteriae; and that a formalinised E. coli clone 
expressing the protein was immunogenic in pigs following intramuscular immunisation (Lee, 
1996). The first stage of this project was the revival of the E. coli clones which had been stored 
at -80°C. Little information was known about the properties of the plasmid vector which 
harboured the gene of interest at that time, and after some unsuccessful attempts, the first 
fragment of B. hyodysenteriae sequence was acquired which quickly lead to the assembly of 
the complete contiguous sequence. Bioinformatics analysis of this sequence identified a gene, 
which has since been designated bhlp29.7, encoding a 29.7 kDa outer membrane lipoprotein   181
Bhlp29.7. The Bhlp29.7 protein was found to be a putative lipoprotein indicated by the 
presence of a signal peptide containing a consensus signal peptidase II cleavage site at the N-
terminal. Annotation of the Bhlp29.7 polypeptide amino acid sequence indicated highest 
similarity with the D-methionine binding lipoprotein (MetQ) of various pathogenic bacteria. 
Subcellular localisation prediction software (PSORTb and HMMTOP) combined with IFAT 
using a monoclonal antibody specific for B. hyodysenteriae indicated that Bhlp29.7 was 
present on the cell surface of B. hyodysenteriae. Radioactive palmitate incorporation assays 
confirmed that Bhlp29.7 was a lipoprotein. 
 
The possible outer membrane localisation and lipoprotein nature of Bhlp29.7 made it a 
potential candidate for use in a serological test for SD, as well as a subunit for a SD vaccine.  
Outer membrane proteins (OMPs) exposed to the cell surface are in a position to interact with 
the environment and subsequently, contribute to the pathogenesis of the bacteria by interacting 
with the host (Haake, 2000). The OMPs of a range of bacterial pathogens, including 
spirochaetes, have diverse roles, including adhesion and invasion (Palaniappa et al., 2002; 
Matsunaga  et al., 2003; Cameron et al., 2004; Li et al., 2006; Seshu et al., 2006). The 
lipoproteins are one subclass of OMPs and have been implicated to participate directly in the 
pathogenesis of the spirochaete (Cullen et al., 2004). For example, the outer surface protein A 
(OspA) of the Lyme disease agent Borrelia burgdorferi is involved in the colonisation of the 
tick midgut and has been used in a transmission-blocking vaccine for humans (Pal et al., 
2004). Similarly, leptospiral immunoglobulin-like (Lig) proteins, a family of surface-exposed 
lipoproteins which have similarity to bacterial adhesions, are believed to contribute to the 
pathogenicity of Leptospira interrogans since the loss of lig expression has been correlated to 
the loss of virulence during culture attenuation of pathogenic strains (Palaniappa et al., 2002; 
Matsunaga et al., 2003).  
 
Spirochaetal lipoproteins are highly immunogenic molecules and have been the subject of 
intense investigation due to their suggested role in immunity. For spirochaetes such as B.   182
burgdorferi and L. interrogans, a substantial number of immunogens have been identified and 
their potential functions characterised (Haake, 2000; Cullen et al., 2004). Little is known about 
the importance of lipoproteins in relation to immunity to B. hyodysenteriae infections or about 
the role of lipoproteins in B. hyodysenteriae pathogenicity, however it can be assumed that the 
roles lipoproteins play in the biology of different spirochaetes are similar. Lipoproteins which 
are prominent immunogens during disease are likely targets for serological detection, and for 
generating protection. With this in mind, the Bhlp29.7 outer membrane lipoprotein was cloned 
and expressed in E. coli as a histidine fusion-protein. The recombinant His6-Bhlp29.7 was 
expressed and purified in denatured form since this allowed the protein to be produced in high 
quantities with few purification artefacts. At the same time subclones representing progressive 
one-quarter truncations of the Bhlp29.7 polypeptide were also cloned and expressed. 
Reactivity of these truncates with the B. hyodysenteriae-specific monoclonal antibody 
(BJL/SH1) revealed that the B. hyodysenteriae-specific epitope was contained at the C-
terminal quarter (Bhlp-29.7-F604) of the Bhlp29.7. It was the intention that this subclone 
would be used for the development of an indirect serological test for detection of SD. 
Unfortunately, due to the inefficient expression of smaller size proteins in the E. coli 
expression system, the recombinant expression of Bhlp29.7-F604 in E. coli was lost and could 
not be recovered. Consequently, the full-length His6-Bhlp29.7 protein was used as the coating 
antigen for development of the ELISA test for SD. The Bhlp29.7-F604 C-terminal fragment 
was subsequently cloned and expressed as a MBP fusion for use as a vaccine subunit. The full-
length His6-Bhlp29.7 was also used for vaccination of mice and pigs. 
 
6.3. DEVELOPMENT OF THE ELISA TEST 
The pig serum collected for the standardisation of the ELISA test were obtained from 
Australian herds which had no prior history of SD, as well as herds in which SD had been 
observed and the animals treated with antibiotics. The serum samples were provided by 
consultant veterinarians who were familiar with the clinical signs of SD. The samples were 
collected from slaughter-aged animals (~22 weeks) at the abattoir. Serum samples were also   183
obtained from several herds in which there was a history of diarrhoea but not laboratory-based 
diagnosis of SD had been confirmed. These samples acted as unknown samples for the 
application of the ELISA test once it had been standardised. In another herd, serum samples 
were taken from 12 to 13 week old pigs with acute clinical SD. Due to the nature of the 
samples obtained, the ELISA test was pitched at the herd level rather than the individual pig 
level. Had each serum sample been accompanied with culture data for B. hyodysenteriae, the 
ELISA test could have been evaluated for diagnosing individual infected animals. 
 
Standardisation of the ELISA test involved two steps. Serum samples from the healthy herds 
(SD not observed) were tested with the ELISA and the mean and standard deviation of the 
ELISA results from these herds used to establish a cut-off value for distinguishing negative 
and positive samples. The ELISA was then tested on the infected herds (SD observed) and the 
relevance of the cut-off value assessed.  
 
When a cut-off value was defined as two standard deviations above the mean ELISA value of 
the healthy herds (95% confidence), none of the healthy herds were deemed negative and all 
six (100%) infected herds were positive. Since this cut-off value gave no sensitivity, it was 
decided that a cut-off value of three standard deviations above the mean would be used. This 
gave the ELISA test a sensitivity of 100% and the specificity remained the same at 100%. For 
the infected herds, serum samples were collected four to six weeks after the observation of 
clinical signs. Antibody titres can be detected in pigs as early as four to seven days after 
exposure to B. hyodysenteriae (Joens et al., 1985) and these titres can persist for up to 17 
weeks (Fisher and Olander, 1981; Fernie et al., 1983; Joens et al., 1981b). This indicates that 
the timing of the sample collection may play an important role in the accurate diagnosis of SD 
using the ELISA test.  
 
Application of the standardised ELISA test to the herds of unconfirmed disease status 
indicated that four of the eight herds had been exposed to B. hyodysenteriae. Regardless of the   184
diagnosis, confirmation of the disease status by bacteriology and PCR on faeces is still 
necessary. This was a major practical limitation for evaluating the ELISA test, since follow-up 
samples are difficult to obtain due to the herds having been depopulated or sold, or the 
consulting veterinarian changed. Unfortunately, it was not possible to confirm the accuracy of 
the ELISA test for the unknown herds by using culture and/or PCR. Future studies should 
include this important step. 
 
6.3. VACCINATION WITH BHLP29.7 
To elicit protective immunity to infection, it is necessary for the putative protective antigens to 
be immunogenic. Since Bhlp29.7 was believed to be a lipoprotein, an E. coli lipidation signal 
was cloned into the construct expressing recombinant His6-Bhlp29.7. The resulting construct 
successfully expressed His6-Bhlp29.7 in lipidated form. Mice vaccinated with the recombinant 
non-lipidated His6-Bhlp29.7 showed no significant difference in systemic antibody response to 
the mice vaccinated with lipidated His6-Bhlp29.7. Vaccination with non-lipidated His6-
Bhlp29.7 provided mice with complete protection from B. hyodysenteriae colonisation. 
Vaccination of pigs with non-lipidated His6-Bhlp29.7 significantly improved previously 
reported attempts to provide protection from SD using vaccines made from whole spirochaete 
cells. The mechanism of the protection provided by the vaccination remains unknown and does 
not appear to correlate with systemic or mucosal antibody specific for B. hyodysenteriae. The 
vaccination regimes examined in this study provided some degree of protection against 
colonisation and disease, although neither provided complete protection. There were less total 
days of colonisation with the vaccinated groups than with the unvaccinated controls and 
colonisation tended to occur later, especially with the pigs given a parenteral and mucosal 
immunisation. There was also less diarrhoea in the vaccinated pigs and fewer animals had 
severe lesions in the colon. The vaccinated pigs which suffered diarrhoea had localised and 
mild lesions in the proximal colon, but were robust and clinically healthy. These pigs appeared 
to be showing early signs of SD, and this delay in disease onset may have been due to the 
immunological responses induced by the vaccination. It is possible that in the pigs vaccinated   185
intramuscularly and orally, the local immunity provided by the oral immunisation was unable 
to extend past the small intestine, hence leaving the colon relatively unprotected. However, 
this may also have been the case in the pigs vaccinated twice intramuscularly, since a similar 
severity of disease was seen. Unfortunately, no clear correlation could be made between the 
antibody response and protection, and it is not known whether the local antibodies detected 
against Bhlp29.7 in the colon of the vaccinated pigs were induced by the vaccination and/or by 
the experimental challenge. Further studies are required to investigate this. 
 
Although the present protection studies shows promising efficacy, the mechanisms involved in 
the immunity has not been elucidated. In future studies involving the immunisation of pigs 
with recombinant Bhlp29.7, a more detailed investigation of the immune response of the 
animal to the infection may be necessary to provide more insight into the mechanisms 
governing the protection provided by vaccination. In particular, elucidation of cell-mediated 
immunity stimulated by vaccination may provide a clearer understanding of the responses 
involved beyond the production of antibodies. Colonisation with B. hyodysenteriae rarely 
results in invasion beyond the lamina propria, therefore it can be assumed that phagocytic 
activity would be of little benefit for the elimination of the invading spirochaete. However, the 
cells involved in cell-mediated responses (such as mucosal mast cells, neutrophils, 
macrophages and T-lymphocytes) have been shown to release mediators which contribute to 
the mucosal inflammatory processes associated with SD (Hontecillas et al., 2005; Jonasson et 
al., 2006). Similar damaging responses have been induced by vaccination (Olsen et al., 1994). 
In some cases, immunity appears to be antibody-mediated, since passive transfer of 
convalescent serum into colonic loops provides protection from B. hyodysenteriae infection 
(Joens et al., 1985), however antibodies detected during infection have not correlated with the 
occurrence of disease (Rees et al., 1989; Wright et al., 1989). The relative significance of the 
cell-mediated and antibody-mediated responses for recovery from infection with B. 
hyodysenteriae remains unclear. 
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The likely influence of the non-lipidated state of the Bhlp29.7 subunit on the immunity 
observed is also not known. In studies involving the B. burgdorferi outer surface lipoprotein 
(OspA), immunogenicity and immunoprotection are enhanced by lipidation (Fikrig et al., 
1990; Erdile et al., 1993; Weis et al., 1994). In light of this, and despite the comparable 
immunogenicity of lipidated and non-lipidated Bhlp29.7 in mice, the current protection 
afforded by vaccination of pigs with Bhlp29.7 might be further enhanced by the immunisation 
with the lipidated form of the immunogen. 
 
6.4. FUTURE WORK 
The search for novel immunogenic and protective antigens from B. hyodysenteriae continues 
to gain interest. The application of biotechnology has resulted in the discovery of antigenic 
molecules for many pathogens, and these have been shown to induce protective immunity in 
laboratory animal models and natural hosts. Research on subunit vaccines has resulted in the 
design and development of some very successful vaccines. One such example is the LYMErix 
vaccine for Lyme disease which used the OspA outer membrane lipoprotein of B. burgdorferi. 
On-going developments for many bacterial subunit vaccines have relied on mining of complete 
genome sequences. The future availability of a complete or partial genome sequence for B. 
hyodysenteriae will allow similar technology to be applied to the search for an effective 
vaccine for SD. It is possible that additional immunogenic subunits could be used in 
combination with Bhlp29.7 to improve vaccine protection. The route of delivery is also 
extremely important, and potential methods that could result in improved protection will be 
summarised. 
 
6.4.1. Methods for identifying potential vaccine candidates 
6.4.1.1. Genomics and reverse-vaccinology 
Since the commencement of the study presented in this thesis, major advances have been made 
in the field of vaccine development and design. Classical approaches, such as those used in this   187
thesis, are less common now following the technological advances of computational (in silico) 
analysis typical of the bioinformatics era. The high-throughput capacity of reverse-vaccinology 
now allows the entire genome of the organism to be mined for potential vaccine candidates. 
One of the forces motivating the new approach to vaccine discovery is the availability of a 
diverse array of full-length bacterial genomes in the public databases. As of September 2006, 
976 bacterial genomes had been sequenced to completion or were currently being completed 
(GOLD; http://www.genomesonline.org/). Although the genome sequence for B. 
hyodysenteriae is currently unavailable, it soon may be given the speed at which sequencing of 
bacterial genomes is being undertaken. The “reverse vaccinology approach” to vaccine 
development takes advantage of the genome sequence of the pathogen. The genome represents 
a list of all the potential protein-encoding genes that the pathogen can express at any time. It 
becomes possible to choose any target protein in a reverse manner, starting from the genome 
rather than from the whole microorganism (Rappuoli, 2000; Rappuoli, 2001). Vaccine 
candidates can now be rapidly identified by mining the pathogen's genome with in silico tools 
that predict secretory signal peptides (Menne et al., 2000), transmembrane domains (Suhan 
and Hovde, 1998), lipoprotein attachment sites (Falquet et al., 2002) and T-cell stimulating 
proteins (De Groot et al., 2002). In the field of molecular biology and immunology, genomics 
provides a vast reservoir of genes that can be screened and tested as putative immunogens for 
serological assays and vaccine subunits. 
6.4.1.2. DNA microarrays 
Whole-genome sequence data can be further exploited to assemble DNA microarrays printed 
with representatives of all the predicted open-reading frames of a sequenced reference strain. 
Microarray technology provides a means of selecting proteins from genomic sequences that 
are highly relevant to immunity (Zagursky et al., 2003; Capecchi et al., 2004). Microarray-
based expression studies can be used to identify genes that are differentially expressed in 
response to an alteration in environmental parameters and provide a strong contribution to 
understanding of how a pathogen orchestrates its’ responses to the host environment (Behr et   188
al., 1999; Dhiman et al., 2001). Avirulent strains of B. hyodysenteriae have previously been 
reported (Milner and Sellwood, 1994; Achacha et al., 1996). The use of differential 
microarrays to compare the gene content and transcriptome of virulent and avirulent strains of 
B. hyodysenteriae would be a useful first step that would limit the search to candidate 
immunogenic proteins of virulent strains. Gene expression studies may also offer insight into 
the suite of genes up-regulated (or down-regulated) during infection. Targeting the products of 
these genes may provide a neat method of preventing colonisation. 
  
6.4.1.3. Proteomics 
Traditionally, protein analysis has been performed by assaying one protein at a time, with very 
little parallel analysis. Proteomics is the large-scale study of proteins and will contribute 
greatly to the understanding of gene function in the post-genomic era (Grandi, 2001). In 
proteomic analysis, protein preparations are separated into their individual components 
typically using two-dimensional gel electrophoresis. Using protease digestion coupled with 
mass spectrometry, the identity of a protein can be determined by comparing the peptide 
fragmentation profile with an in silico predicted profile. Recently, advances in protein-
separation technologies have allowed the elucidation of total protein components of a defined 
subcellular localisation, such as the outer membrane (Scarselli et al., 2005). Studies into the 
purification of proteins present on the cell surface of Brachyspira spp. have previously been 
reported (Thomas et al., 1992; Lee and Hampson, 1996; Plaza et al., 1997; Tenaya et al., 1998; 
Trott et al., 2001; Trott et al., 2004). The characterization of outer membrane and surface-
associated proteins, in conjunction with proteomic analysis and reactivity with convalescent 
serum, may play a particularly important role in identifying the “antigenome” for B. 
hyodysenteriae. 
 
6.4.2. Methods for modulating mucosal immune responses 
A number of new methods have become available to improve the effectiveness of subunit 
vaccines for intestinal infections, and these are briefly described below.   189
6.4.2.1. Antigen delivery systems 
An ideal vaccine should be stable and confer long lasting immunity with minimal adverse side 
effects in the vaccinated animal. Immunisation strategies have been developed to enhance the 
immunogenicity of vaccine candidates. SD is a disease of the mucosal surface of the pig colon. 
Traditional vaccine strategies that involve parenteral immunisation do little to prevent the 
initial interaction between pathogen and the mucosal surfaces (Ogra et al., 2001; Yuki and 
Kiyono, 2003). A great deal of attention has focused on mucosal immunisation as a means of 
inducing specific secretory IgA antibodies directed against the mucosal pathogen. In addition, 
mucosal immunisation can be an effective means of inducing not only secretory IgA, but also 
systemic and cell-mediated immunity. Mucosal adjuvants, bacterial vectors, bacterial ghosts 
DNA vaccines, and plant-derived vaccines are among the most promising antigen delivery 
systems for enteric diseases (Shams, 2005). 
 
6.4.2.2. Mucosal adjuvants 
The induction of immune responses following mucosal immunisation is usually dependent 
upon the co-administration of appropriate adjuvants that can initiate and support the transition 
from innate to adaptive immunity. While a number of substances of bacterial origin have been 
tested as mucosal adjuvants, the three bacterial products with the greatest potential to function 
as mucosal adjuvants are the ADP-ribosylating enterotoxins (cholera toxin (CT), produced by 
various strains of Vibrio cholerae, and the heat-labile enterotoxin (LT) produced by some 
enterotoxigenic strains of E. coli (Clements et al., 1988; Elson, 1989; Lycke et al., 1992; Xu-
Amano et al., 1993; Yamamoto et al., 1996), synthetic oligodeoxynucleotides containing 
unmethylated CpG dinucleotides (Krieg et al., 1998), and monophosphoryl lipid A (Carozzi et 
al., 1989; Henricson et al., 1993; Myers et al., 1995). CT and LT both enhance the systemic 
and mucosal antibody responses to the co-administered antigen, resulting in a long-term 
memory to the antigen (Clements et al., 1988; Vajdy and Lycke, 1995). Binding of CT and LT 
to B-cells favours the induction of the Th2-dominated responses. The induced mucosal 
immune response is concentrated at the mucosal site directly exposed to the adjuvant and   190
antigen (Pierce and Cray, 1982). Unfortunately the toxic effects of CT and LT means that 
doses used in pigs need to be evaluated since high doses can cause severe inflammation (Cox 
et al., 1991). Removal of the toxic subunit of CT and LT reduces the toxicity of the adjuvants 
at the expense of consistent results (Rappuoli et al., 1999; Yamamoto et al., 1999). 
 
Vaccine delivery vehicles mainly assist the uptake, processing and presentation of antigens by 
antigen-presenting-cells, however immuno-stimulatory molecules are mostly derived from 
pathogens and also activate the innate immune responses. Unfortunately, in practice mucosal 
vaccination has often proved inefficient to stimulate strong mucosal IgA immune responses 
and protection (Holmgren et al., 2003a; Holmgren et al., 2003b). 
 
6.4.2.3. Bacterial vectors 
Live bacterial vectors are commensal bacteria (such as Lactobacilli and certain Streptococci 
and Staphylococci) or genetically attenuated pathogens (such as Salmonellae, Shigellae and 
Listeria species) which have been engineered to deliver antigen into mucosal inductive sites to 
induce antigen-specific immune responses. This can be achieved by insertion of one or more 
genes expressing protective antigens from heterologous pathogens into the genome of the 
bacterial vector (Wernerus and Stahl, 2004). Mycobacterium bovis BCG and Salmonellae have 
been studied as vectors for several years, and can induce solid immunity following oral 
administration (Barletta et al., 2000). BCG has great potential to express a large number of 
heterologous antigens and induce cytotoxic T-lymphocyte and mucosal immunity. Salmonella 
is a facultative intracellular bacteria and is able to induce secretary IgA following oral 
administration (Stover et al., 1991). Live attenuated bacteria are also an attractive vaccine 
strategy since they can mimic natural infection and have intrinsic adjuvant properties (Detmer 
and Glenting 2006). Examples of live bacterial vaccines available include Enterisol®Ileitis 
against porcine proliferative enteropathy (Lawsonia intracellularis), Vivotif® against typhoid 
fever (Salmonella typhi), Orochol® against cholera (Vibrio cholerae) and M-NinevaxÂ®-C 
against avian pasteurellosis (Pasteurella multocida). In respect to SD, live attenuated B.   191
hyodysenteriae strains, such as one described by Hudson et al. (1976), may be useful in 
conjuction with other antigen delivery systems. Unfortunately, the molecular biology of gene 
transfer in B. hyodysenteriae remains unclear, and no system for targeted gene insertion has 
been described. In addition, the major concern regarding the use of bacterial vectors derived 
from attenuated strains is the potential reversion to full virulence (Medina and Guzman, 2001).  
 
6.4.2.4. Bacterial ghosts 
The bacterial ghost system is a vaccine delivery system which combines targeting of the 
antigen components to antigen-presenting-cells with adjuvant activity without the need for 
complex formulation. The intrinsic adjuvant properties of the bacterial ghost enhances 
systemic, mucosal and cellular immunity to the target antigens (Mayr et al., 2005). Bacterial 
ghosts are produced by expression of cloned gene E from bacteriophage PhiX174 resulting in 
the cell lysis of Gram-negative bacteria. Gene E encodes a membrane protein which is able to 
fuse to the inner and outer membranes of Gram-negative bacteria, forming a lysis tunnel 
through which the cytoplasm of the cell is expelled. The empty cytoplasmic space have intact 
cell envelope structures devoid of cytoplasmic contents (Witte et al., 1990a; 1990b; Witte et 
al., 1992). Foreign target antigens can be attached to the outer membrane of bacterial ghost 
systems by modifying the genes encoding the outer membrane proteins to incorporate the 
target antigen (Hobom et al., 1995). The resulting bacterial ghosts can be used for different 
routes of mucosal immunisations and are not limited to parenteral modes of delivery. Bacterial 
ghosts have been developed for a range of Gram-negative pathogens including E. coli, 
Mannheimia haemolytica, Actinobacillus pleuropneumoniae, Salmonella Typhimurium, and 
Vibrio cholerae (Mayr et al., 2005). The exceptional adjuvant properties of bacterial ghosts 
makes them a desirable delivery system for B. hyodysenteriae cell surface.  
 
6.4.2.5. Particulate delivery systems 
In general, killed vaccines and subunit antigens are poorly immunogenic when administered 
orally. This has been attributed to antigen degradation or inefficient presentation of the antigen   192
at the mucosal surfaces. Studies in laboratory animals have clearly demonstrated that 
particulate delivery systems, such as immunostimulating complexes (ISCOMs) and liposomes, 
can significantly improve the mucosal antigenicity of administered antigens (Gerdts et al., 
2006). 
 
ISCOMs are nanoparticles composed of saponin adjuvant, lipids and antigen which have been 
demonstrated to be effective antigen delivery systems due to their adjuvant activity and ability 
to target antigen-presenting-cells (Morein et al., 2004). The underlying mechanisms supporting 
the effectiveness of ISCOMs in inducing immunity are related to its ability to stimulate the 
innate responses and modulate antigen uptake by recruitment of antigen-presenting-cells 
(Smith et al., 1999; Furrie et al., 2002). When used to deliver antigens to the mucosa, ISCOMs 
administered orally can induce systemic, mucosal IgA, Th1 and Th2 T-cell responses (Maloy 
et al., 1995; Mowat et al., 1999). Studies using ISCOMs for antigen delivery have been 
focused on inducing immune responses in the upper respiratory tract via intranasal 
immunisation (Carol and Nieto, 1998; Hu et al., 1998; Abusugra et al., 1999), and little is 
known about their effectiveness in the proximal colon. Nonetheless, ISCOMs are potentially 
an attractive mucosal delivery system due to their adjuvant properties and cell targeting.  
 
Liposomes are membrane vesicles which enhance immune responses by increasing antigen 
uptake and presentation (Gregoriadis, 1990). Co-administration of liposomes with adjuvants 
such as CT, can improve mucosal responses by improving the uptake of antigen at the mucosa. 
In mice, the conjugation of liposomes with CT significantly enhanced mucosal IgA and 
systemic IgG responses after oral immunisation (Harokopakis et al., 1998). Liposomes have 
also been successfully used for the oral and intranasal immunisation of chickens (Fukutome et 
al., 2001; Li et al., 2003), fish (Irie et al., 2003)), guinea pigs (Chambers et al., 2004; Kita et 
al., 2005) and monkeys (Kita et al., 2005).  
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Particulate delivery systems appear to be a useful way of improving the mucosal immune 
response to soluble antigens. Although synthesis of the particles can be technically 
challenging, it has the advantage that no complex genetic manipulation is required for its 
preparation.  
 
6.4.2.6. Delivery routes 
The compartmentalisation within the mucosal immune system places constraints on the choice 
of vaccination routes available for inducing effective immune responses at the desired sites. 
Oral immunisation induces substantial antibody responses in the small intestine and ascending 
colon (Kozlowski et al., 1997; Eriksson et al., 1998; Jertborn et al., 2001). Nasal immunisation 
results in antibody responses in the upper respiratory tract and nasal and salivary secretions 
(Johansson et al., 2001; 2004). Rectal immunisation evokes strong local antibody responses in 
the proximal colon and rectum (Quiding et al., 1991; Kozlowski et al., 1997; Eriksson et al., 
1998). Given that B. hyodysenteriae colonises the large intestine, rectal vaccination with 
putative immunogens such as Bhlp29.7 may provide better mucosal immunity than the 
intramuscular route. 
 
For the vaccination of large numbers of animals on the farms, a needle-less route of 
vaccination may be preferred. Incorporation of the vaccine antigen in the drinking water or 
feed may be an alternative. Oral vaccination provided by the drinking water may not induce 
immunity at the proximal colon, however, and degradation of the antigen may reduce the 
effectiveness of the vaccine. Combining the vaccine with animal feed may provide the antigen 
with protection from gastric proteolysis in the stomach, however ensuring the correct dosage is 
consumed by each pig would be difficult to control. An alternative for both these delivery 
methods could be the expression of the vaccine subunit in grain. 
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6.4.2.7. Plant-derived vaccines 
The potential applications for plants as vaccine expression vectors are immense (Streatfield 
and Howard, 2003a; Streatfield and Howard, 2003b; Streatfield et al., 2003; Warzecha and 
Mason, 2003) and they will change the fundamentals of the way antigens are generated and 
delivered. In veterinary vaccinology, transgenic plants can produce and deliver immunogenic 
antigens as animal feed, and therefore eliminate the need for trained staff for the administration 
of vaccines, and cold chain storage and transportation of vaccines. These benefits along with 
the low cost of production make plant-derived vaccines a highly attractive system for vaccine 
delivery. Like all other innovations, plant vaccines need to overcome certain challenges. The 
efficacy of orally administered antigens may not be as strong as parenteral and intranasal 
routes, and the effects of digestive enzymes and adsorption processes on edible antigens will 
need to be addressed adequately. In addition to efficacy, other issues such as the calculation of 
the exact dose to administer, the risk of transgenic plants entering the food chain, and the 
induction of immunological tolerance have highlighted unique safety concerns for plant 
vaccines. However, it seems that the advantages of plant vaccines surpass their disadvantages, 
and resolving these issues should secure commercialisation of plant vaccines as new products 
in the relatively near future (Dus Santos and Wigdorovitz, 2005; Koprowski, 2005; Tacket, 
2005). 
 
6.4.2.8. DNA vaccines 
DNA can be injected into a host using either conventional syringes or by gene guns to 
inoculate DNA-coated gold beads into the muscle. DNA vaccines are very stable, and unlike 
most conventional vaccines they do not require a cold chain. This is of particular importance in 
delivering vaccines in the veterinary field. Direct immunisation with naked DNA containing 
genes encoding antigens leads to the uptake of the DNA and expression of the antigens. 
Therefore, actual production of the immunogenic antigens will take place in the host cells 
(Robinson and Torres, 1997). A heterologous prime-boost immunisation approach has been 
shown to induce strong immunity in several different animal disease models (McShane, 2002).   195
This strategy is based on the use of multiple delivery systems to induce immunity against the 
same antigen. In most cases, priming is done with the DNA vaccine and the protein subunit is 
used for boosting (Shams, 2005). The single reported use of DNA vaccination for SD was 
unsuccessful, and vaccinated animals appeared to have exacerbated disease compared to 
unvaccinated controls (Davis et al., 2005). The failure of this DNA vaccine to provide 
protection may have been due to the use of a gene encoding a non-protective antigen, and not 
due to the mode of delivery. Perhaps with the use of a gene encoding a more potent antigen, 
such as Bhlp29.7, naked DNA immunisation may prove to be a potentially useful mode of 
vaccination. 
 
6.5. CONCLUDING REMARKS 
In this thesis, the traditional method of small-scale proteome analysis coupled with monoclonal 
antibody production has enabled the identification of a potential antigen for the diagnosis and 
vaccination of pigs against SD. Evaluation of an ELISA tested using the recombinant Bhlp29.7 
antigen suggested that this test had potential as a herd-level assay. The vaccination studies 
reported in this thesis indicated a reasonable degree of protection against colonisation and 
disease, however complete protection was not achieved. Further studies into the delivery of the 
antigen to the mucosal surfaces of the pig colon may improve the efficacy of the vaccine. It is 
possible that an effective vaccine for SD may contain a cocktail of subunits working 
synergistically. The identification of virulence factors and immunogenic antigens are important 
future steps towards designing informative diagnostic assays and potent vaccines. With 
explosive advances in genome sequencing, bioinformatics, and the availability of new 
molecular approaches such as reverse-vaccinology, proteomic analysis and DNA microarrays, 
it is expected that the number of putative immunogens for use in vaccines against SD will 
increase rapidly in the next few years.  
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APPENDIX 
 
 
A.1. Suppliers of instruments, chemicals and reagents. 
 
Supplier Address 
Amersham Pharmacia Biotech  Piscataway, NJ, USA 
Becton Dickinson Microbiology Systems  Franklin Lakes, NJ, USA 
Bio-Rad Laboratories  Hercules, CA, USA 
Biotech International  West Perth, Western Australia, Australia 
Commonwealth Serum Laboratories (CSL)  Parkville, Victoria, Australia 
Dynex Technologies  San Francisco, CA, USA 
ELISA Systems  Windsor, Queensland, Australia 
Fuji Photo Film  Tokyo, Japan 
Gibco-BRL Life Technologies  Carlsbad, CA, USA 
GraphPad Software Inc.  San Diego, CA, USA 
Glen Forrest Stockfeeds  Perth, Western Australia, Australia 
Heto-Holten Birkerød,  Denmark 
Hoefer  San Francisco, CA, USA 
InforMax Rockville,  MD,  USA 
Invitrogen  Carlsbad, CA, USA 
Mo Bio Laboratories  West Carlsbad, CA, USA 
MVP Laboratories  Ralston, NE, USA 
New England Biolabs  Ipswich, MA, USA 
Oxoid  Basingstoke, Hampshire, UK 
PE Applied Biosystems  Foster City, CA, USA 
Promega Corporation  Madison, WI, USA 
Schleicher & Schuell  Dassel, Germany   250
A.1. Suppliers of instruments, chemicals and reagents (continued). 
 
Supplier Address 
Qiagen GmbH  Hilden, Germany 
Roche Indianapolis,  IN,  USA 
Sigma Chemical Company  St. Louis, MO, USA 
Southern Biotechnology  Birmingham, AL, USA 
Spectrum Laboratories  Rancho Dominguez, CA, USA 
Stratagene  La Jolla, CA, USA 
Wesfeeds Ltd  Perth, Western Australia, Australia 
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A.2. Compostion of the buffers and solutions used. 
 
Buffer Composition 
Carbonate buffer  15 mM sodium carbonate 
35 mM sodium hydrogen carbonate 
3 mM sodium azide 
pH 9.6 
CBB-G250 destaining solution  5% (v/v) methanol 
7% (v/v) acetic acid 
88% (v/v) distilled water 
CBB-G250 fixing solution  25% (v/v) propanol  
10% (v/v) acetic acid 
65% (v/v) distilled water 
CBB-G250 staining solution  10% (v/v) acetic acid 
90% (v/v) distilled water 
0.06% (w/v) CBB-G250 
Detection buffer (Southern blot)  100 mM Tris-HCl 
100 mM NaCl 
pH 9.5 
LB agar  10 g/l Bacto-tryptone 
5 g/l Yeast extract 
10 g/l NaCl 
20 g/l Bacteriological agar 
pH 7.0 
LB broth  10 g/l Bacto-tryptone 
5 g/l Yeast extract 
10 g/l NaCl 
pH 7.0   252
A.2. Compostion of the buffers and solutions used (continued). 
 
Buffer Composition 
MBP column buffer  20 mM Tris-HCl 
200 mM NaCl 
1 mM EDTA 
pH 7.4 
Ni-NTA denaturing elution buffer  100 mM NaH2PO4 
10 mM Tris-HCl 
8 M urea 
pH 4.5 
Ni-NTA denaturing lysis buffer  100 mM NaH2PO4 
10 mM Tris-HCl 
8 M urea 
pH 8.0 
Ni-NTA denaturing wash buffer  100 mM NaH2PO4 
10 mM Tris-HCl 
8 M urea 
pH 6.3 
1× PCR buffer  
(Biotech International) 
67 mM Tris-HCl (pH 8.8) 
16.6 mM (NH4)2SO4 
0.45% (v/v) Triton X-100 
0.2% (w/v) of gelatin 
PBS  137 mM sodium chloride 
2.68 mM potassium chloride 
10 mM disodium hydrogen phosphate  
1.76 mM monobasic potassium phosphate 
pH 7.4   253
A.2. Compostion of the buffers and solutions used (continued). 
 
Buffer Composition 
PBST  137 mM sodium chloride 
2.68 mM potassium chloride 
10 mM disodium hydrogen phosphate  
1.76 mM monobasic potassium phosphate 
0.05% (v/v) Tween 20 
pH 7.4 
4× SDS-PAGE sample treatment 
buffer 
250 mM Tris-HCl (pH 6.0) 
8% (w/v) SDS 
200 mM DTT 
40% (v/v) glycerol 
0.04% (w/v) bromophenol blue 
SDS-PAGE Separating gel  375 mM Tris-HCl (pH 8.8) 
12% (w/v) acylamide 
0.31% (w/v) bis-acrylamide 
0.1% (w/v) SDS 
SDS-PAGE Stacking gel  125 mM Tris-HCl (ph 6.8) 
4% (w/v) acylamide 
0.15% (w/v) bis-acrylamide 
0.1% (w/v) SDS 
2× SSC  30 mM tri-sodium citrate 
300 mM NaCl 
10× SSC  150 mM tri-sodium citrate 
1.5 M NaCl 
1× TAE  40 mM Tris-acetate  
1 mM EDTA (pH 8.0)   254
A.2. Compostion of the buffers and solutions used (continued). 
 
Buffer Composition 
TBS  20 mM Tris base 
500 mM sodium chloride 
pH 7.5 
TBST  20 mM Tris base 
500 mM sodium chloride 
0.05% (v/v) Tween 20 
pH 7.5 
TE 10  mM  Tris-HCl 
1 mM EDTA 
pH 8.0 
Transfer buffer  
(Electro-transfer) 
25 mM Tris base 
192 mM glycine 
20% v/v methanol 
pH 8.3 
Tris-glycine buffer  25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS 
pH 8.3 
Washing buffer  
(Southern blot) 
100 mM maleic acid 
150 mM NaCl 
0.3% (v/v) Tween 20 
pH 7.5   255
A.3. Strains of Brachyspira spp. used for the distribution analysis of bhlp29.7. 
 
Species Strain  Host 
Country of 
Origin 
Reference 
B. hyodysenteriae  B78
T  Pig  Australia  Taylor and Alexander, 1971 
  881 Pig  Australia  Lee,  1994 
  B/Q02 Pig  Australia  This  study 
  NSW1 (N897)  Pig  Australia  Lee et al., 1993 
  NSW3 (N884)  Pig  Australia  Lee et al., 1993 
  SA3 (SS2206)  Pig  Australia  Milner and Sellwood, 1994 
  Vic 10 (V5237/87)  Pig  Australia  Lee et al., 1993 
  Vic 19 (1070-18)  Pig  Australia  Lee et al., 1993 
  Vic 30 (V833b)  Pig  Australia  Lee et al., 1993 
  Vic 31 (V70)  Pig  Australia  Lee, 1994 
  Vic 32 (V976)  Pig  Australia  Lee et al., 1993 
  Vic 35 (V885)  Pig  Australia  Lee, 1994 
  Vic 5 (V2533)  Pig  Australia  Lee et al., 1993 
  Vic 87 (V2809/87)  Pig  Australia  Hampson et al., 1990 
  Vic2 (V2809/87)  Pig  Australia  Lee et al., 1993 
  Vic23 (V1155/88)  Pig  Australia  Lee et al., 1993 
  Vic24 (3458/88)  Pig  Australia  Lee et al., 1993 
  Vic25 (V3617)  Pig  Australia  Lee et al., 1993 
  Vic26 (3483/90A)  Pig  Australia  Lee et al., 1993 
  Vic29 (V2434)  Pig  Australia  Lee et al., 1993 
  Vic31 (V70)  Pig  Australia  Lee et al., 1993 
  WA1 (155/6)  Pig  Australia  Hampson et al., 1990 
  WA11 (155/16)  Pig  Australia  Lee et al., 1993 
  WA12 (155/17)  Pig  Australia  Lee et al., 1993   256
A.3. Strains of Brachyspira spp. used for the distribution analysis of bhlp29.7 (continued). 
 
Species Strain  Host 
Country of 
Origin 
Reference 
B. hyodysenteriae  WA13 (155/18)  Pig  Australia  Lee et al., 1993 
  WA15 (155/23)  Pig  Australia  Lee et al., 1993 
  WA16 (155/24)  Pig  Australia  Lee et al., 1993 
  WA2 (155/7)  Pig  Australia  Lee et al., 1993 
  WA26 (Williams)  Pig  Australia  Lee et al., 1993 
  WA3 (155/8)  Pig  Australia  Lee et al., 1993 
  WA32 (WP91.1313)  Pig  Australia  Lee et al., 1993 
  WA4 (155/9)  Pig  Australia  Lee et al., 1993 
  WA5 (155/10)  Pig  Australia  Lee et al., 1993 
  WA6 (155/11)  Pig  Australia  Hampson et al., 1990 
  WA7 (155/12)  Pig  Australia  Lee et al., 1993 
  WA8 (155/13)  Pig  Australia  Lee et al., 1993 
  WA9 (155/14)  Pig  Australia  Lee et al., 1993 
  WPW11 (Whites 11)  Pig  Australia  Lee, 1994 
  B169 Pig  Canada  Hampson  et al., 1990 
  FM88-90 Pig  Canada  Harris  et al., 1972 
  FMV89-3323 Pig  Canada  Harris  et al., 1972 
  P18A Pig  UK  Hampson  et al., 1990 
  KF9 Pig  UK  Lee  et al., 1993 
  MC52/80 Pig  UK  Lee  et al., 1993 
  VS1 (FW10)  Pig  UK  Hampson et al., 1990 
  B204 Pig  USA  Kinyon  et al., 1977 
  B234 Pig  USA  Harris  et al., 1972 
  NIV-1 Rhea  USA  Jansson  et al., 2004   257
A.3. Strains of Brachyspira spp. used for the distribution analysis of bhlp29.7 (continued). 
 
Species Strain  Host 
Country of 
Origin 
Reference 
B. pilosicoli  P43/6/78
 T Pig  Scotland  Taylor  et al., 1980 
  7082 Pig  Australia  Lee  et al., 1993 
  3295.90B Pig  Australia  Lee  et al., 1993 
  95/1000 Pig  Australia  Lee,  1994 
  WPP7 (OF2)  Pig  Australia  Lee, 1994 
  WPP8 (OF11)  Pig  Australia  Lee, 1994 
  B1555A Pig  USA  Duhamel,  1998 
  Gut C  Pig  USA  Lee et al., 1993 
  1331-6 Chicken  Netherlands  McLaren  et al., 1997 
  CPSp-1  Chicken  Australia  Stephens and Hampson, 1999 
  Q94.0354.0.6  Chicken  Australia  Stephens and Hampson, 1999 
  Q97.3008.4.2  Chicken  Australia  Stephens and Hampson, 1999 
  Q98.0028.3  Chicken  Australia  Stephens and Hampson, 1999 
  Q98.0072.38  Chicken  Australia  Stephens and Hampson, 1999 
  Dog 17  Dog  Australia  Lee, 1994 
  HRM2 Human  Italy  Sanna  et al., 1982 
  HRM7 Human  Italy  Sanna  et al., 1982 
  Wes B  Human  Australia  Lee and Hampson, 1992 
B. intermedia  PWS/A
 T Pig  UK  Hudson  et al., 1976a 
  P280/1 Pig  UK  Lee  et al., 1993 
  AN983.90 Pig  Sweden  Pettersson  et al., 1996 
  889 Pig  Australia  Lee  et al., 1993 
  2818.5 Pig  Australia  Lee  et al., 1993 
  E2 Chicken  Australia  McLaren  et al., 1997   258
A.3. Strains of Brachyspira spp. used for the distribution analysis of bhlp29.7 (continued). 
 
Species Strain  Host 
Country of 
Origin 
Reference 
B. intermedia  B37iii Chicken  Australia  McLaren  et al., 1997 
  B52-iii Chicken  Australia  McLaren  et al., 1997 
  2A-10 Chicken  Australia  McLaren  et al., 1997 
  HB60-1 Chicken  Australia  McLaren  et al., 1997 
  3B-1 Chicken  Australia  McLaren  et al., 1997 
  1380 Chicken  Netherlands  McLaren  et al., 1997 
B. innocens  B256
 T  Pig  USA  Kinyon and Harris, 1979 
  155/5 Pig  Australia  Lee  et al., 1993 
  Q91.122233 Pig  Australia  Not  available 
  Q91.1530.1 Pig  Australia  Not  available 
  West A  Pig  Australia  Not available 
  WPP11 (Whites 11)  Pig  Australia  Lee, 1994 
  WPP12 (10C)  Pig  Australia  Lee, 1994 
  4/71 Pig  UK  Lee  et al., 1993 
  2A-20 Chicken  Australia  McLaren  et al., 1997 
  94-0354.03 Chicken  Australia  McLaren  et al., 1997 
  Q98.0034.16 Chicken  Australia  McLaren  et al., 1997 
  Q98.0228.5.7 Chicken  Australia  McLaren  et al., 1997 
B. murdochii  56/150
 T Pig  Canada  Stanton  et al., 1997 
  155/20 Pig  Australia  Lee  et al., 1993 
  155/21 Pig  Australia  Lee  et al., 1993 
  Q98.0062.11 Pig  Australia  Not  available 
  T94.6363 Pig  Australia  Not  available 
  CPBB-5  Chicken  Australia  Stephens and Hampson, 1999   259
A.3. Strains of Brachyspira spp. used for the distribution analysis of bhlp29.7 (continued). 
 
Species Strain  Host 
Country of 
Origin 
Reference 
B. murdochii  DL40-7  Chicken  Australia  Stephens and Hampson, 1999 
  I-caec-I  Chicken  Australia  Stephens and Hampson, 1999 
B. alvinpullii  C1
 T Chicken  USA  Stanton  et al., 1998 
  C2 Chicken  USA  Stanton  et al., 1998 
B. aalborgi  513
 T Human  Denmark  Hovind-Hougen  et al., 1982 
“B. canis”  D15 Dog  Australia  Duhamel  et al., 1998 
  D16 Dog  Australia  Duhamel  et al., 1998 
 